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Chapter 1
General introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) form a biologically 
unique group of infectious fatal neurodegenerative disorders, which are caused by the 
improper folding of the normal cellular prion protein (PrPC, Fig. 1A) leading to a structurally 
aberrant, protease-resistant and pathologic isoform (PrPSc, Fig. 1B) [1]. A major feature that 
distinguishes the infectious prion diseases from virus-related diseases is that the transmissible 
particles (prions, derived from proteinaceous and infectious) are devoid of nucleic acid and 
seem to be composed exclusively of PrPSc [2,3]. Endogenous PrPC is required for infection 
since mice lacking the prion protein gene (PRNP0/0) are resistant to the disease [4]. The 
amino acid sequences of PrPC and PrPSc are identical in composition but differ in their three-
dimensional conformations. PrPC is rich in α-helices and has little β-sheets, whereas PrPSc 
is less rich in α-helices and has much more β-sheets [5]. This structural transition from 
α-helices to β-sheets in PrP is the fundamental event underlying prion diseases [6]. Central 
in this thesis is the functioning of the normal prion protein in a neuroendocrine cell. In this 
introductionary chapter, various aspects of PrPC will be dealt with.
 
Figure 1. Schematic of the three-dimensional structures of two conformations of human PrP (obtained 
through the Cohen group; [96]). (A) The normal conformation of PrPC shows mainly α-helices (blue) 
and few β-strands (orange). (B) A proposed model of the abnormal PrPSc isoform. Although the exact 
three-dimensional structure of PrPSc is not known, there is an increased β-sheet content in this prion 
isoform. A part of the N-terminal region of the protein (residues 1-121) is not shown here, as it does not 
have a ﬁ xed structure in aqueous solution.
Prion diseases
Most humans afﬂ icted with prion disease show a rapidly progressing dementia, while 
some manifest cerebellar ataxia. Although the brains of patients appear grossly normal 
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upon postmortem examination, they usually show spongiform degeneration and astrocytic 
gliosis upon microscopic examination of the central nervous system (CNS) [7]. Human 
prion diseases can occur as a sporadic, genetic, or infectious disorder [8]. Sporadic forms 
of prion disease constitute most cases of Creutzfeldt-Jakob disease (CJD) and possibly a 
few cases of Gerstmann-Sträussler-Scheinker syndrome (GSS) [9-11]. Familial CJD, GSS, 
and fatal familial insomnia (FFI) are inherited prion diseases caused by mutations in the 
PRNP gene resulting in nonconservative substitutions [2]. The infectious prion diseases 
include kuru of the Fore people in Papua New Guinea, where prions were transmitted by 
ritualistic cannibalism [12-14]. Sources of prions causing infectious CJD include improperly 
sterilized depth electrodes, transplanted corneas, human growth hormone and gonadotropin 
isolated from cadaveric pituitaries, and dura mater grafts [15]. Prion diseases also occur 
among other mammals such as sheep (scrapie), mink (transmissible mink encephalopathy), 
mule deer and elk (chronic wasting disease), cats (feline spongiform encephalopathy), and 
cattle (bovine spongiform encephalopathy, BSE) [6]. Prion strains and species barrier are 
of dominant importance in understanding the BSE epidemic which broke out beginning in 
Great Britain in the late 1980s and spreading to other European countries, the USA, and 
Canada [16,17]. The variant CJD (vCJD) is caused by the same prion strain as BSE in cattle 
[18]. Epidemiological, biochemical and histological evidence suggests that vCJD represents 
transmission of BSE prions to humans [19-22]. BSE probably originated from a rare case of 
prion disease in either sheep or cattle [23]. Once established, the disease was spread in cattle 
by ingestion of prion-contaminated meat and bone meal.
Mechanisms of prion replication
If the protein-only hypothesis is correct, one could argue that the prion problem is, in essence, 
one of protein structure. Two models for the conformational conversion of PrPC into PrPSc can 
be proposed. The refolding or template assistance model postulates an interaction between 
exogenously introduced PrPSc and endogenous PrPC, which is induced to transform itself into 
additional PrPSc. A high-energy barrier may prevent spontaneous conversion of PrPC into 
PrPSc [24,25]. The seeding or nucleation-polymerization model proposes that PrPC and PrPSc 
are in reversible thermodynamic equilibrium. Only if several monomeric PrPSc molecules 
are mounted into a highly ordered seed, additional monomeric PrPSc can be recruited and 
eventually aggregates to amyloid. Fragmentation of PrPSc aggregates increases the number 
of nuclei, which can recruit further PrPSc and thus results in apparent replication of the agent 
[26-28].
Structure and biogenesis of prion protein
PrP is conserved among many species, including mammals, birds, reptiles, amphibians and 
ﬁ sh, indicating a common physiological role (Fig. 2; [29-34]). The human PRNP gene is 
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Figure 2. Alignment of the amino acid sequences of human, chicken, turtle and Xenopus laevis PrP. 
The locations of the signal peptide, tandem repeats and the GPI-anchor are indicated. White letters on 
a black background denote residues that are identical among at least three sequences and grey brackets 
indicate the repeats.
mapped on the short arm of chromosome 20, has only three exons and the entire open-
reading frame resides within a single exon. The PrPC protein is ubiquitously expressed 
with highest levels found in neurons and other cells of the CNS [35,36]. Human PrPC is 
synthesized as a 253-amino acid polypeptide chain from which the ﬁ rst 22 amino acids (signal 
peptide) are cleaved shortly after translation commences, targeting the newly synthesized 
polypeptide chain to the endoplasmic reticulum (ER). In the ER, PrPC undergoes further 
processing and is subjected to several post-translational modiﬁ cations. PrPC contains two 
N-linked glycosylation sites (residues 181 and 197), which are the sites of high-mannose 
type oligosaccharide attachments in the ER. In addition to N-linked glycosylation, a single 
disulﬁ de bond is formed between cysteine residues 179 and 214 in the C-terminal region, 
and subsequent cleavage of a carboxy-terminal signal sequence precedes attachment of a 
glycosyl-phosphatidylinositol (GPI)-anchor at residue 230, which facilitates glycolipid 
linkage of PrPC to the outer cell membrane. PrPC is transported through the Golgi apparatus 
where further processing of the N-linked oligosaccharides results in a modiﬁ ed glycosylation 
that includes complex sugar types. In all known vertebrates except Xenopus, PrPC harbors a 
putative Cu2+-binding domain consisting of two (in one of the squirrel alleles) up to ten (in 
turtle) repeats [37,38]. Furthermore, PrPC has a toxic/hydrophobic core in the middle of the 
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Figure 3. Schematic representation of the structural motifs within human and Xenopus PrPC. Following 
cleavage of the signal peptide (dark blue), PrPC is GPI-anchored and N-glycosylated at two sites in the 
C-terminal region, and a single disulﬁ de bridge is formed. Human PrPC contains ﬁ ve octarepeats (light 
blue), which are missing in Xenopus PrPC. The α-helices and β-strands are shown, and the conserved 
cleavage site in the toxic core (red) is indicated with an arrow.
protein that contains a metabolic cleavage site (Fig. 3; [39]). In its mature state, human PrPC is a 
di-glycosylated protein of 33-35 kDa transported to the cell surface where it is predominantly 
localized to detergent-resistent microdomains via the GPI-anchor [40]. PrPC may then be 
shed via cleavage of the GPI-anchor or subjected to endocytosis, namely cycling between an 
endocytic compartment and the plasma membrane [41]. Several different topological isoforms 
of PrP have been described that correspond to distinct transmembrane forms of the protein 
[42]. Transmembrane PrPC (TM-PrPC) exists as either a form whereby the C-terminus is 
directed towards the ER lumen (termed CtmPrP) or in the opposite orientation (NtmPrP). In both 
topological forms, the transmembrane domain (residues 111-134) is integrated into the lipid 
bilayer through a mechanism that may involve modulation of the ER targeting step [43-45] 
and/or partitioning of populations at the translocation channel [46]. CtmPrP has been detected 
in some forms of inherited prion disease and can be generated in cell culture and transgenic 
mouse models [45,47]. To date, NtmPrP has not been associated with any TSE disease and has 
only been demonstrated in cultured cell and transgenic animal systems. Differences between 
the two topological isoforms include the addition of the GPI-anchor and N-linked sugars 
to the CtmPrP but not NtmPrP form of PrP [48]. In addition to the existence of topological 
isomers of PrPC, it has been demonstrated that PrPC also undergoes endoproteolytic cleavage 
resulting in amino-terminally truncated forms of the protein. Human PrPC undergoes such 
cleavage between amino acid residues 110-111, resulting in a carboxy-terminal fragment 
of approximately 17 kDa, referred to as ‘C1’ [49]. PrPSc also undergoes cleavage, but the 
cleavage site is more N-terminally located and results in a slightly larger fragment named 
‘C2’. Although the role of these proteolytically cleaved fragments in the pathogenesis of 
TSE diseases remains to be established, it has been reported that calpain inhibitors can 
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prevent PrPSc cleavage and PrPSc accumulation in infected cell cultures, suggesting a link 
between cleavage and propagation of PrPSc [50]. The extent of N-terminal truncation of PrPC 
is determined by the degree of glycosylation of the PrPC molecule [51,52]. The truncation of 
PrPC and the heterogeneity of the linked glycans may play a role in regulating PrPC function 
[49]. This raises the possibility that the cleavage of PrPSc and subsequent prion pathogenesis 
may be inﬂ uenced by the degree of its glycosylation.
The Xenopus prion protein
The ﬁ rst non-mammalian PrP has been identiﬁ ed in chicken and, despite a low degree of amino 
acid sequence identity, all structural motifs are conserved between chicken and mammalian 
PrP [32,53]. This also holds for turtle PrP, representing the ﬁ rst example of such a protein in 
reptiles, which precede birds and mammals from an evolutionary point of view [30]. More 
recently, even a more primitive PrPC was isolated and characterized as the ﬁ rst amphibian 
PrP, namely from the South-African claw-toed frog Xenopus laevis. The Xenopus PrP protein 
is central in this thesis and exhibits ~44% amino acid sequence identity to avian and turtle 
PrP, and shares a lower degree of identity with mammalian PrP (~28%). An N-terminal signal 
peptide of 22 amino acids allows the amphibian PrP to enter the secretory pathway. As other 
PrP structures, the amphibian primary sequence contains cysteines (residues 148 and 185) 
for intramolecular disulﬁ de bonding and two predicted N-glycosylation sites at asparagines 
residues 150 and 165. Furthermore, it has a comparable C-terminal hydrophobic signal 
sequence at residue 193 for the addition of a GPI-anchor [29]. Remarkably, one structural 
motif lacking in the Xenopus PrP sequence concerns the octarepeat. Intriguingly, the Xenopus 
sequence shows a considerable conservation of the amino acids ﬂ anking the octarepeats, 
suggesting a genetic deletion event in the Xenopus PrP sequence during evolution [29].
Proposed roles for PrPC 
In spite of elaborate research on PrPC and the fact that the ﬁ rst PRNP knock-out mice are 
available for more than a decade [54], the normal physiological function of PrPC remains 
elusive. Subtle abnormalities have been found in PrP-deﬁ cient mice [55,56], but the only 
clear phenotype concerns their striking resistance to prion inoculation [4].
As mentioned above, one of the characteristics of PrPC concerns a hydrophobic C-terminal 
signal sequence that regulates the addition of a GPI-anchor and may play an important role 
in PrPC functioning. GPI-proteins are cleaved within the ER at the so-called ω amino acid 
residue, thereby attaching a GPI-moiety to the new C-terminus, which directs these proteins 
to the cell surface and present them to the external environment. The GPI-anchor is thought 
to direct proteins to speciﬁ c subsets of the cell membrane called lipid rafts [57]. Lipid rafts 
are ordered phases in plasma membranes rich in cholesterol and spingolipids [58] and are 
believed to play a role in certain signal transduction pathways, cholesterol transport and 
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endocytosis (reviewed by Parton and Richards [59]). The presence of PrPC in lipid rafts has 
a great inﬂ uence on its internalization, mature state and behavior [40,57,60,61]. PrPC may 
use distinct intracellular routes for internalization. Similar to other GPI-anchored proteins, 
mammalian PrPC and PrPSc might be internalized independently of clathrin [40,61,62], 
but it is still unclear whether in neuronal cells caveolae-mediated endocytosis is involved 
in PrPC trafﬁ cking. Many internalizing PrPC molecules are found in clathrin-coated pits 
[57,63,64], providing growing evidence for a role of classical endosomal organelles in PrPC 
intracellular trafﬁ cking. In either way, internalized PrPC can cycle constitutively between 
the plasma membrane and an endocytic compartment, as shown by co-localization of PrPC 
with endosomal markers [65]. The fate of PrPC following endosomal passage is still poorly 
characterized. Trafﬁ cking to lysosomes and degradation of the protein is one of the possible 
routes [66].
Recent studies have advanced the hypothesis that PrPC may play a role in signal transduction. 
In an early study, a caveolin- and clathrin-dependent coupling of PrPC to the soluble non-
receptor tyrosine kinase Fyn was reported in a neuronal-like cell line, indicating a cellular 
pathway through which PrPC inﬂ uences synaptic functioning [67]. Other studies indicate 
that PrPC may interact with components of signal transduction pathways, such as Grb2 [68]. 
This signaling pathway seems crucial for cell survival [69]. Other experimental ﬁ ndings also 
suggest that PrPC may play a major role in neuroprotective signaling. For instance, PrPC can 
bind to the anti-apoptotic factor Bcl-2 [70]. Moreover, PrPC protects human primary neurons 
against Bax-mediated cell death to a degree similar to that of the neuroprotective Bcl-2 
protein [71]. Recent efforts to identify PrPC-binding molecules have led to the discovery 
of several receptor candidates including the 37-kDa/67-kDa laminin receptor [72] and the 
murine stress-inducible protein 1 [73]. PrPC is capable of binding Cu2+ ions and a Cu2+-binding 
domain has been mapped to the region of four or ﬁ ve octarepeats containing histidine and 
glycine residues [37,74,75]. This conserved region of mammalian PrPC appears to coordinate 
binding of four Cu2+ ions [37,76,77]. The octarepeat domain is remarkably selective for Cu2+ 
and harbors a weaker afﬁ nity for Zn2+, Cu+ or other metal ions [78-80]. In addition to the 
octarepeat region, another binding site for Cu2+ has been identiﬁ ed and is centered around 
histidine residues 96 and 111 [81-84]. This site has been suggested to have a much higher 
afﬁ nity for Cu2+ ions than reported for the octarepeats [82]. Interestingly, intracellular Cu2+ 
is decreased in brain extracts from PrP-knockout mice compared to control mice [21]. Thus, 
the ability of PrPC to bind Cu2+ is not just incidental but indeed inﬂ uences tissue Cu2+ content. 
Moreover, these mice also showed reduced activity of Cu-Zn superoxide dismutase and were 
more vulnerable to oxidative stress [85-87]. Both Cu2+ and Zn2+ dramatically increase the rate 
of PrPC endocytosis thus demonstrating that metal ions inﬂ uence PrPC trafﬁ cking in the cell 
[88]. Elimination of the octarepeat domain abolishes this activity [89]. As mentioned above, 
the complete absence of histidine residues within the Xenopus PrP sequence is striking, 
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suggesting that Cu2+ binding is not the primary function of the amphibian PrPC [29,37,38]. 
Nevertheless, the role of metal ions in prion diseases cannot be easily dismissed.
The amphibian Xenopus laevis as a model system
For decades, the South-African claw-toed frog Xenopus laevis has been used as an animal model 
system for developmental, endocrinological and molecular studies. Xenopus laevis has many 
advantages in comparison with other animal models. For instance, Xenopus females generate 
oocytes and eggs in large quantities, which are accessible for manipulation from fertilization 
onwards and can be easily followed in time due to the large size and fast development outside 
the uterus. Furthermore, Xenopus laevis is reared with ease and reproduces in a fairly short 
period of time. Interestingly, this amphibian represents an intermediate stage between relatively 
simple invertebrates and highly complex mammals. The oocytes of Xenopus laevis appear to 
be a good expression system for exogenous genes. Injected mRNAs are effectively translated 
and their function in development has yielded a wealth of information [90]. However, mRNA 
injections are only practical for global expression studies early in embryogenesis. For many 
purposes, transgenes in which spatial and temporal expression can be precisely targeted are 
much more useful. Here, we exploit the melanotrope cells of the intermediate pituitary of 
the amphibian Xenopus laevis as a model system to study the normal physiological function 
of PrPC in vivo. Depending on whether the animal is kept on a black or a white background, 
these cells are differentially innervated by neuronal cells of hypothalamic origin (e.g. strong 
synapses are formed in white animals) and become highly active or inactive, respectively. 
The Xenopus melanotrope cells constitute a homogeneous population of strictly regulated 
neuroendocrine secretory cells. In the melanotrope cells of the intermediate pituitary of 
black-background-adapted Xenopus laevis, the major biosynthetic product is the prohormone 
proopiomelanocortin (POMC) that is processed to a number of bioactive peptides, including 
α-melanophore-stimulating hormone (α-MSH). Once released into the blood, α-MSH 
mediates the process of background adaptation by causing dispersion of pigment granules 
in skin melanophores resulting in blackening of the skin [91]. POMC constitutes about 80% 
of the newly synthesized proteins in the highly active melanotrope cells, which is reﬂ ected 
by an increased cell size and a well-developed biosynthetic machinery. The key function 
of the melanotrope cells appears to be the production and processing of massive amounts 
of POMC. This cellular function in combination with the identiﬁ cation of the innervating 
neuronal cells of hypothalamic origin (reviewed by Roubos [92]) provides us with a well-
deﬁ ned opportunity to perform functional studies. Since PrPC is known to enter the secretory 
pathway, the intermediate pituitary melanotrope cells of Xenopus laevis are ideally suited to 
study the fate of PrPC.
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Stable transgenesis of Xenopus laevis
The potential of the use of Xenopus laevis as an experimental animal model system expanded 
tremendously when Enrique Amaya and colleagues developed a technique for making stable, 
non-mosaic transgenic Xenopus embryos [93], later simpliﬁ ed by the group of Mohun [94], 
who showed that without the use of interphase egg extract and restriction-mediated integration 
(REMI) of the transgene, the generation of transgenic Xenopus is a convenient system for 
studying the normal physiological function of proteins. Previously, studies on molecular 
events occuring after mid-blastula transition were problematic due to the bad integration 
and/or mosaic expression of the introduced DNA.
Figure 4. Flow diagram of the stable Xenopus transgenesis procedure and the generation of F1 transgenic 
animals. This schematic represents the transgenesis technique described by Amaya and collegues [93], 
and modiﬁ ed by Mohun and co-workers [94]. For the generation of F1 transgenic animals, we used 
either transgenic sperm and wild-type eggs or wild-type sperm and transgenic eggs.
In short, the transgenesis method involves mixing Xenopus laevis sperm nuclei with linearized 
DNA encoding the gene of interest and subsequently the suspension is microinjected into 
unfertilized eggs to generate transgenic Xenopus embryos (Fig. 4). In our experiments, we 
have used stable Xenopus transgenesis to drive transgene expression of PrPC in a tissue-
speciﬁ c manner. For this purpose, a Xenopus POMC gene A promoter fragment [95] was 
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utilized to direct transgene expression of Xenopus PrPC fused to the C-terminus of the green 
ﬂ uorescent protein (GFP-PrPC) speciﬁ cally to the melanotrope cells of the intermediate 
pituitary. In this manner, we combined the technique of stable Xenopus transgenesis with 
the unique properties of the well-deﬁ ned neuroendocrine melanotrope cells to examine cell-
biological aspects of PrPC.
Aim and outline of this thesis
Since PrPC has a fundamental role in prion diseases, understanding the functioning of PrPC 
may help in deciphering prion pathology and maybe even devising therapeutic approaches. 
Great efforts have been taken to unravel the highly debated normal physiological role of PrPC 
in the cell. However, the results obtained so far have not provided conclusive answers. The 
main goal of this thesis was to investigate the normal physiological role of PrPC in vivo in the 
highly specialized Xenopus intermediate pituitary melanotrope cells. Chapter 2 describes 
the temporal and spatial mRNA expression of PrP in Xenopus laevis. Microinjection of 
PrP mRNA into fertilized Xenopus eggs revealed that early embryonic development was 
not affected. Furthermore, this chapter shows that the PrP mRNA levels were similar in the 
melanotrope cells of black- and white-adapted frogs and were thus not coregulated with 
POMC. In chapter 3, the technique of stable Xenopus transgenesis in combination with the 
POMC gene promoter was used as a tool to express the GFP-PrPC fusion protein speciﬁ cally 
in the Xenopus melanotrope cells and to study the biosynthesis and intracellular fate of 
PrPC in these neuroendocrine cells. Chapter 4 reports the functional analysis of Xenopus 
transgenic for GFP-PrPC. We found that the overexpression of PrPC affects the secretory 
pathway and induces the process of crinophagy in the transgenic melanotropes. Chapter 5 
describes the functional analysis of Xenopus melanotrope cells with transgene expression of 
mutated forms of the GFP-PrPC protein (the non-cleavable GFP-PrPCK82A, the GPI-lacking 
GFP-PrPCΔGPI, the octarepeat-containing GFP-PrPCocta and the GFP-GPI mutant fusion 
proteins). Finally, in chapter 6 we summarize and discuss the results described in this thesis 
and propose a model for PrPC functioning.
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Abstract
In mammals, the prion protein (PrP) is expressed in most tissues, but predominantly in 
neuronal tissues. Here, we investigated the temporal and spatial mRNA expression of PrP 
in the non-mammalian South-African claw-toed frog Xenopus laevis. PrP transcripts were 
maternally expressed and detected throughout embryonic development, most strongly from 
neurulation onwards and including the tadpole stage. Microinjection of PrP mRNA into 
fertilized Xenopus eggs did not affect early embryonic development. In adult frogs, PrP mRNA 
expression was observed in all tissues examined, with high expression in brain, pituitary and 
testis. In Xenopus, the intermediate pituitary melanotrope cells are involved in background 
adaptation of the animal and produce high levels of the prohormone proopiomelanocortin 
(POMC) when the melanotrope cells are active (i.e. when the animal is black adapted). 
Remarkably and in contrast to most secretory pathway components, PrP was not upregulated 
in the melanotropes of black-adapted animals, arguing against a direct role of this protein in 
POMC biosynthesis.
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Introduction
Transmissible spongiform encephalopathies (TSEs or prion diseases) form a biologically 
unique group of infectious fatal neurodegenerative disorders, which are caused by changes 
in the three-dimensional conformation of the normal cellular prion protein (PrPC) that lead 
to the formation of the abnormal, protease-resistant, disease-associated prion protein (PrPSc) 
[1]. Mature PrPC is a glycosylphosphatidylinositol (GPI)-anchored sialoglycoprotein, which 
is expressed in nearly all tissues, but highest levels are found in the central nervous system 
[2-5]. Despite sequence variations among different species, PrP from turtle to human retains 
certain structural elements such as a signal peptide, tandem repeats, a hydrophobic region, 
two glycosylation sites, a disulphide bridge, and a GPI-anchor site [6-9]. The isolation and 
characterization of the full-length coding sequence have shown that Xenopus PrP harbors 
considerable conservation, but lacks the repeats found in all known PrPs [7]. Thus far, no 
studies on PrP expression in this primitive vertebrate have been performed.
In this study, we aimed to characterize Xenopus PrP during development by examining the 
temporal and spatial expression patterns of PrP transcripts in Xenopus eggs, embryos and 
tadpoles. Furthermore, we examined PrP expression in a number of tissues in the adult animal, 
including in the neuroendocrine melanotrope cells of the intermediate pituitary. In Xenopus, 
the process of background adaptation provides the opportunity to manipulate the activity of 
the melanotrope cells in vivo. In animals adapted to a black background, the melanotrope cells 
are very active and produce vast amounts of the prohormone proopiomelanocortin (POMC), 
which is processed to a number of bioactive peptides, including α-melanophore-stimulating 
hormone. This hormone causes pigment dispersion in skin melanophores, giving the animal a 
black appearance. In white-background-adapted animals, the activity of the melanotrope cells 
is inhibited by neurons originating from the hypothalamic suprachiasmatic nucleus, which 
make direct synaptic contacts with the melanotrope cells [10]. Placing the amphibian on a 
white or black background thus allows physiological manipulation of the biosynthetic and 
secretory activity of the melanotrope cell. Here, we explored the developmental expression 
and egg microinjection of Xenopus PrP mRNA as well as its expression in the adult frog, in 
particular in the pituitary gland.
Experimental procedures 
Xenopus eggs and embryos
Mature female South-African claw-toed frogs Xenopus laevis were directly obtained from 
South-Africa (Xenopus Express, Cape Town, South-Africa), and bred and reared at the 
Central Animal Facility of the Radboud University Nijmegen (Nijmegen, The Netherlands). 
To harvest unfertilized eggs, female Xenopus laevis were injected with 375 iU human 
gonadotropic hormone (Pregnyl; Organon, Oss, The Netherlands) into their dorsal lymphatic 
cavities. Eggs were collected from the females 18 hr following injection and used for in vitro 
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fertilization experiments. For in vitro fertilization, the testes of male transgenic Xenopus 
frogs were isolated and gently pulled apart prior to use. Pieces of testes were rubbed against 
the unfertilized eggs harvested from wild-type Xenopus females. After 10 min, the fertilized 
eggs were incubated in 0.1×MMR (1xMMR; 100 mM NaCl, 1 mM KCl, 0.5 mM MgCl2, 1.5 
mM CaCl2, and 5 mM Hepes; pH 8.0) and selected, and various developmental stages were 
used for RNA isolation (staging was carried out according to Nieuwkoop and Faber [11]). 
For RNA microinjection, unfertilized eggs harvested from wild-type Xenopus females were 
fertilized using testes of male wild-type Xenopus frogs. The fertilized eggs were dejellied 
in 2% cysteine/0.25×MMR, extensively washed with 0.1×MBS (8.8 mM NaCl, 0.1 mM 
KCl, 0.7 mM CaCl2, 0.25 mM NaHCO3, 0.1 mM MgSO4, and 0.5 mM Hepes; pH 7.8), 
put in 0.25×MMR/3% Ficoll-400 with 50 μg/ml gentamicin, and immediately used for 
microinjection. All animal experiments were carried out in accordance with the European 
Communities Council Directive 86/609/EEC for animal welfare, and permit TRC 99/15072 
to generate and house Xenopus.
Semi-quantitative RT-PCR
For semi-quantitative RT-PCR analysis, total RNA was isolated from several developmental 
stages and Xenopus tissues according to the manufacturer’s instructions (Life Technologies, 
Inc.). The RNA was dissolved in 20 μl RNase-free H2O and the concentration was measured 
with a GeneQuant RNA/DNA calculator (Pharmacia). Two μg of total RNA was reverse 
transcribed to ﬁ rst-strand cDNA according to manufacturer’s instructions (Gibco BRL). 
To examine Xenopus PrP RNA expression in a number of developmental stages and 
Xenopus tissues, the cDNA was used for RT-PCR analysis with primer sets that gave a 
225-bp product; the forward primer used was PrP-fw (5’-GTCCTTATCTCCCTAGTAT
GCACATTG-3’) and reverse primer PrP-rev (5’-GGCCACCGACTTCATGTTG-3’). 
As a positive control, Xenopus glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
cDNA was ampliﬁ ed using primers that gave a 230-bp product; forward primer GAPDH-
fw (5’-GCCGTGTATGTGGTGGAATCT-3’) and the reverse primer GAPDH-rev (5’-
AAGTTGTCGTTGATGACCTTTGC-3’). Of each primer, 0.5 μM was used in a 25 μl reaction 
volume containing 2 μl cDNA, 200 μM dNTPs, 3 mM MgCl2, PCR-buffer (Fermentas), and 
1 U Taq polymerase (Fermentas). Ampliﬁ cations were performed for 1 min at 94°C, 1 min at 
55°C, and 1 min at 72°C, and various numbers of ampliﬁ cation cycles were used to ensure 
ampliﬁ cation in the exponential phase. The generated cDNA fragments were resolved in 2% 
agarose gels containing ethidium bromide. Speciﬁ city of the PCR procedure was checked by 
omission of the cDNA template or reverse transcriptase in the ampliﬁ cation reaction.
Real-time quantitative RT-PCR
For real-time quantitative RT-PCR analysis, neurointermediate lobes (NILs; pools of 3-5 
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lobes) and anterior lobes (ALs; pools of 3-5 lobes) of pituitaries from black- and white-adapted 
Xenopus were dissected and total RNA was isolated as described above. One μg of total 
RNA was reverse transcribed to ﬁ rst-strand cDNA by incubating 11 μl RNA and 1 μl pd(N)6 
(random primers, 5 mU/μl, Roche) for 10 min at 70°C, followed by double-strand synthesis 
in 20 μl strand buffer (Life Technologies, Inc.) supplemented with 10 mM DTT, 20 URNAsin 
(Promega), 0.5 mM dNTPs (Roche), and 100 U reverse transcriptase (SuperScriptTM II, Gibco 
BRL) for 90 min at 37°C. Samples were diluted ﬁ ve times in RNAse-free H2O and subjected 
to real-time quantitative RT-PCR on a 5700 GeneAmp PCR system (PE Applied Biosystems, 
Foster City, CA) as follows: 5 μl template cDNA was added to 0.625 μM of each primer and 10 
μl iTaq SYBR Green supermix with ROX (Biorad, Hercules, CA) in a 20 μl reaction volume. 
The PrP-fw and PrP-rev primers, and the GAPDH-fw and GAPDH-rev primers were used 
to amplify the PrP and GAPDH nucleotide sequence, respectively. Xenopus POMC cDNA 
was ampliﬁ ed using forward primer POMC-fw (5’-AGGGAACGATGGAAGCAACA-3’) 
and reverse primer POMC-rev (5’-TGTCACCTGGAGCATTCTGAT-3’). PCR conditions 
consisted of a denaturing cycle at 95°C for 10 min, followed by 40 ampliﬁ cation cycles 
consisting of 15 sec at 95°C and 1 min at 60°C. For each reaction, the cycle threshold 
(Ct) was determined, i.e. the cycle number at which ﬂ uorescence was detected above an 
arbitrary threshold (0.5). At this threshold, Ct values are within the exponential phase of the 
ampliﬁ cation. Ct values for PrP and POMC mRNAs in lobes from black- and white-adapted 
animals were normalized to that of the internal standard (GAPDH) mRNA.
cDNA cloning of Xenopus PrP and microinjections of Xenopus PrP mRNA
The open-reading frame of Xenopus PrP (+69 to +648; not including the signal sequence SS) 
and its GPI-anchor (+540 to +648) were PCR-ampliﬁ ed using primers based on the Xenopus 
PrP coding sequence (5’-XPrP(ΔSS)-EcoRI, 5’-GGGGGAATTCAAGAAGAGCGGTGGT
GGGAA-3’ and 5’-XPrP(GPI)-EcoRI, 5’-GGGGGAATTCATTCGCGAGATGTGCATCA
C-3’ as the 5’ primer for Xenopus PrP and its GPI-anchor sequence, respectively, and 3’-
XPrP-XbaI, 5’-GGGGTCTAGATCACTCTATCACAAAGTAAACAAAGAGAGT-3’ as the 
3’ primer for the ampliﬁ cation of both Xenopus PrP and its GPI-anchor sequence) resulting 
in a 579-bp and a 128-bp PCR product, respectively [7]. The PCR products were digested 
with EcoRI and XbaI, and cloned in-frame into the pPOMC-GFP vector (in which the signal 
sequence of Xenopus Ac45 was fused to the N-terminus of the green ﬂ uorescent protein GFP 
lacking its starting methionine) generating the pPOMC-GFP-PrP and pPOMC-GFP-GPI 
fusion constructs. The pPOMC-GFP-PrP and pPOMC-GFP-GPI constructs were linearized 
with NotI and transcribed with the mMESSAGE mMACHINE SP6 Kit (Ambion, Austin, 
TX). One ng of GFP-PrP or GFP-GPI mRNA in 7 nl 0.1x MR (10 mM NaCl, 0.18 mM 
KCl, 0.1 mM MgCl2, 0.2 mM CaCl2, and 0.5 mM Hepes; pH 7.6) was microinjected into the 
animal pole of undivided fertilized Xenopus eggs. Speciﬁ city of the microinjection procedure 
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was checked by omission of the mRNA in the microinjection volume. The injected embryos 
were screened for GFP ﬂ uorescence using a Leica MZ FLIII ﬂ uorescent stereomicroscope 
and photographs were taken with a Leica DC200 color camera using the Leica DCviewer 
software.
Statistics
Data are presented as means ± SEM; three independent real-time quantitative RT-PCR 
experiments were performed on three independently isolated RNAs (n = 3). Statistical 
evaluation was performed using an unpaired Student’s t-test.
Results and discussion
Temporal and spatial distribution of PrP mRNA in Xenopus
We analyzed the temporal expression proﬁ le of Xenopus PrP transcripts by RT-PCR, using 
GAPDH as internal standard, and ensured that the measurements were performed in the 
exponential phase of PCR by determining the number of PCR cycles necessary for a quantitative 
ampliﬁ cation. Xenopus PrP mRNA was maternally expressed and zygotic expression was 
detected at a low level from stage 1 onwards and markedly increased up to stage 13 after 
which the level of expression remained stable during further development (Fig. 1).
Figure 1. Temporal expression pattern of PrP during Xenopus development. Total RNA was extracted 
from embryos at the indicated developmental stages and used for RT-PCR analysis (staging according 
to Nieuwkoop and Faber [11]). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
a control for the amount of input RNA. The generated PCR products were 225- and 230-bp in size 
for PrP and GAPDH, respectively. Negative controls without reverse transcriptase (not shown) or 
without cDNA for each primer pair used (H2O) showed no contamination of genomic DNA for all 
developmental stages.
 We next investigated the tissue distribution of PrP mRNA in adult Xenopus. RT-PCR revealed 
that PrP mRNA was expressed in every tissue examined, but most abundantly in the central 
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nervous system (brain and pituitary) and testis (Fig. 2). This expression pattern is in line with 
that found in mammalian tissues, including human and mouse, in which PrP is also expressed 
mainly in the central nervous system [12-15].
Figure 2. PrP mRNA expression in various tissues of adult Xenopus. Total RNA was extracted from the 
indicated tissues including the neurointermediate lobe (NIL) and the anterior lobe (AL) of the pituitary 
of black-adapted (B) and white-adapted (W) animals, and used for RT-PCR analysis. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as a control for the amount of input RNA. The 
generated PCR products were 225- and 230-bp in size for PrP and GAPDH, respectively. Negative 
controls without reverse transcriptase (not shown) or without cDNA for each primer pair used (H2O) 
showed no contamination of genomic DNA for all developmental stages.
Microinjection of Xenopus PrP mRNA into in vitro fertilized Xenopus eggs
To investigate the function of PrPC in Xenopus development, we microinjected mRNA 
encoding Xenopus PrP that was fused to the C-terminus of GFP (GFP-PrP) into the animal 
pole of undivided fertilized Xenopus eggs. In parallel, we injected 0.1x MR (not shown) 
and control mRNA encoding GFP-GPI (in which the GPI-anchor signal sequence of PrP 
was fused to the C-terminus of GFP). Expression of the GFP-PrP (Fig. 3A-F) and GFP-
GPI (Fig. 3G-L) fusion proteins was followed in time under a ﬂ uorescence microscope. For 
both GFP-PrP- and GFP-GPI-microinjected embryos, GFP ﬂ uorescence and thus fusion 
protein expression (Fig. 3M) was detected already at stage 9 and eventually diminished after 
reaching the tadpole stage (staging according to Nieuwkoop and Faber [11]). No phenotype 
was observed and the microinjected embryos developed normally.
PrP mRNA expression in the pituitary of black- and white-adapted Xenopus
The Xenopus pituitary consists of the NIL and the AL. The melanotrope cells of the NIL 
constitute a homogeneous population of strictly regulated neuroendocrine secretory cells that 
are involved in the process of background adaptation [10]. POMC is the major cargo protein in 
the melanotropes and during adaptation to a black background the amount of POMC mRNA is 
highly induced, and cell activity and cell size increase enormously (reviewed by Roubos [16]). 
The AL of the pituitary of Xenopus consists of corticotrope cells and its activity is not affected 
by background adaptation.
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Figure 3. Expression of GFP-PrPC and GFP-GPI fusion proteins in microinjected Xenopus embryos. 
In vitro synthesized GFP-PrP or GFP-GPI mRNA (1 ng) was microinjected into the animal pole of 
undivided fertilized Xenopus eggs. Expression of the GFP-PrPC (A-F) and GFP-GPI (G-L) fusion 
proteins was followed in time under a ﬂ uorescence microscope. Arrows indicate the sites of fusion 
protein expression.  (A, G) stage 9, (B, H) stage 12, (C, I) stage 14, (D, J) stage 22, (E, K) stage 26, 
and (F, L) stage 45  (staging according to Nieuwkoop and Faber [11]). Bar equals 0.4 mm. (M) Western 
blot analysis of stage-9, -12 and -45 Xenopus embryos microinjected with 1 ng GFP-PrP mRNA, 1 ng 
GFP-GPI mRNA or 0.1x MR; an anti-GFP antibody (α-GFP) was used.
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To investigate whether PrP was also upregulated in the NIL of black-adapted Xenopus, 
we examined PrP mRNA expression in the NIL and the AL of the pituitary of black- and 
white-adapted animals by real-time quantitative RT-PCR (Fig. 4). PrP mRNA was detected 
in both lobes of the pituitary. As expected, the levels of PrP mRNA expression were not 
signiﬁ cantly different in the ALs of black- and white adapted animals. Remarkably, PrP 
mRNA expression was also similar in the NILs of black- and white adapted animals (Fig. 
4A). In contrast, POMC mRNA levels showed an ∼10-fold increase in the NIL of black-
adapted animals, while its mRNA expression in the AL showed no signiﬁ cant differences 
(Fig. 4B). Moreover, it has been reported previously that mRNA levels of Ac45, prohormone 
convertase PC2, carboxypeptidase H [17], amyloid-β precursor protein APP [18], p24 
proteins [19], secretogranin II and III [20], and neuroserpin [21] are increased 3- to 10-fold 
in the biosynthetically active Xenopus melanotrope cells.
Figure 4. PrP mRNA expression in the neurointermediate and anterior pituitary of black- and white-
adapted Xenopus. PrP (A) and POMC (B) mRNA expression levels in the neurointermediate lobe (NIL) 
and the anterior lobe (AL) of the pituitary of black-adapted (B; black bars) Xenopus compared with 
those of white-adapted (W; white bars) animals were determined by real-time quantitative RT-PCR. 
All values were normalized to GAPDH mRNA levels and are expressed as means ± SEM (n = 3). A 
signiﬁ cant difference is indicated by *** (P < 0.001).
Taken together, the results presented here show that Xenopus PrP mRNA is expressed 
maternally and throughout whole embryonic development. In addition, like in mammals, 
Xenopus PrP mRNA is expressed predominantly in neuronal tissues, including the 
pituitary. Overexpression of PrP mRNA did not result in a visible phenotype during 
Xenopus development. Of special interest was the ﬁ nding that PrP mRNA expression is 
not induced in the biosynthetically active melanotrope cells from black-adapted Xenopus 
compared with the inactive cells of white-adapted animals, indicating that the function of 
PrP is not directly coupled to the POMC biosynthetic machinery in the melanotrope cells.
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Abstract
The cellular form of prion protein (PrPC) is anchored to the plasma membrane of the cell and 
expressed in most tissues, but predominantly in the brain, including in the pituitary gland. 
Thus far, the biosynthesis of PrPC has been studied only in cultured (transfected) tumor cell 
lines and not in primary cells. Here, we investigated the intracellular fate of PrPC in vivo by 
using the neuroendocrine intermediate pituitary melanotrope cells of the South-African claw-
toed frog Xenopus laevis as a model system. These cells are involved in background adaptation 
of the animal and produce high levels of its major secretory cargo proopiomelanocortin 
(POMC) when the animal is black adapted. The technique of stable Xenopus transgenesis 
in combination with the POMC gene promoter was employed as a tool to express Xenopus 
PrPC amino-terminally tagged with the green ﬂ uorescent protein (GFP-PrPC) speciﬁ cally in 
the melanotrope cells. The GFP-PrPC fusion protein was expressed from stage-25 tadpoles 
onwards to juvenile frogs, the expression was induced on a black background and the fusion 
protein was subcellularly located mainly in the Golgi apparatus and at the plasma membrane. 
Pulse-chase metabolic cell labeling studies revealed that GFP-PrPC was initially synthesized 
as a 45-kDa protein that was subsequently stepwise glycosylated to 48-, 51-, and eventually 
55-kDa forms. Furthermore, we revealed that the mature 55-kDa GFP-PrPC protein was 
sulfated, anchored to the plasma membrane and cleaved to a 33-kDa product. Despite the 
high levels of transgene expression, the subcellular structures as well as POMC synthesis 
and processing, and the secretion of POMC-derived products remained unaffected in the 
transgenic melanotrope cells. Hence, we studied PrPC in a neuroendocrine cell and in a well-
deﬁ ned physiological context.
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Introduction
Transmissible spongiform encephalopathies (TSEs or prion diseases) form a biologically 
unique group of infectious fatal neurodegenerative disorders, which are caused by changes 
in the three-dimensional conformation of the normal cellular prion protein (PrPC) leading to 
the formation of the abnormal, protease-resistant, disease-associated prion protein (PrPSc) 
[1]. Mature PrPC is a glycosylphosphatidylinositol (GPI)-anchored sialoglycoprotein, which 
is expressed in nearly all tissues, but highest levels are found in the central nervous system, 
including the pituitary gland [2-5]. Subcellular localization studies with cultured cells 
transfected with PrPC fused to the reported green ﬂ uorescent protein (GFP) have revealed 
that PrPC is localized in the Golgi apparatus and at the plasma membrane [6-10]. A similar 
subcellular localization has been found in neurons of mice transgenic for GFP-PrPC [11]. 
PrPC is synthesized in the rough endoplasmic reticulum (ER) and transits the Golgi on its 
way to the cell surface. Biosynthetic studies with cell lines, cultured neurons and hamster 
brain tissue have revealed the turnover of PrPC and shown that PrPC is subjected to a number 
of post-translational modiﬁ cations, including GPI-anchoring, disulﬁ de bond formation, 
and N-linked high-mannose type oligosaccharide attachments with subsequent complex 
glycosylation [12-16]. Having reached the cell surface, PrPC undergoes post-translational 
proteolytic cleavage [15,17-22]. 
Since most of the above-mentioned studies on PrPC have been performed in in vitro systems, 
we decided to apply a more in vivo approach with the intermediate pituitary melanotrope 
cells of the South-African claw-toed frog Xenopus laevis. Depending on the color of the 
background of the animal (black or white), these cells are differentially innervated by neuronal 
cells of hypothalamic origin (e.g. strong inhibitory synapses are formed in white animals). 
The Xenopus melanotrope cells constitute a homogeneous population of strictly regulated 
neuroendocrine secretory cells. In these cells, the prohormone proopiomelanocortin (POMC) 
is processed to a number of bioactive peptides, including α-melanophore-stimulating 
hormone (α-MSH). Once released into the blood, α-MSH mediates the process of background 
adaptation by causing dispersion of melanin pigment granules in skin melanophores resulting 
in darkening of the skin [23]. POMC is the major cargo protein in this cell type and during 
adaptation to a black background the amount of POMC mRNA is induced 30-fold, and cell 
activity and cell size increase enormously (reviewed by Roubos [24]). Placing the amphibian 
on a white or black background thus allows physiological manipulation of the biosynthetic 
and secretory activity of the melanotrope cell.
In this study, we combined the unique properties of the melanotrope cell with the technique 
of stable Xenopus transgenesis [25,26] to drive transgene expression of PrPC in a cell-speciﬁ c 
manner. A DNA construct was made that encodes Xenopus PrP amino-terminally fused to GFP 
and under the control of a Xenopus POMC gene A promoter fragment directing expression 
of the fusion protein speciﬁ cally to the Xenopus melanotrope cells, leaving the integrity of 
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the regulation by the hypothalamic neurons intact. We studied for the ﬁ rst time in an in vivo 
situation the biosynthesis and fate of PrPC in the secretory pathway.
Experimental procedures
Animals
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the Radboud University Nijmegen (Nijmegen, The Netherlands). For the 
transgenesis experiments, female Xenopus were directly obtained from South-Africa (Xenopus 
Express, Cape Town, South-Africa). Animals were adapted to a black or white background 
under constant illumination at 28°C for at least three weeks. All animal experiments were 
carried out in accordance with the European Communities Council Directive 86/609/EEC for 
animal welfare, and permit TRC 99/15072 to generate and house transgenic Xenopus.
Antibodies
A rabbit polyclonal anti-Xenopus PrP antibody (M55) was raised against the synthetic 
peptide NRVYRPMYRGEEY (residues 127-139). The oligopeptide was conjugated to 
keyhole limpet hemocyanin for immunization. A second rabbit polyclonal anti-Xenopus PrP 
antibody (M56) was raised against a recombinant fusion protein that constituted the carboxy-
terminal part of Xenopus PrP fused to glutathione S-transferase (GST). For this purpose, 
we cloned a PCR-ampliﬁ ed fragment, encoding amino acids 93-194 of Xenopus PrP, in the 
expression vector pGEX-2T (Qiagen, Hilden, Germany). Next, recombinant GST-PrP fusion 
protein was produced in Escherichia coli, isolated with glutathione sepharose 4B (Amersham 
Biosciences, Piscataway, NJ), and used for immunization. A further approach to obtain an 
anti-Xenopus PrP antibody concerned phage display [27] in combination with the Xenopus 
PrP peptide or the recombinant Xenopus GST-PrP fusion protein, but this approach was 
unsuccessful. Monoclonal anti-human PrP antibodies 2-40 and 3-11 were kindly provided 
by Dr. B. Solomon [28], monoclonal anti-mouse PrP antibody 8H4 was a kind gift from Dr. 
M.-S. Sy [29], and rabbit polyclonal anti-human PrP antibody Sal1 was kindly provided by 
Dr. T. Sklaviadis [30]. The rabbit polyclonal antibody raised against the C-terminal region of 
Xenopus p24δ1/2 (anti-1262CH) has been described previously [31,32]. A polyclonal antiserum 
against GFP was kindly provided by Dr. B. Wieringa [33], against Xenopus POMC (ST62, 
recognizing only the precursor isoform) by Dr. S. Tanaka (Shizuoka University, Hamamatsu, 
Japan; [34]), against recombinant mature human PC2 by Dr. W.J.M. van de Ven (University 
of Leuven, Belgium; [35]), and against the protein-folding chaperones calnexin and binding 
protein BiP by Dr. K. Geering (University of Lausanne, Switzerland; [36]). Monoclonal anti-
tubulin antibody E7 has been described previously [37].
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Generation of the DNA construct encoding PrP fused amino-terminally to GFP
For the preparation of PrP cDNA, a DNA fragment containing the Xenopus PrP open-reading 
frame (+69 to +648; [38]) was ampliﬁ ed by PCR using primers containing EcoRI and XbaI 
restriction sites at their 5’ ends (5’-XPrP(ΔSS)-EcoRI: 5’-GGGGGAATTCAAGAAGAGCG
GTGGTGGGAA-3’ and 3’-XPrP(ΔSS)-XbaI: 5’-GGGGTCTAGATCACTCTATCACAAA
GTAAACAAAGAGAGT-3’, respectively) resulting in a 599-bp PCR product. Inserting the 
EcoRI×XbaI-digested PCR fragment behind the GFP sequence in the pPOMC-GFP vector 
(containing a 529-bp Xenopus POMC gene A promoter fragment (pPOMC), a signal sequence 
of the Xenopus secretory pathway component Ac45 [39], a GFP sequence, and a CMV 
polyA signal) generated the pPOMC-GFP-PrP fusion construct; pPOMC directs transgene 
expression speciﬁ cally to the melanotrope cells of the Xenopus intermediate pituitary [40].
DNA sequence analysis
Constructs were veriﬁ ed by cycle DNA sequencing using the Big Dye Ready Reaction system 
(Applied Biosystems, Foster City, CA) and the primer (5’-AGTCCGCCCTGAGCAAAGAC-
3’) that allowed sequence analysis from the GFP sequence into the PrP DNA sequence. DNA 
sequencing was performed with single-stranded DNA by automatic sequencing with the 
use of the ABI-PRISM DNA sequencing kit and the ABI-PRISM310 automatic sequencer 
(Applied Biosystems).
Preparation of Xenopus unfertilized eggs
To harvest unfertilized eggs, mature female Xenopus laevis were injected with 375 iU human 
gonadotropic hormone (Pregnyl; Organon, Oss, The Netherlands) into their dorsal lymphatic 
cavities. Eggs were collected from the females 18 hr following injection, dejellied in 2% 
cysteine/1×MMR (100 mM NaCl, 1 mM KCl, 0.5 mM MgCl2, 1.5 mM CaCl2, and 5 mM 
Hepes; pH 8.2), extensively washed with 1×MMR, put in 0.4×MMR/6% Ficoll-400 with 50 
μg/ml gentamicin, and immediately used for transgenesis.
Generation of Xenopus embryos transgenic for GFP-PrPC
A 2301-bp SalI/BssHII fragment, containing the SV40 polyA signal behind the pPOMC-GFP-
PrP fragment, was puriﬁ ed using a Qiaex II Gel Extraction Kit (Qiagen). The DNA fragment 
(~50 ng/μl) was mixed with sperm nuclei (2.5×105 in 2.5 μl), incubated for 15 min at room 
temperature (RT), and diluted to 500 μl. About 10 nl was injected per egg. Sperm nuclei were 
prepared as described previously [25,40]. Normally cleaving embryos were selected at the 
4-cell stage and cultured in 0.1×MMR/6% Ficoll-400 with 50 μg/ml gentamicin at 18°C until 
gastrulation (stage 12) was reached. At that time point, embryo culturing was continued in 
0.1×MMR with 50 μg/μl gentamicin at 22°C. From stage 45 onwards, tadpoles were raised 
in tap water at 22°C. The presence of GFP ﬂ uorescence was examined in living embryos 
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anaesthetized with 0.25 mg/ml MS222 (3-aminobenzoic acid ethyl ester; Sigma, St. Louis, 
MO) using a Leica MZ FLIII ﬂ uorescent stereomicroscope and photographs were taken 
with a Leica DC200 color camera using the Leica DCviewer software. Staging of Xenopus 
embryos was carried out according to Nieuwkoop and Faber [41].
In vitro fertilization of wild-type Xenopus eggs with transgenic sperm cells
For in vitro fertilization, the testes of male transgenic Xenopus frogs were isolated and gently 
pulled apart prior to use. Pieces of testes were rubbed against unfertilized eggs harvested 
from wild-type Xenopus females. After 10 min, the eggs were incubated in 0.1×MMR. 
The fertilized eggs were selected in their 4-cell stage and screened for speciﬁ c pituitary 
ﬂ uorescence during early development (∼stage 40). Remaining pieces of testes were used 
to isolate sperm nuclei that were stored at –80°C for future injection experiments to obtain 
additional transgenic animals.
Isolation of melanotrope cells
For the isolation of melanotrope cells, Xenopus were anaesthetized by immersion in tap 
water containing 1 g/l MS-222 and 1.5 g/l NaHCO3, and blood was removed by perfusing 
the animals with 0.025 mg/ml MS-222 containing 95%O2/5%CO2 gassed Ringer’s medium 
(112 mM NaCl, 15 mM Hepes, 2 mM KCl, 2 mM CaCl2, 2 mg/ml D-glucose, 0.3 mg/ml 
BSA; pH 7.4). Neurointermediate lobes (NILs) were dissected and washed in Xenopus L15 
(XL15) medium containing 67% Leibowitz medium (L15, Gibco BRL, Paisley, UK), 0.1% 
kanamycin (Gibco BRL) and 0.1% antibiotic/antimyotic solution (Gibco BRL) with 0.08 mg/
ml CaCl2 and 0.2 mg/ml glucose (pH 7.4). NILs were incubated in Ringer’s medium without 
CaCl2 containing 0.25% trypsin (Gibco BRL) for 45 min. The lobes were gently triturated 
and isolated melanotrope cells were ﬁ ltered (58 μm mesh) in XL15 medium with 10% fetal 
calf serum (Gibco BRL) to separate them from tissue fragments. After centrifugation at 50 g 
for 10 min at RT, the cell pellet was resuspended into XL15 and plated on cover slips coated 
with 0.5% poly-L-lysine (Sigma). Cells were allowed to attach to the cover slip for three days 
in an incubator at 95%O2/5%CO2 atmosphere at 21°C.
Microscopy
For confocal microscopy, Xenopus brains with the pituitaries attached were dissected and 
ﬁ xed in 4% paraformaldehyde in phosphate-buffered saline. After cryoprotection in 10% 
sucrose-phosphate-buffered saline, sagittal 20-μm cryosections were mounted on poly-L-
lysine-coated slides, dried for 2 hr at 45°C, and studied with an MRC 1024 confocal laser 
scanning microscope (Bio-Rad, Hercules, CA). To examine direct ﬂ uorescence as a result of 
GFP fusion protein expression, isolated melanotrope cells and cryosections of the pituitary 
were directly viewed under a Leica DM RA ﬂ uorescence microscope and photographs were 
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taken with a Cohu high-performance charge-coupled device camera using the Leica Q Fluoro 
software. Immunohistochemistry for POMC was performed as described previously [40].
Western blot analysis
For Western blot analysis, Xenopus NILs were homogenized in TTD buffer (50 mM 
Hepes, 140 mM NaCl, 0.1% Triton X-100, 1% Tween-20, 0.1% deoxycholate, 1 mM 
EDTA, 1 mM PMSF, and 0.1 mg/ml soybean trypsin inhibitor; pH 7.3). After the lysates 
were cleared by centrifugation at 18000 g at 4°C, they were denatured in Laemmli sample 
buffer at 100°C for 5 min, separated on 12.5% SDS-PAGE, and transferred to nitrocellulose 
(Protran; Schleicher & Schuell, Keene, NH) or PVDF (Hybond-P; Amersham Biosciences) 
membranes. For extraction under native conditions, NILs were ﬁ rst homogenized in 250 
mM sucrose, 20 mM Hepes (pH 7.4), 1 mM PMSF, and 0.1 mg/ml soybean trypsin inhibitor 
followed by centrifugation at 1000 g for 10 min at 4°C yielding a post-nuclear supernatant. 
This supernatant was further extracted using an equal amount of extraction buffer (100 mM 
NaCl, 0.2% Triton X-100, 0.2% Tween-20, 0.1% deoxycholate, and 10 mM EDTA). After the 
lysates were cleared by centrifugation at 18000 g for 7 min at 4°C, they were separated on 
8% SDS-PAGE (0.02% SDS) using 2×Tris/glycine sample buffer. Before protein transfer to 
PVDF membranes, the BSA molecular weight marker was cut off and stained with Coomassie 
brilliant blue. Following blocking in 5% skimmed milk/1% Tween-20/PBS for one hr, blots 
were incubated with an anti-GFP (1:5000), ST62 (1:10000), anti-PC2 (1:5000), anti-calnexin 
(1:10000), anti-BiP (1:5000), 1262CH (1:2500), or anti-tubulin (1:500) antibody overnight at 
4°C. After extensively washing with 1% skimmed milk/1% Tween-20/PBS for 30 min at RT, 
blots were incubated with a peroxidase conjugated secondary antibody (1:5000) for 45 min at 
RT, and subsequently thoroughly washed with 1% skimmed milk/1% Tween-20/PBS for 30 
min at RT. Proteins on Western blots were immunodetected using Lumi-LightPLUS substrate 
(Roche Diagnostics, Mannheim, Germany) and subsequently exposed to X-ray ﬁ lm (Kodak, 
Rochester, NY). Quantiﬁ cation was performed using a BioChemi imaging system and signals 
were analyzed using Labworks 4.0 software (UVP BioImaging systems, Cambridge, UK).
Solubility assay
For PrPC solubility analysis, Xenopus NILs were homogenized in 150 mM NaCl, 5 mM 
DTT, 5 mM EDTA, 25 mM Tris-HCl (pH 7.4), 1 mM PMSF and 0.1 mg/ml soybean trypsin 
inhibitor, and the lysate was centrifuged at 1000 g for 10 min at 4 °C to yield a post-nuclear 
supernatant (PNS) that was adjusted to 1% TritonX-100 and incubated on ice for 30 min. 
The PNS was centrifuged at 100000 g for 1 hr at 4°C in a Beckman SW60Ti rotor, and 
the resulting supernatant (soluble fraction) and the resuspended pellet (insoluble fraction) 
were denatured in Laemmli sample buffer at 100°C for 5 min, separated by SDS-PAGE and 
analyzed by Western blotting using an anti-GFP antibody.
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N-glycosidase F treatment
For protein deglycosylation, N-glycosidase F (which cleaves N-linked sugar chains from 
proteins) was used. The Xenopus NIL lysates were boiled for 10 min in 6 mM Hepes (pH 7.4) 
containing 0.06% SDS and subsequently supplemented with 0.5% NP40, 10 μg/ml soybean 
trypsin inhibitor, 0.1 μM PMSF, and incubated with or without 40 mU/μl N-glycosidase F 
(Roche Diagnostics) for 6 hr at 37°C. The digestion was stopped by boiling for 5 min and 
subsequently used for Western blot and immunoprecipitation analysis.
Metabolic cell labeling and immunoprecipitation analysis
For metabolic cell labeling, NILs of black- or white-adapted wild-type and transgenic 
Xenopus were rapidly dissected and preincubated in Ringer’s medium for 15 min at 22°C. 
Radioactive labeling of newly synthesized proteins was performed by incubating the NILs 
in Ringer’s medium containing 5 mCi/ml [35S]-Met/Cys (Tran35S-label, MP Biomedicals, 
Irvine, CA) or 6.67 mCi/ml Na2[
35S]SO4 (MP Biomedicals) for 30 min at 22°C, rinsed, and 
chased with 0.5 mM L-methionine or 1 mM Na2SO4, respectively, in Ringer’s medium for 
the indicated time periods. After the chase, NILs were homogenized on ice in TTD buffer 
and the lysates were cleared by centrifugation at 18000 g for 7 min at 4°C. Parts of the lysates 
and incubation media were analyzed directly on SDS-PAGE, while the remainder was used 
for immunoprecipitation and Western blot analysis. For immunoprecipitation analysis, NIL 
lysates were diluted with TTD buffer to 1 ml, and supplemented with SDS (ﬁ nal concentration 
of 0.08%) and an anti-GFP antibody (1:500). Precipitation was performed overnight at 4°C 
while rotating the samples. Immune complexes were precipitated with protein A-sepharose 
(Amersham Biosciences) for 6 hr at 4°C while rotating the samples and resolved by SDS-
PAGE. Radiolabeled proteins were detected using autoradiography at -70°C.
Endoglycosidase H treatment
To remove high-mannose glycans from proteins, endo H was used. Xenopus NILs were pulse 
labeled with [35S]-Met/Cys for 4 hr and homogenized on ice in TTD buffer. The lysates were 
then boiled for 10 min in 100 mM NaAc/HAc (pH 5.5) containing 0.05% SDS, 0.1% 2-
mercaptoethanol and 1 mM PMSF, and subsequently supplemented with 0.25% Triton X-100 
and incubated with or without 0.1 mU/μl endo H (Roche Diagnostics) for 6 hr at 37°C. The 
digestions were stopped by boiling for 5 min, and the boiled lysates were immunoprecipitated 
with an anti-GFP antibody and analyzed by SDS-PAGE on a 10% gel. Radiolabeled proteins 
were visualized by autoradiography at -70°C.
Phosphatidylinositol-speciﬁ c phospholipase C treatment
To examine if newly synthesized Xenopus NIL proteins contained a GPI-anchor, NILs were 
pulse labeled with [35S]-Met/Cys for 4 hr and lysed in TTD buffer supplemented with 50 mM 
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Tris-HCl (pH 7.5), 0.1% SDS, 1% NP-40 and 0.1 mM PMSF, and the lysate was incubated 
with (+) or without (-) 0.6 mU/μl PIPLC from Bacillus cereus (Sigma) for 2 hr at 30°C. PIPLC-
activity was stopped by boiling for 5 min, and the boiled lysates were immunoprecipitated 
with an anti-GFP antibody and analyzed by SDS-PAGE on a 10% gel. Radiolabeled proteins 
were visualized by autoradiography at -70°C. To examine proteins that are GPI-anchored to 
the outside of the plasma membrane, 4-hr-pulse-labeled NILs were incubated in the presence 
(+) or absence (-) of 0.6 mU/μl PIPLC in Ringer’s medium for 2 hr at 30°C. Following the 
incubation, the NILs were homogenized on ice in TTD buffer, and the lysates and media 
were cleared by centrifugation at 18000 g for 7 min at 4°C. PIPLC-activity was stopped by 
boiling, and the boiled lysates and media were used for immunoprecipitation, SDS-PAGE 
and autoradiography as described above.
Statistics
Data are presented as means ± SEM (n = 3). Statistical evaluation was performed using an 
unpaired Student’s t-test.
Results
Generation of Xenopus transgenic for the GFP-PrPC fusion protein
To study PrPC, we generated Xenopus transgenic for Xenopus PrPC fused to the C-terminus of 
GFP (GFP-PrPC). For this purpose, we ﬁ rst made a DNA construct (pPOMC-GFP-PrP, Fig. 
1A) containing the sequence encoding GFP-PrPC downstream of a 529-bp Xenopus POMC 
gene A promoter fragment, which directs transgene expression speciﬁ cally to the melanotrope 
cells of the Xenopus intermediate pituitary [40]. The linearized pPOMC-GFP-PrP DNA 
was mixed with Xenopus sperm nuclei and the mixture was microinjected into unfertilized 
Xenopus eggs. The different levels of GFP-PrPC expression among the various F0 transgenic 
animals could be readily and directly established by visual inspection of the living Xenopus 
embryos under a ﬂ uorescence microscope (Fig. 1B). The expression of the GFP-PrPC fusion 
protein was restricted to the intermediate lobe (IL; neuroendocrine melanotrope cells) of the 
pituitary, while the pituitary anterior lobe (AL), in which the POMC-producing corticotrope 
cells are located, and other brain structures did not show any ﬂ uorescence (Fig. 1C). An F1 
offspring was generated by in vitro fertilization of eggs harvested from wild-type Xenopus 
females with sperm isolated from the testis of a male Xenopus frog transgenic for pPOMC-
GFP-PrP. We selected a transgenic F1 line (#102) of which the offspring showed relatively 
high GFP-PrPC transgene expression and raised these embryos for further analysis.
Localization of the GFP-PrPC fusion protein in Xenopus intermediate pituitary cells
In the Xenopus intermediate pituitary, melanotrope cells produce vast amounts of POMC. 
Confocal microscopy using an anti-POMC antibody recognizing only intact POMC in 
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combination with direct GFP ﬂ uorescence showed that the GFP-PrPC fusion protein was 
expressed in the melanotrope cells of the Xenopus intermediate pituitary (Fig. 2A). We 
next examined the subcellular localization of the GFP-PrPC fusion protein in the Xenopus 
melanotrope cells. Confocal microscopy analyses were performed on whole intermediate 
pituitary tissue and individual melanotrope cells of black-adapted animals transgenic for 
GFP-PrPC. The intermediate pituitary of a black-adapted transgenic animal showed strong 
GFP-ﬂ uorescence and in the melanotrope cells the fusion protein was located in the ER and 
Golgi areas, and at the plasma membrane (Fig. 2B).
Steady-state levels of the GFP-PrPC fusion protein, POMC, and p24δ1/2 in the pituitary cells 
of black- and white-adapted Xenopus
From the Xenopus pituitary (consisting of the pars nervosa, IL, and AL), the AL can be 
dissected, but the pars nervosa (containing nerve terminals of hypothalamic origin) is 
intimately associated with the IL. To examine steady-state levels of GFP-PrPC protein 
expression, the NIL was dissected from frogs transgenic for GFP-PrPC and non-transgenic 
animals. Western blot analysis of NIL lysates of transgenic black-adapted animals revealed 
that the majority of the GFP-PrPC fusion protein migrated as an ∼55-kDa protein and a small 
amount as an ∼51-kDa product (Fig. 3A). We have not been able to detect endogenous 
Xenopus PrPC (extensive attempts to study the endogenous protein with a series of antibodies 
directed against Xenopus or mammalian PrPC have not been successful). In a solubility 
assay, following ultracentrifugation of a NIL lysate, the GFP-PrPC fusion protein was found 
predominantly in the soluble fraction (Fig. 3B). To test whether the steady-state 51- and 55-
kDa GFP-PrPC fusion proteins were N-glycosylated, NIL lysates were treated with peptide 
N-glycosidase F (PNgase F) that removes N-linked oligosaccharides. After treatment, the 
GFP-PrPC products migrated as an ∼47-kDa protein and thus, like endogenous hamster PrPC 
[12], both 51- and 55-kDa GFP-PrPC transgene products were N-glycosylated (Fig. 3C). 
Extraction and separation of the NIL proteins under native conditions showed that the GFP-
PrPC fusion protein was mainly expressed as a monomer (>90%) and only a minor fraction 
appeared as a dimer (Fig. 3D). 
Adaptation of the transgenic frogs to a black or a white background resulted in high and low 
levels of ﬂ uorescence in the intermediate pituitary, respectively (Fig. 4A). In line with these 
data, Western blot analysis of NIL lysates of black- and white-adapted animals transgenic 
for GFP-PrPC showed that the levels of the fusion protein were reduced ∼3-fold in the white-
adapted animals (Fig. 4B, upper panel), suggesting that the level of GFP-PrPC transgene 
expression was dependent on the color of the background of the animal. The fusion protein 
was found only in the NIL and not in the AL of black- and white-adapted transgenic animals 
(Fig. 4B, upper panel), in line with the data obtained by direct ﬂ uorescence analysis and thus 
indicating that the expression of the transgene product is melanotrope cell speciﬁ c. 
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Figure 1. Intermediate pituitary-speciﬁ c ﬂ uorescence in Xenopus embryos transgenic for GFP-PrPC. 
(A) Schematic representation of the linear injection fragment pPOMC-GFP-PrP containing the Xenopus 
POMC gene A promoter fragment (pPOMC) and the GFP-PrP fusion protein-coding sequence, which 
was used to generate transgenic Xenopus; SS, signal sequence; GPI, glycosylphosphatidylinositol signal 
sequence. (B) Pituitary-speciﬁ c ﬂ uorescence in living Xenopus embryos (stage ~40) transgenic for 
the GFP-PrPC fusion protein. Arrows indicate the localization of the ﬂ uorescent intermediate pituitary 
expressing the fusion product; the positions of the eye (E), nose (N) and gut (G) are also indicated. Bars 
equal 0.5 mm. (C) Ventrocaudal view on the brain of a black-adapted 6-month-old frog transgenic for 
GFP-PrPC. The brain was lifted to reveal intense ﬂ uorescence in the intermediate lobe (IL), but not in 
the anterior lobe (AL) of the pituitary. Bar equals 0.4 mm.
Figure 2. Confocal microscopy on the intermediate pituitary and melanotrope cells transgenic for GFP-
PrPC from black-adapted Xenopus. (A) Sagittal brain-pituitary cryosections of Xenopus transgenic for 
GFP-PrPC showed direct GFP ﬂ uorescence in the intermediate pituitary melanotrope cells (middle 
panels) and were stained for POMC using an antibody recognizing the entire prohormone and a Texas-
Red conjugated second antibody (left panels). The panels on the right show the merged pictures of the 
direct GFP ﬂ uorescent signal and the signal for endogenous POMC. Upper bars equal 20 μm; lower 
bars equal 5 μm. (B) Confocal micrographs of whole intermediate pituitary tissue (left and middle 
panel) and individual melanotrope cells (right panels) of Xenopus transgenic for GFP-PrPC showing 
direct GFP ﬂ uorescence. GFP-PrPC was observed in structures that resemble the Golgi apparatus (G) 
and plasma membrane. Bars equal 20 μm (left panel); 5 μm (middle panel); and 250 nm (right panel).
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Figure 3. Steady-state levels of GFP-PrPC transgene expression speciﬁ c in intermediate pituitary cells 
from black-adapted Xenopus. (A) Western blot analysis of tissue lysates of neurointermediate lobes 
(NILs) from wild-type (wt) animals and animals transgenic for the GFP-PrPC fusion protein (tr) using 
an anti-GFP antibody (α-GFP). (B) Solubility assay. NILs from wt and tr animals were lysed in buffer 
containing 1% Triton X-100 and the PNS was centrifuged for 1 hr at 100000 g. The insoluble (P, 
pellet) and soluble (S) fractions were analyzed by Western blot analysis using an anti-GFP antibody. 
(C) Western blot analysis of NIL proteins from wt and tr animals using an anti-GFP antibody following 
treatment of the proteins either with (+) peptide N-glycosidase F (PNgase F) to remove N-linked 
oligosaccharides or without (-). The arrow indicates the position of the unglycosylated 47-kDa GFP-
PrPC fusion protein. (D) Western blot analysis of NIL proteins from wt and tr animals using an anti-GFP 
antibody and with the proteins extracted under native conditions and separated by SDS-PAGE on an 
8% gel (0.02% SDS). BSA molecular weight marker (BSA) shows monomer (67 kDa) and dimer (133 
kDa) forms under these conditions.
The steady-state levels of POMC and the putative ER-to-Golgi cargo receptor proteins p24δ2 
and p24δ1 were ∼18-, ∼8-, and ∼3-fold higher in black-adapted than in white-adapted animals, 
respectively (Fig. 4B, middle panels), suggesting that the expression of the GFP-PrPC fusion 
protein in the intermediate pituitary is coregulated with these proteins. The POMC and 
p24δ1/2 protein levels were similar in the ALs of black- and white adapted frogs (Fig. 4B, 
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middle panels). In conclusion, expression of the GFP-PrPC fusion protein was restricted to 
the intermediate pituitary melanotrope cells and its level depended on the background color 
of the animal.
Figure 4. Steady-state levels of GFP-PrPC, POMC, and p24δ1/2 expression in intermediate and anterior 
pituitary cells from black- and white-adapted Xenopus. (A) Fluorescence in the intermediate lobe of 
black-and white-adapted Xenopus transgenic (tr) for the GFP-PrPC fusion protein. Ventrocaudal view 
with the anterior part of the pituitary removed. Bar equals 0.5 mm. (B) Western blot analysis of lysates 
of NILs and anterior lobes (ALs) derived from black-adapted (BA) and white-adapted (WA) tr animals 
using anti-GFP, anti-POMC, anti-p24δ1/2, and anti-tubulin antibodies. Tubulin was used as a control for 
protein loading.
Biosynthesis of newly synthesized GFP-PrPC fusion protein in Xenopus intermediate pituitary 
cells
To investigate the biosynthesis of GFP-PrPC, we monitored the fate of the newly synthesized 
fusion protein in Xenopus NILs transgenic for GFP-PrPC by pulse-chase metabolic cell labeling 
and immunoprecipitation analysis. During the 30-min pulse, three GFP-PrPC products of ∼45, 
∼48, and ∼51 kDa were synthesized (Fig. 5A). Following subsequent chase incubations of 
90 and 180 min, these products were converted into a protein migrating at ∼55 kDa. The 
chase incubation medium contained a major GFP-PrPC cleavage product of ∼33 kDa and 
a number of minor immunoreactive products, probably representing intermediates in the 
proteolytic processing of the 55-kDa to the 33-kDa transgene product. To examine the size of 
the initial newly synthesized GFP-PrPC product, we next used a short (3-min) pulse period. 
This analysis revealed that the fusion protein was synthesized as the 45-kDa product that 
during the subsequent 10-min chase was converted to the 48- and 51-kDa forms (Fig. 5B). 
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Figure 5. Biosynthesis of the GFP-PrPC protein in the intermediate pituitary from black-adapted 
Xenopus. (A) Wild-type (wt) neurointermediate lobes (NILs) and NILs transgenic for GFP-PrPC (tr) 
were pulse labeled with [35S]-Met/Cys for 30 min (P30) and subsequently chase incubated for 0, 90 (C90) 
or 180 (C180) min. Newly synthesized proteins produced in the NILs and secreted into the medium (M) 
were analyzed. (B) NILs from wt and tr animals were pulsed for 3 min (P3) and subsequently chased 
for 0 or 10 (C10) min. (C) NILs from tr animals were pulse labeled for 30 min (P30) and chased for 0 
or 180 (C180) min, and subsequently the proteins were extracted and incubated in the presence (+) or 
absence (-) of peptide N-glycosidase F (PNgase F). (D) NILs from wt and tr animals were incubated in 
the presence of Na2[
35S]SO4 for 30 min (pulse) and chased for 180 min, and subsequently the proteins 
were extracted and incubated in the presence (+) or absence (-) of PNgase F. (E) NILs from tr animals 
were pulse labeled for 4 hr and subsequently the proteins were extracted and incubated in the presence 
(+) or absence (-) of endoglycosidase H (endo H). (F) NILs from tr animals were pulse labeled for 4 
hr, and either lysed and incubated in the presence (+) or absence (-) of phosphatidylinositol-speciﬁ c 
phospholipase C (PIPLC), or ﬁ rst incubated with (+) or without (-) PIPLC, and then the lobe extract (L) 
and the incubation medium (M) were analyzed. In all cases, newly synthesized proteins extracted from 
the lobes or secreted into the incubation medium were immunoprecipitated using an anti-GFP antibody, 
the immunoprecipitates were resolved by SDS-PAGE on a 15% (A, B, C, D) or 10% (E, F) gel and the 
radiolabeled proteins were visualized by autoradiography.
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Following a 30-min pulse and treatment with PNgase F, the majority of the newly synthesized 
GFP-PrPC fusion proteins migrated as a 45-kDa product (Fig. 5C), indicating that the 48- and 
51-kDa fusion proteins were mono- and di-N-glycosylated, respectively. After a 30-min pulse 
and 180-min chase, PNgase F-treatment of the newly synthesized fusion products resulted in 
a 47-kDa fusion protein (Fig. 5C). This ﬁ nding, together with the results of the Western blot 
analysis (Fig. 3B), suggests that during the chase period an additional, presently unknown, 
post-translational modiﬁ cation of the 55-kDa fusion protein had occurred. Sulfation may 
represent this relatively late modiﬁ cation event, since metabolic labeling of the transgenic 
NILs in the presence of Na2[
35S]SO4 followed by immunoprecipitation analysis of the sulfate-
labeled newly synthesized proteins revealed that the 55-kDa form of the GFP-PrPC fusion 
protein was sulfated. This post-translational modiﬁ cation can take place at carbohydrate site 
chains or speciﬁ c tyrosine residues [42,43] and we therefore used a PNgase F-treatment 
to show that the sulfation occurred on the Xenopus PrPC backbone and not on the sugar 
moiety (Fig. 5D). To further characterize the maturation of the glycosylated forms of PrPC 
observed in the pulse-chase studies, we treated radiolabeled newly synthesized NIL proteins 
with endoglycosidase H (endo H) to remove high-mannose glycans [44]. Endo H-treatment 
resulted in the conversion of the 51-kDa GFP-PrPC fusion protein to 45- and 48-kDa products 
(Fig. 5E), indicating that high-mannose glycans were attached to the 51-kDa product and 
that this product comprises an immature, core-glycosylated form of the GFP-PrPC protein 
that had not yet transited beyond the mid-Golgi. In contrast, the 55-kDa fusion protein was 
resistant to endo H-digestion (Fig. 5E) and thus represents a mature, complex-glycosylated 
form that had moved beyond the mid-Golgi to later compartments of the secretory pathway. 
To examine whether the GFP-PrPC fusion protein was anchored by a GPI moiety, we used 
phosphatidylinositol-speciﬁ c phospholipase C (PIPLC), an enzyme that has been shown to 
speciﬁ cally cleave phosphatidylinositol anchors from proteins [45]. Treatment of NIL lysates 
with PIPLC caused the 51- and 55-kDa fusion proteins to migrate as ~53- and ~57-kDa 
products, respectively, due to the loss of the diacylglycerol moiety [13] (Fig. 5F). To test 
whether GFP-PrPC was attached to the plasma membrane and which form of the fusion protein 
was attached, we treated intact transgenic NILs with PIPLC. The migration of the 51-kDa 
fusion protein was not changed, suggesting that the enzyme did not affect the intracellular 
fusion protein. In contrast, following PIPLC-treatment a portion of the 55-kDa fusion protein 
was released into the incubation medium and migrated as an ~57-kDa product, indicating 
that mature 55-kDa GFP-PrPC was anchored by a GPI moiety to the outside of the plasma 
membrane of the melanotrope cells (Fig. 5F).
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Figure 6. Biosynthesis and processing of newly synthesized POMC in wild-type intermediate 
pituitary cells and cells transgenic for GFP-PrPC from black-adapted Xenopus. (A) Wild-type (wt) 
neurointermediate lobes (NILs) and NILs transgenic for GFP-PrPC (tr) were pulse labeled with [35S]-
Met/Cys for 30 min. Newly synthesized proteins were extracted from the lobes, directly resolved by 
SDS-PAGE on 15% gels, and visualized by autoradiography. The experiments were performed in 
triplicate and a representative example is shown. (B) The amounts of newly synthesized 37-kDa POMC 
were quantiﬁ ed by densitometric scanning and are presented in arbitrary units (AU), relative to the 
amounts of newly synthesized actin. Shown are the means ± SEM (n = 3). (C) NILs from wt and tr 
animals were pulse labeled for 30 min and subsequently chased for 3 hr. Newly synthesized proteins 
extracted from the lobes (5%) or secreted into the incubation medium (20%) were resolved by SDS-
PAGE on 15% gels and visualized by autoradiography. (D) The amounts of newly synthesized 37-kDa 
POMC and the 18-kDa POMC-derived product were quantiﬁ ed by densitometric scanning and are 
presented in arbitrary units (AU), relative to the amounts of newly synthesized actin. Shown are the 
means ± SEM (n = 3).
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Biosynthesis and processing of newly synthesized POMC in Xenopus intermediate pituitary 
cells transgenic for the GFP-PrPC fusion protein
To examine the effect of the overexpressed Xenopus GFP-PrPC protein on the biosynthesis and 
processing of POMC as well as the secretion of the POMC-derived products, we performed 
pulse and pulse-chase analyses of newly synthesized proteins produced in the tissue and 
secreted into the incubation medium from NILs of Xenopus transgenic for GFP-PrPC and 
wild-type animals. Because besides the melanotrope cells, the Xenopus NIL consists of nerve 
terminals of hypothalamic origin that are biosynthetically inactive (the pars nervosa), the 
radiolabeled proteins are synthesized by the melanotropes. After a 30-min pulse labeling of 
wild-type and transgenic NILs, the 37-kDa POMC precursor protein was clearly the major 
newly synthesized protein (Fig. 6A). No signiﬁ cant difference between the levels of newly 
synthesized 37-kDa POMC were found in NILs transgenic for GFP-PrPC in comparison 
to wild-type NILs (Fig. 6B). During the following 3-hr chase incubation of wild-type and 
transgenic NILs, most of the 37-kDa POMC was processed to an 18-kDa POMC cleavage 
product which was subsequently secreted into the incubation medium (Fig. 6C). The 18-kDa 
product represents the N-terminal portion of 37-kDa POMC and is generated by the ﬁ rst 
endoproteolytic cleavage step during POMC processing [46]. The amounts of the 37-kDa 
POMC precursor and the 18-kDa POMC cleavage product did not signiﬁ cantly differ between 
wild-type and transgenic NILs (Fig. 6D). Together, these results indicate that the transgene 
expression of the GFP-PrPC fusion protein in the intermediate pituitary melanotrope cells 
had no effect on POMC biosynthesis and processing, and the release of the POMC-derived 
products.
Figure 7. Steady-state levels of a number of intermediate pituitary proteins from black-adapted Xenopus. 
Western blot analysis of lysates of neurointermediate lobes (NILs) derived from wild-type (wt) animals 
and animals transgenic for the GFP-PrPC fusion protein (tr) using anti-POMC, anti-PC2, anti-BiP, anti-
calnexin, anti-p24δ1/2, and anti-tubulin antibodies. Tubulin was used as a control for protein loading.
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Steady-state levels of POMC, its processing enzyme prohormone convertase PC2, and a 
number of secretory pathway components in Xenopus intermediate pituitary cells transgenic 
for the GFP-PrPC fusion protein
We then investigated whether the transgenic manipulation had affected the steady-state 
level of 37-kDa POMC in the melanotrope cells transgenic for GFP-PrPC. No differences in 
POMC levels were observed between wild-type and transgenic NILs (Fig. 7). Also, in the 
transgenic melanotrope cells the steady-state amounts of both the proenzyme and mature 
forms of the POMC cleavage enzyme PC2 (75-kDa proPC2 and 69-kDa PC2, respectively) 
were not affected when compared to those in the wild-type situation. In addition, the steady-
state levels of the protein-folding chaperones calnexin and BiP, and the p24δ1/2 proteins were 
unaffected in the transgenic melanotrope cells (Fig. 7).
Discussion
The aim of the present study was to investigate the intracellular fate of PrPC by examining 
for the ﬁ rst time its biosynthesis in the secretory pathway of neuroendocrine cells in 
vivo and the effect of the transgene expression of PrPC on prohormone biosynthesis and 
processing, and secretion of the prohormone-derived peptides. For several reasons, the 
Xenopus neurointermediate pituitary melanotrope cells represent an attractive cell model 
system. First, the Xenopus melanotrope cells constitute a homogeneous population of strictly 
regulated neuroendocrine secretory cells and their biosynthetic and secretory activity can be 
physiologically manipulated by simply placing the amphibian on a black or white background. 
Secondly, these cells synthesize large amounts of a single cargo molecule with a well-deﬁ ned 
role; the prohormone POMC is synthesized, transported in the regulated secretory pathway 
and processed to a number of bioactive peptides including α-MSH, which is responsible for 
darkening of the skin [23]. The Xenopus melanotrope cells also produce PrP mRNA but its 
expression is not induced in black-adapted animals [47]. Third, the regulatory mechanisms 
and pathways as well as many proteins present in these cells are highly conserved between 
Xenopus and mammals. In general, studies on the Xenopus melanotrope cells have provided 
information that has been valuable for understanding the functioning of mammalian cells 
[48-50]. Thus, it appears reasonable to assume that the data obtained for Xenopus PrPC can 
be extrapolated to mammalian systems, including human. 
For our studies, we generated and analyzed transgenic Xenopus laevis that express a GFP-
PrPC fusion protein speciﬁ cally in the intermediate pituitary melanotrope cells since transgene 
expression was under the control of a POMC gene promoter fragment. The temporal and 
spatial expression pattern observed for GFP-PrPC during early embryonic development 
of transgenic Xenopus (from stage 25 onwards and gradually speciﬁ c to the intermediate 
pituitary) resembles that found in Xenopus transgenic for POMC promoter-driven expression 
of GFP itself [40]. In addition, the pattern is in line with the expression pattern of the 
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endogenous POMC-derived α-MSH-peptide in developing Xenopus [51]. Non-speciﬁ c brain 
ﬂ uorescence other than the ﬂ uorescence found in the intermediate pituitary was generally 
not observed in the tadpoles transgenic for GFP-PrPC. The few cases of non-speciﬁ c brain 
ﬂ uorescence in transgenic tadpoles were probably due to the integration of the transgene 
fragment into regions of the genome that harbor brain gene promoters that are active during 
early development. Still, all juvenile frogs transgenic for GFP-PrPC showed ﬂ uorescence 
speciﬁ c in the melanotrope cells of the intermediate pituitary and in these cases we never 
observed non-speciﬁ c anterior pituitary or brain ﬂ uorescence.
Figure 8. Schematic of the biosynthesis and processing of GFP-PrPC in intermediate pituitary cells 
from transgenic Xenopus. The GFP-PrPC fusion protein is readily N-glycosylated in the endoplasmic 
reticulum (ER), GPI-anchored, and subsequently complex glycosylated and sulfated in the Golgi 
apparatus. The mature GFP-PrPC is presented at the plasma membrane (PM) where enzymatic cleavage 
occurs. On the left, a schematic of the secretory pathway is depicted. SS, signal sequence; GPI, glycosyl-
phosphatidylinositol signal sequence; CGN, cis-Golgi network; TGN, trans-Golgi network; , 
enzymatic cleavage site; , GPI-anchor; , N-linked glycosylation; , complex glycosylation; 
, sulfation.
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GFP-PrPC was found to be localized in all compartments of the secretory pathway of the 
Xenopus melanotrope cells, but besides the plasma membrane most notably in the Golgi 
apparatus, i.e. where complex N-glycan modiﬁ cations occur. These in vivo observations are 
in agreement with the results of in vitro studies on cultured baby hamster kidney, chinese 
hamster ovary, murine neuroblastoma (N2a) and murine septal cells transfected with GFP-
tagged PrPC showing that the fusion protein was localized to the Golgi apparatus and plasma 
membrane [6-10]. In the transgenic melanotrope cells, the GFP-PrPC transgene product 
was mainly present as a monomer and only a small portion existed as a dimer, in line with 
previous studies on puriﬁ ed hamster PrPC, recombinant PrP and native PrPC from bovine 
brain [52-54].
We found that in the active intermediate pituitary melanotrope cells of black-adapted Xenopus, 
GFP-PrPC was upregulated and thus coregulated with POMC and the type I transmembrane, 
putative ER-to-Golgi cargo receptors p24δ1/2, whereas no transgene product was detected in 
the anterior pituitary cells. This cell-speciﬁ c induction of GFP-PrPC expression occurs because 
when the frog is adapted to a black background the POMC promoter becomes highly active 
only in the melanotrope cells (the melanotrope cells are controlled by neurons of hypothalamic 
origin that innervate the melanotropes differentially depending on the background color of 
the animal, while the anterior pituitary cells are not involved in background adaptation [55]). 
In black- and white-adapted animals, we observed less difference in the activity of the POMC 
transgene promoter than in the activity of the endogenous POMC gene promoter, probably 
because only a 529-bp fragment of the POMC gene promoter was used in the transgene 
construct [49].
Our pulse-chase metabolic cell labeling studies revealed that in the transgenic melanotrope 
cells the GFP-PrPC fusion protein was initially synthesized as a 45-kDa product. 
Subsequently, the initial product was rapidly GPI-anchored and stepwise mono- and di-N-
linked glycosylated to give rise to the 48-kDa and 51-kDa GFP-PrPC forms, respectively, 
which is consistent with the fact that Xenopus PrPC contains two conserved N-glycosylation 
sites at amino acid positions 150 and 165 [38]. The ﬁ nding that already during the short (3-
min) pulse not only the 45-kDa but also the 48-, and 51-kDa GFP-PrPC forms were labeled 
(Fig. 5B) is in line with the addition of glycosylphosphatidylinositol and N-glycans during 
or soon after translation and translocation of polypeptides into the lumen of the ER [56,57]. 
The high-mannose type oligosaccharides attached to the 51-kDa fusion protein were further 
processed to yield complex sugar types on the 55-kDa GFP-PrPC protein, presumably during 
passage through the mid-Golgi [58,59]. In mouse N2a cells, PrPC was also N-linked and 
complex glycosylated [15]. Furthermore, our work demonstrated for the ﬁ rst time that the 
55-kDa GFP-PrPC fusion protein was sulfated and that this post-translational modiﬁ cation is 
a relatively late event, presumably in the trans-Golgi network (TGN) [60]. At present it is not 
clear whether sulfation of GFP-PrPC accelerates its transport from the TGN to the cell-surface 
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and/or promotes speciﬁ c protein-protein interactions, as suggested to be the case for other 
sulfated proteins [42]. We further found that the 55-kDa GFP-PrPC fusion protein was GPI-
anchored to the plasma membrane of the melanotrope cell. In the chase incubation medium, 
we observed a 33-kDa metabolic cleavage product of the radiolabeled transgene product, 
indicating that the newly synthesized 55-kDa GFP-PrPC was partly cleaved. In baby hamster 
kidney, chinese hamster ovary, murine N2a and murine septal cells, PrPC undergoes post-
translational proteolytic cleavage at the plasma membrane as part of its normal metabolism 
[15,17-22]. The biosynthesis of GFP-PrPC in Xenopus melanotrope cells is schematically 
depicted in Fig. 8.
Since in the pulse-chase metabolic cell labeling studies on the Xenopus intermediate 
pituitary the amounts of 37-kDa POMC and the 18-kDa POMC-derived product in the cells 
and incubation media were similar for the wild-type and transgenic melanotrope cells, the 
introduction of the GFP-PrPC fusion protein did not affect prohormone biosynthesis and 
processing, and the secretion of the prohormone-derived proteins. In addition, the steady-
state levels of POMC as well as of other secretory pathway components, such as the POMC 
cleavage enzyme PC2, the p24δ1/2 proteins, and the protein-folding chaperones BiP and 
calnexin, were not changed in the wild-type and transgenic melanotrope cells.
In conclusion, we have successfully targeted GFP-PrPC to the Xenopus intermediate 
pituitary melanotrope cells. The results of our transgenic approach in a physiological context 
give insight into the biosynthesis of PrPC and our preliminary studies on the effect of the 
overexpressed PrPC show that the transgene product does not affect the functioning of a 
neuroendocrine cell. With the availability of the Xenopus melanotrope cell-speciﬁ c PrPC 
transgene expression system we are now in the position to obtain more understanding of 
the normal physiological role of PrPC, e.g. by examining the effect of mutant PrPC proteins 
on melanotrope cell functioning, including copper ion transport, PrPC internalization, cell 
protection from oxidative stress, and cell adhesion, signaling and survival. Furthermore, 
and in contrast to the PrPC-GFP transgenic mouse model [11], the process of background 
adaptation in combination with our transgenic Xenopus melanotrope cell model allows in 
vivo manipulation of not only the biosynthetic and secretory activities of a homogeneous 
population of neuroendocrine cells, but also of PrPC transgene expression, providing an 
additional tool for studying PrPC function. 
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Abstract
The cellular form of the prion protein (PrPC) is a plasma membrane-anchored glycoprotein 
whose physiological function is poorly understood. Here we report the effect of transgene 
expression of Xenopus PrPC fused to the C-terminus of the green ﬂ uorescent protein (GFP-
PrPC) speciﬁ cally in the neuroendocrine intermediate pituitary melanotrope cells of Xenopus 
laevis.  In the transgenic melanotrope cells, the level of the prohormone proopiomelanocortin 
(POMC) in the secretory pathway was reduced when the cells were (i) exposed for a relatively 
long time to the transgene product (by physiologically inducing transgene expression), (ii) 
metabolically stressed or (iii) forced to produce unfolded POMC. Intriguingly, although the 
overall ultrastructure was normal, electron microscopy revealed the induction of lysosomes 
taking up POMC secretory granules (crinophagy) in the transgenic melanotrope cells, likely 
causing the reduced POMC levels. Together, our results indicate that in neuroendocrine cells 
transgene expression of PrPC affects the functioning of the secretory pathway and induces 
crinophagy.
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Introduction
Changes in the three-dimensional conformation of the cellular prion protein (PrPC) lead to 
the formation of an abnormal, protease-resistant, disease-associated prion protein (PrPSc) that 
is known to cause infectious fatal neurodegenerative disorders (transmissible spongiform 
encephalopathies or prion diseases) in humans and other mammals [1-3]. PrPC is a glycosyl
phosphatidylinositol (GPI)-anchored sialoglycoprotein whose physiological function is still 
elusive. The mature form of PrPC is attached to the outer cell membrane and is expressed in 
nearly all tissues, but highest levels are found in the central nervous system [4-6]. A wide 
variety of functions have been attributed to PrPC, e.g. a role in transmembrane signaling [7], 
cell adhesion [8], neurite outgrowth, neuronal differentiation and survival [9-12], copper 
metabolism [13,14] and protection against metabolic stress [15].
Since most of the above-mentioned studies on PrPC have been performed in in vitro systems, 
we decided to investigate PrPC in vivo in a highly specialized secretory cell, namely the 
intermediate pituitary melanotrope cell of the South-African claw-toed frog Xenopus laevis. 
This cell is a well-deﬁ ned, strictly regulated neuroendocrine secretory cell that produces a 
single major soluble cargo protein, namely the prohormone proopiomelanocortin (POMC) 
[16]. In the trans-Golgi network and immature secretory granules of the melanotrope cells, 
POMC is endoproteolytically cleaved into a number of bioactive peptides, including α-
melanophore-stimulating hormone (α-MSH). Once released into the blood, α-MSH mediates 
adaptation of the animal to a black background by causing dispersion of melanin pigment 
granules in skin melanophores resulting in darkening of the skin [17]. Depending on the color 
of the background of the animal (black or white), the melanotrope cells are differentially 
innervated by neuronal cells of hypothalamic origin (e.g. strong inhibitory synapses are 
formed in white animals). On a black background melanotrope cell activity and cell size 
increase enormously, and the cells produce vast amounts of POMC that represents ~80% of 
all newly synthesized melanotrope proteins. On a white background POMC mRNA levels 
are decreased ~30-fold and α-MSH secretion into the blood stream is inhibited leading to 
melanosome aggregation and whitening of the skin [16]. Placing the amphibian on a black or 
white background thus allows physiological manipulation of the biosynthetic and secretory 
activity of the melanotrope cell.
To explore the physiological function of PrPC in the Xenopus melanotrope cell, we combined 
the unique properties of this cell with the technique of stable Xenopus transgenesis [18,19]. 
We used a Xenopus POMC gene promoter fragment to target transgene expression of 
Xenopus PrPC fused to the C-terminus of the green ﬂ uorescent protein GFP (GFP-PrPC) 
speciﬁ cally to the Xenopus melanotrope cells, leaving the integrity of the regulation by the 
hypothalamic neurons intact. We previously characterized the biosynthesis of GFP-PrPC in 
transgenic Xenopus and found that the GFP-PrPC fusion protein was GPI-anchored, stepwise 
glycosylated, sulfated, anchored to the plasma membrane and partially cleaved, similar to 
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endogenous PrPC biosynthesis [20]. In this preliminary functional characterization of the 
Xenopus melanotrope cells transgenic for GFP-PrPC, we observed no effect of GFP-PrPC 
expression on the functioning of the transgenic melanotrope cells [20]. However, in the present 
more elaborate functional study we placed the transgenic Xenopus on a black background for 
a long time period, implying prolonged exposure of the melanotrope cells to the transgene 
GFP-PrPC product, and applied stress to the transgenic cells. We now ﬁ nd that the transgene 
expression of GFP-PrPC affected the handling of POMC in the secretory pathway and caused 
crinophagy in the transgenic Xenopus melanotrope cells.
Experimental procedures
Animals
South-African claw-toed frogs Xenopus laevis were bred, reared and adapted to a black 
or white background, and unfertilized eggs were harvested from mature female Xenopus 
laevis (Xenopus Express, Cape Town, South-Africa), as described previously [20]. All 
animal experiments were carried out in accordance with the European Communities Council 
Directive 86/609/EEC for animal welfare, and permit RBD0166(H10) to generate and house 
transgenic Xenopus.
Antibodies
The rabbit polyclonal antibody raised against the C-terminal region of Xenopus p24δ1/2 
(1262CH) has been described previously [21,22]. A polyclonal antiserum against GFP was 
kindly provided by Dr. B. Wieringa [23], against Xenopus POMC (ST62, recognizing only 
the precursor form) by Dr. S. Tanaka (Shizuoka University, Hamamatsu, Japan; [24], against 
recombinant mature human PC2 by Dr. W.J.M. van de Ven (University of Leuven, Belgium; 
[25], and against the protein-folding chaperones calnexin and binding protein BiP by Dr. K. 
Geering (University of Lausanne, Switzerland; [26]. Monoclonal anti-tubulin antibody E7 
has been described previously [27].
Generation of Xenopus transgenic for GFP-PrPC or GFP-GPI
The open-reading frame of Xenopus PrP (+69 to +648; [28]; not including the signal 
sequence) and of the GPI-anchor of Xenopus PrP (+540 to +648; [28] were ampliﬁ ed by 
PCR and used to generate constructs pPOMC-GFP-PrP and pPOMC-GFP-GPI, respectively. 
The constructs contained a 529-bp Xenopus POMC gene A promoter fragment (pPOMC) 
which directs transgene expression speciﬁ cally to the melanotrope cells of the Xenopus 
intermediate pituitary [29], the signal-peptide-coding sequence of the Xenopus secretory 
pathway component Ac45 [30], GFP cDNA, Xenopus PrP or GPI cDNA and the CMV polyA 
signal [31]. Constructs were veriﬁ ed by cycle DNA sequencing [20]. Applying a stable 
Xenopus laevis transgenesis method [18,19], a 2301-bp SalI/BssHII fragment containing the 
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SV40 polyA signal behind the pPOMC-GFP-PrP fragment was used to generate Xenopus 
transgenic for GFP-PrPC (line #102 and #131). In addition, a 1817-bp SalI/BssHII fragment 
containing the SV40 polyA signal behind the pPOMC-GFP-GPI fragment was used to 
generate Xenopus with transgene expression of GFP-GPI (line #150). The presence of GFP 
ﬂ uorescence was examined in living embryos anaesthetized with 0.25 mg/ml MS222 (3-
aminobenzoic acid ethyl ester; Sigma, St. Louis, MO) using a Leica MZ FLIII ﬂ uorescence 
stereomicroscope and photographs were taken with a Leica DC200 color camera using the 
Leica DCviewer software.
In vitro fertilization of wild-type Xenopus eggs with transgenic sperm cells
In vitro fertilization to generate transgenic Xenopus has been described previously [20]. 
Brieﬂ y, pieces of testes of male transgenic Xenopus frogs were rubbed against unfertilized 
eggs harvested from wild-type Xenopus females and subsequently the fertilized eggs 
were selected in their 4-cell stage and screened for speciﬁ c pituitary ﬂ uorescence during 
early development (∼stage 40). Staging of Xenopus embryos was carried out according to 
Nieuwkoop and Faber [32].
Western blot analysis
Western blot analysis was performed as described previously [20]. Brieﬂ y, neurointermediate 
lobes (NILs) from black-adapted wild-type and transgenic adult Xenopus were individually 
homogenized and ~25% of the single-NIL lysates were denatured, separated on 12.5% SDS-
PAGE, and transferred to nitrocellulose (Protran; Schleicher & Schuell, Keene, NH) or PVDF 
(Hybond-P; Amersham Biosciences) membranes. Following blocking, blots were incubated 
with an anti-GFP (1:5000), ST62 (1:10000), anti-PC2 (1:5000), anti-calnexin (1:10000), 
anti-BiP (1:5000), 1262CH (1:2500), or anti-tubulin (1:500) antibody overnight at 4°C and 
subsequently with a peroxidase conjugated secondary antibody (1:5000) for 45 min at room 
temperature. Proteins on Western blots were immunodetected using Lumi-LightPLUS substrate 
(Roche Diagnostics, Mannheim, Germany) and subsequently exposed to X-ray ﬁ lm (Kodak, 
Rochester, NY). Quantiﬁ cation was performed using a BioChemi imaging system and signals 
were analyzed using Labworks 4.0 software (UVP BioImaging systems, Cambridge, UK).
Metabolic cell labeling and immunoprecipitation analysis
Metabolic cell labeling and immunoprecipitation analysis have been described previously 
[20]. Brieﬂ y, NILs of black-adapted wild-type and transgenic Xenopus were rapidly 
dissected and preincubated in Ringer’s medium for 15 min at 22°C. Radioactive labeling 
of newly synthesized proteins was performed by incubating the NILs in Ringer’s medium 
containing 5 mCi/ml [35S]-Met/Cys (Tran35S-label, MP Biomedicals, Irvine, CA) for 30 
min at 22°C, rinsed, and chased with 0.5 mM L-methionine in Ringer’s medium for 3 hr 
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at 22°C. In some experiments, lobes were preincubated in the presence or absence of 2 mg/
ml D-, L- (Sigma), 2-deoxy-D-glucose (MP Biomedicals) or 5 mM dithiothreitol (DTT; MP 
Biomedicals), and remained present for the indicated periods. After the chase, NILs were 
homogenized and parts of the lysates and incubation media were analyzed directly on SDS-
PAGE, while the remainder was used for immunoprecipitation and Western blot analysis. For 
immunoprecipitation analysis, NIL lysates were incubated with an anti-GFP antibody (1:500) 
and protein A-sepharose (Amersham Biosciences), and the immune complexes were resolved 
by SDS-PAGE. Radiolabeled proteins were detected using autoradiography at -70°C.
Electron microscopy
For ultrastructural studies, freshly dissected NILs of wild-type Xenopus and Xenopus 
transgenic for GFP-GPI or GFP-PrPC were used. Whole lobes were ﬁ xed overnight at 4°C 
in 2% glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.3). Following rinsing in the 
same buffer, ﬁ xed tissues were osmicated for one hour in 1% osmium tetroxide in 0.1 M 
PB, rinsed in PB, dehydrated through graded series of ethanol and embedded in Epon 812. 
One-micron thick sections were cut and toluidine blue-stained. Subsequently, the sections 
were examined in a phase-contrast microscope (Dialux 20, Leitz). Ultrathin sections were 
cut, double contrasted with uranyl-acetate/lead-citrate and photographed in a transmission 
electron microscope (JEOL 1010).
Statistics
Data are presented as means ± SEM (n = 3). Statistical evaluation was performed using an 
unpaired Student’s t-test.
Results
Generation of Xenopus transgenic for GFP-PrPC or GFP-GPI
To study the role of PrPC, we generated Xenopus transgenic for Xenopus PrPC fused to the 
C-terminus of GFP (GFP-PrPC). For this purpose, we made a DNA construct (pPOMC-GFP-
PrP; Fig. 1A) containing the sequence encoding GFP-PrPC downstream of a Xenopus POMC 
gene promoter fragment that directs transgene expression speciﬁ cally to the melanotrope 
cells of the Xenopus intermediate pituitary [29]. The expression of the GFP-PrPC fusion 
protein could be observed by direct visual inspection of the living Xenopus embryos under a 
ﬂ uorescence microscope (Fig. 1B, upper left panel). Lifting the brain of the adult transgenic 
Xenopus showed that the expression of GFP-PrPC was restricted to cells located in the 
pituitary intermediate lobe (IL; neuroendocrine melanotrope cells), while no ﬂ uorescence 
was observed in the pituitary anterior lobe (AL; containing the POMC-producing corticotrope 
cells) and other brain structures (Fig. 1B, upper right panel). F1 offsprings were generated by 
in vitro fertilization of eggs harvested from wild-type Xenopus females with sperm isolated 
from the testis of a male frog transgenic for GFP-PrPC (line #102). 
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Figure 1. Intermediate pituitary-speciﬁ c ﬂ uorescence and transgene expression in Xenopus embryos 
transgenic for GFP-PrPC or GFP-GPI. (A) Schematic representation of the linear injection fragments 
pPOMC-GFP-PrP and pPOMC-GFP-GPI containing the Xenopus POMC gene A promoter fragment 
(pPOMC), and the GFP-PrP and GFP-GPI fusion protein-coding sequence, which were used to generate 
transgenic Xenopus lines 102 and 150, respectively; SS, signal peptide sequence; GPI, glycosylphos-
phatidylinositol signal sequence. (B) Pituitary-speciﬁ c ﬂ uorescence in living Xenopus embryos (stage 
~40, staging according to Nieuwkoop and Faber [32]; left panels) and in black-adapted 6 month-old 
frogs transgenic for GFP-PrPC or GFP-GPI (ventrocaudal view; right panels). In adult Xenopus, the 
brain was lifted to reveal intense ﬂ uorescence in the intermediate lobe (IL), but not in the anterior 
lobe (AL) of the pituitary. Arrows indicate the localizations of the ﬂ uorescent intermediate pituitaries 
expressing the fusion product; the positions of the eye (E), nose (N) and gut (G) are also indicated. The 
ﬂ uorescence in the gut represents autoﬂ uorescence. Bars equal 0.5 mm. The upper two panels were 
taken from van Rosmalen and Martens [20]. (C) Tissue lysates of neurointermediate lobes (NILs) and 
ALs from wild-type (wt) animals and animals transgenic for the GFP-PrPC (102) or GFP-GPI (150) 
fusion protein were subjected to SDS-PAGE. Western blot analysis was performed using an anti-GFP 
antibody (α-GFP).
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To establish that any effect of the GFP-PrPC product on the melanotrope cells was not due to 
the transgenic procedure per se, we also generated Xenopus transgenic for the GPI-anchor of 
Xenopus PrPC with the anchor fused to the C-terminus of GFP (GFP-GPI) by using the DNA 
construct pPOMC-GFP-GPI for Xenopus transgenesis (Fig. 1A). Xenopus embryos and adult 
frogs transgenic for GFP-GPI (line #150) showed pituitaries with a ﬂ uorescent signal similar 
to those of Xenopus transgenic for GFP-PrPC (Fig. 1B, lower panels). The expression patterns 
observed for GFP-PrPC and GFP-GPI during early embryonic development of the transgenic 
Xenopus resemble those seen in Xenopus with POMC promoter-driven transgene expression 
of GFP itself [29], namely speciﬁ c expression in the intermediate pituitary cells. From the 
Xenopus pituitary (consisting of the pars nervosa, IL and AL), the AL can be dissected, but 
the pars nervosa (containing nerve terminals of hypothalamic origin) is intimately associated 
with the IL. To examine the steady-state levels of the GFP-PrPC and GFP-GPI proteins, the 
neurointermediate lobe (NIL, IL together with pars nervosa) and AL were dissected from 
frogs transgenic for GFP-PrPC or GFP-GPI, and from wild-type animals. Western blot 
analysis of NIL lysates from GFP-PrPC-transgenic black-adapted animals using an anti-GFP-
antibody revealed a mature, complex-glycosylated ∼55-kDa GFP-PrPC fusion protein and 
a relatively small amount of an N-glycosylated ∼51-kDa product (Fig. 1C). We have not 
been able to detect endogenous Xenopus PrPC; extensive attempts to study the expression of 
the endogenous protein with a series of antibodies directed against Xenopus or mammalian 
PrPC have not been successful [20]. Analysis of NILs from the GFP-GPI-transgenic control 
animals showed a GFP-GPI fusion protein of ∼35 kDa, while the NILs of wild-type animals 
did not contain an immunoreactive product (Fig. 1C). The GFP-PrPC and GFP-GPI transgenes 
were not expressed in the AL, showing the restricted expression of these fusion proteins in 
the NIL (Fig. 1C). 
Steady-state levels of POMC and a number of other secretory pathway components in wild-
type and transgenic Xenopus intermediate pituitary cells
We next investigated whether the transgenic manipulation had affected the steady-state levels 
of POMC, the POMC cleavage enzyme prohormone convertase PC2, the protein-folding 
chaperones calnexin and binding protein BiP, and the putative ER-to-Golgi cargo receptor 
p24δ1/2 proteins in the melanotrope cells of Xenopus transgenic for GFP-PrP
C and adapted to 
a black background for >8 weeks. Following this long-term adaptation and relative to wild-
type NILs, in the GFP-PrPC-transgenic NILs the steady-state protein levels of POMC and BiP 
had decreased ~3- and ~6-fold, respectively, while the steady-state levels of PC2, calnexin 
and the p24δ1/2 proteins remained unaffected (Fig. 2A and B). This phenotype is probably not 
due to a position effect (transgene integration), since transgenic melanotrope cells from >8-
weeks-black-adapted frogs of a second independent line transgenic for GFP-PrPC (line #131) 
also showed an ~3- and ~6-fold reduction of POMC and BiP levels, respectively (data not 
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shown). In the NILs from animals transgenic for GFP-GPI and black adapted for >8 weeks, 
the steady-state levels of POMC, PC2, calnexin, BiP and p24δ1/2 were similar when compared 
to wild-type NILs (Fig. 2A and B). No signiﬁ cant differences in POMC, PC2, calnexin, BiP 
and p24δ1/2 protein levels were observed between wild-type, GFP-PrP
C-transgenic and GFP-
GPI-transgenic NILs from Xenopus adapted to a black background for 3 weeks [20]; Fig. 2A 
and B).
Figure 2. Steady-state levels of a number of intermediate pituitary proteins from wild-type and 
transgenic black-adapted Xenopus. (A) Tissue lysates of neurointermediate lobes (NILs) derived from 
wild-type (wt) animals and animals transgenic for the GFP-PrPC (102) or GFP-GPI (150) fusion protein 
were subjected to SDS-PAGE. Western blot analysis was performed using anti-POMC, anti-PC2, anti-
calnexin, anti-BiP, anti-p24δ1/2, and anti-tubulin antibodies. Tubulin was used as a control for protein 
loading. Animals were adapted to a black background for 3 or >8 weeks. (B) The steady-state protein 
levels of POMC, PC2, calnexin, BiP and p24δ1/2 in NILs from wild-type and transgenic animals adapted 
to a black background for >8 weeks were quantiﬁ ed by densitometric scanning and are presented in 
arbitrary units (AU), relative to the steady-state levels of tubulin. Shown are the means ± SEM (n = 3). 
A signiﬁ cant difference is indicated by ** (P < 0.01) or *** (P < 0.001).
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Figure 3. Biosynthesis and processing of newly synthesized POMC in wild-type Xenopus intermediate 
pituitary cells and cells transgenic for GFP-PrPC or GFP-GPI. (A) Neurointermediate lobes (NILs) 
from wild-type (wt) animals and animals transgenic for the GFP-PrPC (102) or GFP-GPI (150) fusion 
protein were pulse labeled with [35S]-Met/Cys for 30 min and subsequently chased for 3 hr. Newly 
synthesized proteins extracted from the lobes (5%) or secreted into the incubation medium (20%) 
were resolved by SDS-PAGE on 15% gels and visualized by autoradiography. Animals were adapted 
to a black background for 3 weeks (short-term adaptation) or >8 weeks (long-term adaptation). The 
experiments were performed in triplicate and a representative example is shown. (B) The amounts of 
newly synthesized 37-kDa POMC (black bars) and the 18-kDa POMC-derived product (grey bars) 
were quantiﬁ ed by densitometric scanning, and are presented in arbitrary units (AU), relative to the 
amounts of newly synthesized actin. Shown are the means ± SEM (n = 3). Signiﬁ cant differences are 
indicated by ** (P < 0.01) or *** (P < 0.001).
Chapter 4
74
Biosynthesis and processing of newly synthesized POMC in wild-type and transgenic Xenopus 
intermediate pituitary cells
In view of the reduced steady-state levels of POMC in the GFP-PrPC-transgenic melanotrope 
cells from Xenopus black adapted for >8 weeks, we wondered what the dynamics of the 
biosynthetic and secretory processes were in these cells. We therefore performed pulse-
chase analyses of newly synthesized proteins produced in wild-type NILs and NILs 
transgenic for GFP-PrPC or GFP-GPI, and secreted into the incubation medium. Besides 
the melanotrope cells, the Xenopus NIL consists of nerve terminals of hypothalamic origin 
that are biosynthetically inactive (the pars nervosa) and thus the radiolabeled proteins are 
synthesized by the melanotropes. Frogs were either black adapted for 3 weeks or long-term 
black adapted for more than 8 weeks. Following a 30-min pulse labeling and subsequent 3-
hr chase incubation of wild-type and transgenic NILs from animals black adapted for either 
3 or >8 weeks, most of the 37-kDa POMC was processed to an 18-kDa POMC cleavage 
product which was subsequently secreted into the incubation medium (Fig. 3A). The 18-kDa 
product represents the N-terminal portion of 37-kDa POMC and is generated by the ﬁ rst 
endoproteolytic cleavage step during POMC processing [33]. Thus, for both time periods 
of black-background adaptation, and in both wild-type and transgenic cells the biosynthesis 
and processing of newly synthesized POMC was not affected. However, in the GFP-PrPC-
transgenic melanotrope cells from animals black adapted for >8 weeks the levels of the 
newly synthesized 37- and 18-kDa POMC proteins remaining in the cells were signiﬁ cantly 
decreased (~11- and ~3-fold, respectively).  In the wild-type cells and cells transgenic for GFP-
GPI from animals adapted to a black background for >8 weeks, no signiﬁ cant differences in 
the levels of the POMC pool were observed (Fig. 3A and B). Also, both wild-type NILs and 
NILs transgenic for GFP-PrPC or GFP-GPI from animals black adapted for 3 weeks showed 
normal levels of newly synthesized 37- and 18-kDa POMC remaining in the cells (Fig. 3A 
and B). We conclude that the long-term transgene expression of GFP-PrPC in transgenic 
NILs of Xenopus adapted to a black background for >8 weeks did not affect the biosynthesis 
and processing of the major portion of POMC, but the minor portions of newly synthesized 
37- and 18-kDa POMC remaining in the cells were not properly handled by the transgenic 
melanotrope cells.
Effect of metabolic stress on the biosynthesis and processing of newly synthesized POMC in 
wild-type and transgenic Xenopus intermediate pituitary cells
Since long-term (>8 weeks) adaptation of GFP-PrPC-transgenic animals to a black background, 
and thus extensive exposure of the melanotrope cells to the transgene product, led to affected 
cells, we wondered how the transgenic melanotrope cells of animals black adapted for 3 
weeks would handle cellular stress. We therefore decided to challenge with metabolic stress 
the wild-type and transgenic melanotrope cells from 3-weeks black-adapted animals.
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Figure 4. Effect of glucose depletion on the biosynthesis and processing of newly synthesized POMC 
in wild-type Xenopus intermediate pituitary cells and cells transgenic for GFP-PrPC. (A) Wild-type (wt) 
neurointermediate lobes (NILs) and NILs transgenic for GFP-PrPC (102) were preincubated for 2 hr and 
pulse labeled with [35S]-Met/Cys for 30 min in the presence or absence of glucose. Newly synthesized 
proteins were extracted from the lobes, directly resolved by SDS-PAGE on 15% gels, and visualized by 
autoradiography. The experiments were performed in triplicate and a representative example is shown. 
(B) The amounts of newly synthesized 37-kDa POMC were quantiﬁ ed by densitometric scanning 
and are presented in arbitrary units (AU), relative to the amounts of newly synthesized actin. Shown 
are the means ± SEM (n = 3). (C) Neurointermediate lobes (NILs) from wild-type (wt) animals and 
animals transgenic for the GFP-PrPC fusion protein were pulse labeled with [35S]-Met/Cys for 30 min 
and subsequently chased for 3 hr in the presence or absence of glucose. Newly synthesized proteins 
extracted from the lobes (5%) or secreted into the incubation medium (20%) were resolved by SDS-
PAGE on 15% gels and visualized by autoradiography. (D) The amounts of newly synthesized 37-kDa 
POMC and the 18-kDa POMC-derived product were quantiﬁ ed by densitometric scanning and are 
presented in arbitrary units (AU), relative to the amounts of newly synthesized actin. Shown are the 
means ± SEM (n = 3). A signiﬁ cant difference is indicated by *** (P < 0.001). In all cases, animals were 
adapted to a black background for three weeks (short-term adaptation).
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For the induction of metabolic stress, we incubated wild-type and GFP-PrPC-transgenic NILs 
in medium without glucose. To test whether the metabolic stress had affected the biosynthesis 
and processing of POMC as well as the secretion of the POMC-derived products, we performed 
pulse and pulse-chase analyses of newly synthesized proteins produced in the tissue and 
secreted into the medium. Following a 30-min pulse labeling of wild-type and transgenic 
NILs in either the presence or absence of glucose (during both pre-incubation and pulse), 
the 37-kDa POMC precursor was clearly the major newly synthesized protein (Fig. 4A). No 
signiﬁ cant difference was observed between the levels of newly synthesized 37-kDa POMC 
in wild-type and transgenic NILs incubated with and without glucose (Fig. 4B). During the 
3-hr glucose-depleted chase incubation (no glucose during pre-incubation, pulse and chase) 
in both the wild-type as well as the transgenic cells most of the 37-kDa POMC was processed 
to an 18-kDa POMC cleavage product which was subsequently secreted into the incubation 
medium (Fig. 4C). However, the amounts of newly synthesized 37-kDa POMC and the 18-
kDa POMC cleavage product left in the glucose-depleted transgenic melanotrope cells were 
signiﬁ cantly decreased in comparison to the wild-type cells incubated without glucose (~10- 
and ~6-fold reduction, respectively; Fig. 4C and D).
To further study the metabolic stress response of the GFP-PrPC-transgenic melanotrope 
cells, we decided to examine the effect of glucose analogs on wild-type and transgenic cells 
from animals black adapted for 3 weeks. We therefore performed pulse and pulse-chase 
analyses with NILs incubated in the presence of L-glucose (an inactive form of glucose) or 
2-deoxy-D-glucose (a non-degradable analog of glucose) during pre-incubation, pulse, and 
chase. Following a 30-min pulse labeling and subsequent 3-hr chase incubation, like for 
D-glucose, both L- and 2-deoxy-D-glucose did not affect the biosynthesis and processing of 
POMC, and the secretion of the 18-kDa POMC cleavage product (Fig. 5A). The 2-deoxy-D-
glucose-treatment caused 37-kDa and 18-kDa POMC to migrate faster in the gel, probably 
because this glucose analog interferes with proper protein glycosylation resulting in the 
premature termination of carbohydrate chain extensions and production of glycoproteins 
of lower molecular weight [34]. Similar to D-glucose depletion, both L- and 2-deoxy-D-
glucose signiﬁ cantly decreased the relative amounts of newly synthesized 37-kDa and 18-
kDa POMC remaining in the transgenic cells in comparison to the wild-type cells under the 
same conditions (~10- and ~2-fold reduction for L-glucose, respectively, and ~4- and ~2-fold 
reduction for 2-deoxy-D-glucose, respectively; Fig. 5A and B). These ﬁ ndings indicate that 
in melanotrope cells transgenic for GFP-PrPC and from Xenopus black adapted for 3 weeks 
metabolic stress did not affect the biosynthesis and processing of the major portion of newly 
synthesized 37- and 18-kDa POMC, but caused improper handling of the minor portions of 
37-/18-kDa POMC remaining in the cells.
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Figure 5. Effect of L- or 2-deoxy-D-glucose on the biosynthesis and processing of newly synthesized 
POMC in wild-type Xenopus intermediate pituitary cells and cells transgenic for GFP-PrPC. (A) 
Neurointermediate lobes (NILs) from wild-type (wt) animals and animals transgenic for the GFP-
PrPC fusion protein (102) were preincubated for 2 hr and pulse labeled with [35S]-Met/Cys for 30 min 
and subsequently chased for 3 hr in the presence of D-, L-, or 2-deoxy-D-glucose. Newly synthesized 
proteins extracted from the lobes (5%) or secreted into the incubation medium (20%) were resolved 
by SDS-PAGE on 15% gels and visualized by autoradiography. The experiments were performed in 
triplicate and a representative example is shown. (B) The amounts of newly synthesized 37-kDa POMC 
and the 18-kDa POMC-derived product were quantiﬁ ed by densitometric scanning and are presented in 
arbitrary units (AU), relative to the amounts of newly synthesized actin. Shown are the means ± SEM 
(n = 3). Signiﬁ cant differences are indicated by ** (P < 0.01) or *** (P < 0.001). In all cases, animals 
were adapted to a black background for three weeks (short-term adaptation).
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Figure 6. Effect of a reducing agent on the biosynthesis and processing of newly synthesized POMC in 
wild-type Xenopus intermediate pituitary cells and cells transgenic for GFP-PrPC. (A) Neurointermediate 
lobes (NILs) from wild-type (wt) animals and animals transgenic for GFP-PrPC (102) were preincubated 
for 30 min, pulse labeled with [35S]-Met/Cys for 30 min and subsequently chased for 3 hr in the absence 
(-) or presence (+) of 5 mM dithiothreitol (DTT). Newly synthesized proteins extracted from the lobes 
(5%) or secreted into the incubation medium (20%) were resolved by SDS-PAGE on 15% gels and 
visualized by autoradiography. The experiments were performed in triplicate and a representative 
example is shown. (B) The amounts of newly synthesized 37-kDa POMC and the 18-kDa POMC-
derived product were quantiﬁ ed by densitometric scanning and are presented in arbitrary units (AU), 
relative to the amounts of newly synthesized actin. Shown are the means ± SEM (n = 3). A signiﬁ cant 
difference is indicated by ** (P < 0.01). In all cases, animals were adapted to a black background for 
three weeks (short-term adaptation).
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Effect of a reducing agent on the biosynthesis and processing of newly synthesized POMC in 
wild-type and transgenic Xenopus intermediate pituitary cells
Since long-term adaptation of the GFP-PrPC transgenic animal and the application of 
metabolic stress on the transgenic melanotrope cells affected the minor portion of newly 
synthesized POMC remaining in the cells, we next examined the effect of stress in the early 
secretory pathway (the presence of unfolded POMC) on the functioning of the melanotrope 
cells. To induce the biosynthesis of improperly folded newly synthesized 37-kDa POMC, 
we incubated wild-type and transgenic NILs from 3-weeks black-adapted frogs during a 
30-min pulse labeling and subsequent 3-hr chase incubation in the presence of the thiol-
reducing agent dithiothreitol (DTT) which directly interferes with the folding of newly 
synthesized proteins in the ER [35]. In wild-type Xenopus melanotrope cells, DTT prevents 
disulﬁ de bond formation of newly synthesized proteins, blocks POMC transport out of the 
early secretory pathway and strongly inhibits POMC processing. When the thiol-reducing 
agent is removed during the chase period the disulﬁ de bonds are allowed to be reformed, 
indicating that treatment with DTT is reversible [25]. When DTT was present during the 
pre- and pulse-, but not the chase-incubation the pulse-chase analysis showed normal POMC 
production and processing in both the wild-type and the transgenic cells, indicating that the 
transgenic melanotropes were also able to recover from the DTT-treatment (Fig. 6A and B). 
However, while in both wild-type and transgenic NILs prohormone cleavage was strongly 
inhibited and no POMC-derived proteins were secreted when the tissue was incubated in the 
presence of DTT during the whole incubation period (pre, pulse and chase), a signiﬁ cantly 
lower amount of 37-kDa POMC was detected in the transgenic than in the wild-type NILs 
(~4-fold reduction) (Fig. 6A and B).  Thus, the transgenic cells handled improperly folded 
newly synthesized POMC differently from wild-type cells.
The ultrastructure of wild-type and transgenic Xenopus intermediate pituitary cells
The reduced POMC levels observed in the transgenic Xenopus melanotrope cells prompted 
us to examine the consequences of the transgene expression of GFP-PrPC on the ultrastructure 
of the cells. Electron microscopy studies were performed on NILs from long-term black-
adapted wild-type, GFP-GPI-transgenic and GFP-PrPC-transgenic animals. As expected, the 
wild-type and transgenic melanotrope cells from the fully black-adapted animals showed 
a well-developed rough ER and extensive Golgi areas, as these cells are highly active in 
synthesizing POMC (Fig. 7A-C). Furthermore, electron-dense secretory granules containing 
POMC-derived peptides [24]; here referred to as POMC secretory granules) were visible 
in both wild-type and transgenic melanotrope cells (Fig. 7A-C). However, a striking 
ultrastructural feature of the GFP-PrPC-transgenic melanotrope cells was the formation of 
electron-dense pleiomorphic lysosomes (crinosomes) (Fig. 7B). 
Chapter 4
80
Figure 7. Electron microscopy on wild-type Xenopus melanotrope cells and cells transgenic for GFP-
PrPC or GFP-GPI. (A-C) Electron micrographs of wild-type (wt), GFP-PrPC-transgenic (102) and GFP-
GPI-transgenic (150) melanotrope cells. Animals were adapted to a black background for >8 weeks. 
Wild-type and transgenic melanotrope cells show well-developed rough endoplasmic reticulum and 
extensive Golgi areas. Only transgenic melanotrope cells from line 102 contain pleiomorph electron-
dense lysosomes (crinosomes).  (D-G) Details of various stages of crinophagy in transgenic melanotrope 
cells from line 102. (D) Accumulation of a number of autophagic vacuoles (encircled) containing a 
variety of membraneous and electron-grey material. Arrows indicate large electron-dense lysosomal 
structures. (E) Higher magniﬁ cation of autophagic vacuoles and electron-dense secretory granules. 
Fusing autophagic vacuoles are encircled. (F) A large electron-dense crinosome containing electron-
grey debris and invaginating membraneous cytoplasmic material. (G) Aggregating dense crinosomes 
with capricious extensions. Av, Autophagic vacuoles; Cr, crinosomes; ER, endoplasmic reticulum; Go, 
Golgi area; N, nucleus; Sg, secretory granules. Bars equal 1 μm.
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The crinosomes did not contain the GFP-PrPC fusion protein since confocal microscopy 
studies using lysotracker in combination with direct GFP ﬂ uorescence did not show a 
colocalization of the GFP-PrPC protein with lysosomes (data not shown). Various stages 
of crinosome formation were detected in the GFP-PrPC-transgenic melanotropes (Fig. 7D-
G). At an early stage, autophagic vacuoles with a variety of morphological appearances 
accumulated. In addition, electron-dense POMC secretory granules were found in close 
vicinity of the autophagic vacuoles (Fig. 7D). As a next step in the process, the membranes of 
the autophagic vacuoles fused, resulting in the formation of autophagosomes (Fig. 7E). Then, 
the autophagosomes fused with dense lysosomes and invaginated membraneous cytoplasmic 
material (Fig. 7F). In the ﬁ nal stage, dense capriciously shaped crinosomes with varying 
sizes were formed (Fig. 7B and G). Thus, intriguingly and in line with the observed reduced 
POMC levels, the process of crinophagy (lysosomal uptake of POMC secretory granules) 
was induced in the GFP-PrPC-transgenic cells. Crinosomes were not detected in the wild-type 
and control GFP-GPI-transgenic melanotrope cells (Fig. 7A and C).
Discussion
The aim of the present study was to explore the effect of transgene expression of PrPC on 
the functioning of Xenopus intermediate pituitary melanotrope cells. We examined the 
Xenopus melanotrope cells since for a number of reasons they represent an attractive cell 
model system. First, the Xenopus melanotropes constitute a homogeneous population of 
strictly regulated neuroendocrine secretory cells, and their biosynthetic and secretory activity 
can be physiologically manipulated by simply placing the amphibian on a black or a white 
background. Secondly, these cells synthesize large amounts of a single cargo molecule with 
a well-deﬁ ned role; the prohormone POMC is synthesized, transported through the regulated 
secretory pathway and processed to a number of bioactive peptides, including α-MSH that is 
responsible for darkening of the skin [17]. Third, the regulatory mechanisms and pathways 
as well as many proteins present in these cells are highly conserved between Xenopus and 
mammals, and therefore studies on the Xenopus melanotrope cells have provided information 
that has been valuable for understanding the functioning of mammalian cells [36-38]. 
Fourth, for functional studies on proteins with an unknown role we employ stable Xenopus 
transgenesis in combination with a POMC gene promoter fragment to generate transgenic 
frogs that express the protein of interest speciﬁ cally and physiologically inducible in the 
melanotrope cells.
In the present study, we examined the effect of three experimental manipulations on 
the functioning of the Xenopus melanotrope cells transgenic for GFP-PrPC. As a ﬁ rst 
manipulation, we exposed the melanotrope cells to the transgene product for a relatively 
long time period by adapting the GFP-PrPC-transgenic animals for >8 weeks to a black 
background. We found that the transgene expression of the GFP-PrPC fusion protein in the 
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active intermediate pituitary melanotrope cells of 8-weeks-black-adapted Xenopus affected 
the secretory pathway, namely a reduction of steady-state and newly synthesized levels 
of POMC. As controls, we used melanotrope cells from wild-type Xenopus and Xenopus 
transgenic for POMC gene promoter-driven GFP-GPI to establish that any effect of the GFP-
PrPC product on melanotrope cell functioning was not due to the transgenic procedure per 
se. The functioning of the melanotropes from the long-term (>8 weeks) black-adapted wild-
type and GFP-GPI-transgenic animals was not affected, indicating that the phenotype of 
the GFP-PrPC-transgenic melanotrope cells was due to the transgene expression of GFP-
PrPC. In a previous, preliminary functional characterization of the GFP-PrPC-transgenic 
melanotrope cells from frogs black adapted for only 3 weeks, we observed no effect of the 
expression of the fusion protein on the functioning of the transgenic cells [20]. Apparently, 
only a relatively long exposure of the transgenic melanotrope cells to the transgene product 
causes a phenotypic effect. A second manipulation of the GFP-PrPC-transgenic melanotrope 
cells involved glucose deprivation of cells from frogs adapted to a black background for 3 
weeks, causing a phenotype similar to that of untreated transgenic melantrope cells from 
8-weeks-adapted animals. Since glucose deprivation of cells is known to cause metabolic 
stress [39,40] and wild-type melanotrope cells were not affected by this energy deprivation, 
the GFP-PrPC-transgenic cells were apparently more sensitive to metabolic stress. Similarly, 
treatment of the GFP-PrPC-transgenic cells with the glucose analogs L-glucose (an inactive 
form of glucose) and 2-deoxy-D-glucose (a non-degradable analog of glucose) resulted in 
the cellular phenotype. Forcing the melanotrope cells to produce unfolded POMC in the 
early secretory pathway by treatment of the cells with the reducing agent DTT constituted a 
third experimental manipulation. DTT treatment of cells causes stress in the early secretory 
pathway since cysteine-containing proteins that carry incorrectly paired or no disulﬁ de 
bonds are not properly folded and are retained in the ER [41-43]. In wild-type DTT-treated 
melanotrope cells, we found that disruption of the disulﬁ de bonds in newly synthesized 
POMC (carrying four cysteines) prevented the prohormone from arriving at the trans-Golgi 
network and caused its accumulation in the early secretory pathway. While in the presence of 
DTT the unfolded pool of POMC remained unaffected in the wild-type cells, the DTT-treated 
melanotrope cells transgenic for GFP-PrPC were not able to properly handle the unfolded 
POMC pool. Thus, cellular stress caused by reducing conditions affected the POMC pool in 
GFP-PrPC-transgenic but not wild-type Xenopus melanotrope cells. 
The observed reduced levels of POMC in the GFP-PrPC-transgenic melanotrope cells can 
be explained by either a relatively fast transport and processing of POMC in the secretory 
pathway or through degradation of the prohormone. However, the ﬁ rst possibility appears 
to be unlikely, because our detailed pulse-chase metabolic cell labeling studies showed no 
faster transport and processing of POMC, and secretion of the POMC-derived peptides by the 
transgenic cells. The second explanation, namely reduced POMC levels through prohormone 
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degradation, thus appears to be more likely. Such a degradation probably occurred through 
the lysosomal rather than the proteasomal pathway, since if the proteasomal pathway would 
be involved one would expect the amounts of the BiP protein to be increased [44-47], whereas 
the steady-state levels of BiP were actually reduced in the GFP-PrPC-transgenic melanotrope 
cells. Moreover, our electron microscopy studies indicated that transgene expression of 
GFP-PrPC in the Xenopus melanotrope cells caused an induction of the lysosomal uptake 
of POMC secretory granules, a process generally known as crinophagy. A similar process 
of crinophagy, namely lysosomal uptake of zymogen granules, was induced in pancreatic 
exocrine cells from starved rats [48]. We here demonstrate for the ﬁ rst time that crinophagy 
is induced when neuroendocrine cells are exposed to the expression of the PrPC transgene. 
In scrapie-infected neurons, only the formation of autophagic vacuoles, but not the process 
of crinophagy, has been observed (reviewed by Liberski et al. [49]). Unfortunately, previous 
studies concerning the effect of PrPC expression in transfected cells or in transgenic animal 
models did not include an ultrastructural analysis [50-55].
In conclusion, we have successfully targeted GFP-PrPC as well as the control GFP-GPI fusion 
protein speciﬁ cally to the Xenopus intermediate pituitary melanotrope cells. Furthermore, 
and most importantly, our transgenic studies in a physiological context showed that transgene 
expression of PrPC caused malfunctioning of the secretory pathway and induced crinophagy 
in neuroendocrine cells.
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Abstract
The cellular prion protein (PrPC) is generally accepted to be involved in the development 
of prion diseases, but its physiological role is still under debate. To obtain more insight 
into PrPC functioning, we here used stable Xenopus transgenesis in combination with the 
proopiomelanocortin (POMC) gene promoter to express mutated forms of Xenopus PrPC 
fused to the C-terminus of the green ﬂ uorescent protein GFP speciﬁ cally in the neuroendocrine 
Xenopus intermediate pituitary melanotrope cells. Similar to GFP-PrPC, the newly synthesized 
GFP-PrPCK81A mutant protein was stepwise mono- and di-N-glycosylated to 48- and 51-kDa 
forms, respectively, and eventually complex glycosylated to yield a 55-kDa mature form. 
Unlike GFP-PrPC, the mature GFP-PrPCK81A mutant protein was not cleaved, demonstrating 
the endoproteolytic processing of Xenopus PrPC at lysine residue 81. Surprisingly, removal of 
the glycosylphosphatidylinositol (GPI) anchor signal sequence or insertion of an octarepeat 
still allowed N-linked glycosylation, but the GFP-PrPCΔGPI and GFP-PrPCocta mutant 
proteins were not complex glycosylated and not cleaved, indicating that the GPI/octa mutants 
did not reach the mid-Golgi compartment of the secretory pathway. The transgene expression 
of the mutant proteins did not affect the ultrastructure of the melanotrope cells nor POMC 
biosynthesis and processing, or POMC-derived peptide secretion. Together, our ﬁ ndings 
reveal the evolutionary conservation of the site of metabolic cleavage and the importance 
of the presence of the GPI-anchor and the absence of the octarepeat in Xenopus PrPC for its 
correct biosynthesis.
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Introduction
Prion diseases or transmissible spongiform encephalopathies are a group of neurodegenerative 
diseases caused by changes in the three-dimensional conformation of the cellular form of 
prion protein (PrPC) [1,2]. PrPC is a glycoprotein anchored to the cell surface by a glycosy
lphosphatidylinositol (GPI) moiety and is expressed in most cell types, but highest levels 
are found in the central nervous system [3-5]. Biosynthetic studies with cell lines, cultured 
neurons and hamster brain tissue have shown that mammalian PrPC is subjected to a number 
of post-translational modiﬁ cations, including GPI-anchoring, N-linked high-mannose 
type oligosaccharide attachments with subsequent complex glycosylation and disulﬁ de 
bond formation [6-10]. After reaching the plasma membrane of the cell, mammalian PrPC 
undergoes post-translational proteolytic cleavage [9,11-16]. The physiological role of PrPC 
is unknown and a variety of functions have been proposed [17]. For instance, since ﬁ sh, 
reptile, avian and mammalian PrP sequences contain from two to ten copies of a repeat 
that in neurons binds Cu2+, PrPC may regulate the Cu2+ content of the synaptic cleft [18-20]. 
Remarkably, the South-African claw-toed frog Xenopus laevis is the only species known to 
lack an octarepeat in its PrP amino acid sequence. The elusive physiological function of PrPC 
encouraged us to perform transgenic studies in vivo with Xenopus laevis as a model system, 
and in particular with the highly specialized melanotrope cells of the Xenopus intermediate 
pituitary. These cells are well-deﬁ ned, strictly regulated neuroendocrine secretory cells that, 
when the animal is placed on a black background, produce high amounts (~80% of all newly 
synthesized proteins) of proopiomelanocortin (POMC), a prohormone that mediates the 
process of background adaptation [21]. In the trans-Golgi network and immature secretory 
granules of the melanotrope cells, POMC is endoproteolytically cleaved into a number of 
bioactive peptides, including α-melanophore-stimulating hormone (α-MSH). Once released 
into the blood, α-MSH mediates adaptation of the animal to a black background by causing 
dispersion of melanin pigment granules (melanosomes) in skin melanophores, resulting in 
darkening of the skin [22]. Depending on the color of the background of the animal (black or 
white), the melanotrope cells are differentially innervated by neuronal cells of hypothalamic 
origin (e.g. strong inhibitory synapses are formed in white animals). 
To examine the structural elements required for correct PrPC biosynthesis in the Xenopus 
melanotrope cell, we combined the unique properties of this cell with the technique of stable 
Xenopus laevis transgenesis [23,24]. We used a Xenopus POMC gene promoter fragment to 
target transgene expression of Xenopus PrPC fused to the C-terminus of the green ﬂ uorescent 
protein GFP (GFP-PrPC) speciﬁ cally to the Xenopus melanotrope cells, leaving the integrity 
of the regulation by the hypothalamic neurons intact. We have previously observed that the 
biosynthesis of the exogenous GFP-PrPC was similar to that found for endogenous PrPC 
[25] and that the transgene expression of GFP-PrPC induced the process of crinophagy 
in the transgenic Xenopus melanotrope cells [26]. In the present study, we used Xenopus 
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melanotrope cell-speciﬁ c transgene expression of mutated forms of GFP-PrPC (the non-
cleavable GFP-PrPCK81A, the GPI-deleted GFP-PrPCΔGPI and the octarepeat-containing 
GFP-PrPCocta mutant proteins) to explore structural elements within the PrP sequence that 
may affect its biosynthesis.
Experimental procedures
Animals
South-African claw-toed frogs Xenopus laevis were bred, reared and adapted to a black 
or white background, and unfertilized eggs were harvested from mature female Xenopus 
laevis (Xenopus Express, Cape Town, South-Africa) as described previously [25]. All 
animal experiments were carried out in accordance with the European Communities Council 
Directive 86/609/EEC for animal welfare, and permit RBD0166(H10) to generate and house 
transgenic Xenopus.
Generation of Xenopus transgenic for GFP-PrPC, GFP-PrPCK81A, GFP-PrPCΔGPI, GFP-
PrPCocta or GFP-GPI
The open-reading frame of Xenopus PrP (+69 to +648; [27]; not including the signal sequence) 
and of the GPI-anchor of Xenopus PrP (+540 to +648; [27]) were ampliﬁ ed by PCR and used 
to generate constructs pPOMC-GFP-PrP and pPOMC-GFP-GPI, respectively. Transgene 
construct pPOMC-GFP-PrPK81A (in which the lysine at the metabolic cleavage site at codon 
81 was substituted by an alanine) was generated via site-directed mutagenesis performed 
on construct pPOMC-GFP-PrP using a Pfu DNA polymerase-mediated mutagenesis system 
(Quickchange, Stratagene) and the following mutagenic oligonucleotide primers: 5’-
XPrPK81A: 5’-GTCCAAAACCAACATGGCGTCGGTGGCCATAGGC and its reverse 
complement oligonucleotide. For the generation of construct pPOMC-GFP-PrPΔGPI, a 
stop codon was introduced at amino acid position 193 by site-directed mutagenesis and the 
mutagenic oligonucleotide primers: 5’-XPrPΔGPI): 5’-GCATCACTGAGTACAGGTGAGG
ATCGGGATTCAAAGTGC and its reverse complement oligonucleotide. The GFP-PrPK81A 
and GFP-PrPΔGPI DNA templates were digested with restriction enzyme DpnI, speciﬁ c for 
methylated and hemi-methylated DNA, in order to eliminate these parental DNA templates. 
For the generation of transgene construct pPOMC-GFP-PrPocta (in which a human PrP 
octarepeat sequence was inserted into the Xenopus PrP sequence at codon 61), ﬁ rst a BglII 
restriction site was introduced at amino acid position 61 by site-directed mutagenesis and the 
mutagenic oligonucleotide primers: 5’-XPrP-BglII: 5’-GGAGGCAGCTGGGGGCAAGAT
CTTTATAATCCTAGCGG and its reverse complement oligonucleotide. Furthermore, the 
human PrPC octarepeat was generated by annealing two complementary oligonucleotides 
containing BglII restriction sites at their 5’ ends: 5’-octa-BglII (5’-GGGGAGATCTTCCT
CATGGTGGTGGCTGGGGGCAGCCTCATGGTGGTGGCTGGGGGCAGCCCCATGGT
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G and 3’-octa-BglII: 3’-GGGGAGATCTGGTTGTTGACCCCAGCCACCACCATGAGG
CTGTCCCCAGCCACCACCATGGGGCTGCCCCCAG) followed by BglII digestion. The 
BglII-digested human PrP octarepeat fragment was then inserted into the introduced BglII 
restriction site of construct pPOMC-GFP-PrP to generate construct pPOMC-GFP-PrPocta. 
All transgene constructs contained a 529-bp Xenopus POMC gene A promoter fragment 
(pPOMC) which directs transgene expression speciﬁ cally to the melanotrope cells of the 
Xenopus intermediate pituitary [28], the signal-peptide-coding sequence of the Xenopus 
secretory pathway component Ac45 [29], GFP cDNA, Xenopus (mutant) PrP cDNA and the 
CMV polyA signal [30]. The sequence of the transgene constructs were veriﬁ ed by cycle 
DNA sequencing [25]. The 2301-, 1817-, 2301- and 2301-bp SalI/BssHII fragments, and a 
2345-bp SalI/NotI fragment, containing the SV40 polyA signal behind the pPOMC-GFP-
PrP, pPOMC-GFP-GPI, pPOMC-GFP-PrPK81A, pPOMC-GFP-PrPΔGPI and pPOMC-
GFP-PrPocta fragment, respectively, were puriﬁ ed and used to generate transgenic Xenopus 
embryos as described previously [25]. The presence of GFP ﬂ uorescence was examined in 
living embryos anaesthetized with 0.25 mg/ml MS222 (3-aminobenzoic acid ethyl ester; 
Sigma, St. Louis, MO) using a Leica MZ FLIII ﬂ uorescence stereomicroscope and photographs 
were taken with a Leica DC200 color camera using the Leica DCviewer software.
In vitro fertilization of wild-type Xenopus eggs with transgenic sperm cells
In vitro fertilization to generate transgenic Xenopus has been described previously [25]. Brieﬂ y, 
pieces of testes of male transgenic Xenopus laevis frogs were rubbed against unfertilized 
eggs harvested from wild-type Xenopus laevis females and subsequently the fertilized eggs 
were selected in their 4-cell stage and screened for speciﬁ c pituitary ﬂ uorescence during 
early development (∼stage 40). Staging of Xenopus embryos was carried out according to 
Nieuwkoop and Faber [31].
Western blot analysis
Western blot analysis was performed as described previously [25]. Brieﬂ y, neurointermediate 
lobes (NILs) of black-adapted wild-type and transgenic Xenopus were homogenized and the 
lysates were denatured, separated on 12.5% SDS-PAGE, and transferred to nitrocellulose 
(Protran; Schleicher & Schuell, Keene, NH) or PVDF (Hybond-P; Amersham Biosciences) 
membranes. Following blocking, blots were incubated with a polyclonal rabbit anti-
GFP (1:5000) antibody (kindly provided by Dr. B. Wieringa; [32]) overnight at 4°C and 
subsequently with a peroxidase conjugated secondary antibody (1:5000) for 45 min at 
room temperature. Proteins were immunodetected using Lumi-LightPLUS substrate (Roche 
Diagnostics, Mannheim, Germany) and subsequently exposed to X-ray ﬁ lm (Kodak, 
Rochester, NY). Signals were analyzed using Labworks 4.0 software (UVP BioImaging 
systems, Cambridge, UK).
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Metabolic cell labeling and immunoprecipitation analysis
Metabolic cell labeling and immunoprecipitation analysis have been described previously 
[25]. Brieﬂ y, NILs of black-adapted wild-type and transgenic Xenopus were rapidly dissected 
and preincubated in Ringer’s medium for 15 min at 22°C. Radioactive labeling of newly 
synthesized proteins was performed by incubating the NILs in Ringer’s medium containing 
5 mCi/ml [35S]-Met/Cys (Tran35S-label, MP Biomedicals, Irvine, CA) for 30 min at 22°C, 
rinsed, and chased with 0.5 mM L-methionine in Ringer’s medium for 3 hr at 22°C. Following 
the 180-min chase, NILs were homogenized and parts of the lysates and incubation media 
were analyzed directly on SDS-PAGE, while the remainder was used for immunoprecipitation 
and Western blot analysis. For immunoprecipitation analysis, NIL lysates were incubated 
with the anti-GFP antibody (1:500) and protein A-sepharose (Amersham Biosciences), and 
the immune complexes were resolved by SDS-PAGE. Radiolabeled proteins were detected 
using autoradiography at -70°C.
Electron microscopy
For ultrastructural studies, freshly dissected NILs of wild-type Xenopus and Xenopus 
transgenic for GFP-PrPC, GFP-PrPCK81A, GFP-PrPCΔGPI, GFP-PrPCocta or GFP-GPI were 
used. Whole lobes were ﬁ xed overnight at 4°C in 2% glutaraldehyde in 0.1 M phosphate 
buffer (PB, pH 7.3). Following rinsing in the same buffer, ﬁ xed tissues were osmicated for 
one hour in 1% osmium tetroxide in 0.1 M PB, rinsed in PB, dehydrated through graded series 
of ethanol and embedded in Epon 812. One-micron thick sections were cut and blue-stained 
with toluidine. Subsequently, the sections were examined in a phase-contrast microscope 
(Dialux 20, Leitz). Ultrathin sections were cut, double contrasted with uranyl-acetate/lead-
citrate and photographed in a transmission electron microscope (JEOL 1010).
Statistics
Data are presented as means ± SEM (n = 3). Statistical evaluation was performed using an 
unpaired Student’s t-test.
Results
Generation of Xenopus transgenic for mutated forms of the GFP-PrPC fusion protein
To explore which structural elements in the Xenopus PrP sequence are important for its 
proper biosynthesis, we generated a number of Xenopus lines transgenic for mutated forms of 
Xenopus PrPC fused to the C-terminus of GFP (GFP-PrPC), namely a line containing a point 
mutation at the putative metabolic cleavage site of PrPC (GFP-PrPCK81A with lysine residue 
81 mutated into an alanine); a line containing a stop codon upstream of the GPI-anchor signal 
sequence at residue 191 (GFP-PrPCΔGPI); a line containing the human octarepeat following 
residue 61 (GFP-PrPCocta); and a line containing the GPI-anchor signal sequence of Xenopus 
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PrPC fused to the C-terminus of GFP (GFP-GPI) (Fig. 1A). The DNA fragments encoding 
the mutated GFP-PrPC proteins were cloned downstream of a Xenopus POMC gene promoter 
fragment that directs transgene expression speciﬁ cally to the melanotrope cells of the Xenopus 
intermediate pituitary [28]. Transgenic F1 offsprings were generated by in vitro fertilization 
of eggs harvested from wild-type Xenopus females with sperm isolated from the testis of a 
male frog transgenic for the respective mutated GFP-PrPC. The expression of the transgene 
products could be observed by direct visual inspection of the living Xenopus embryos under 
a ﬂ uorescence microscope (Fig. 1B, left panel). We selected transgenic F1 lines that displayed 
similar GFP ﬂ uorescence in the intermediate pituitary (#102 for GFP-PrPC, #140 for GFP-
PrPCK81A, #160 for GFP-PrPCΔGPI, #170 for GFP-PrPCocta and #150 for GFP-GPI) and 
raised the embryos for further analysis. Lifting the brain of adult Xenopus transgenic for 
the various mutants showed that the expression of the transgene product was restricted to 
cells located in the pituitary intermediate lobe (IL; neuroendocrine melanotrope cells), while 
no ﬂ uorescence was observed in the pituitary anterior lobe (AL; containing the POMC-
producing corticotrope cells) and other brain structures (Fig. 1B, right panel). The expression 
patterns observed during early embryonic development of the transgenic Xenopus resembled 
those seen in Xenopus with POMC promoter-driven transgene expression of GFP itself [28], 
namely speciﬁ c expression in the intermediate pituitary cells. From the Xenopus pituitary 
(consisting of the pars nervosa, IL and AL), the AL can be dissected, but the pars nervosa 
(containing nerve terminals of hypothalamic origin) is intimately associated with the IL. To 
examine the steady-state levels of the mutated GFP-PrPC proteins, the neurointermediate lobe 
(NIL, IL together with pars nervosa) and AL were dissected from wild-type and transgenic 
frogs. Western blot analysis of NIL lysates from GFP-PrPC- and GFP-PrPCK81A-transgenic 
black-adapted animals using an anti-GFP-antibody revealed a mature, complex-glycosylated 
∼55-kDa fusion protein and a relatively small amount of an N-glycosylated ∼51-kDa product 
(Fig. 1C). The GFP-PrPCΔGPI fusion protein appeared as an ∼49-kDa product. In addition, 
the NIL lysate from the GFP-PrPCΔGPI-transgenic animals showed a number of other 
immunoreactive products, presumably GFP-PrPCΔGPI degradation products. We detected 
two GFP-PrPCocta products of ∼57 and ∼59 kDa in NIL lysates from Xenopus transgenic 
for GFP-PrPCocta, but the steady-state levels of these products were relatively low when 
compared with the steady-state levels of the other mutated GFP-PrPC proteins. Analysis of 
NILs from the GFP-GPI-transgenic animals showed a GFP-GPI fusion protein of ∼35 kDa, 
while the NILs of wild-type animals did not contain an immunoreactive product. The mutated 
GFP-PrPC proteins were not expressed in the AL, showing that the expression of these fusion 
proteins was restricted to the NIL (Fig. 1C).
Structural elements for correct PrPC biosynthesis
95
Chapter 5
Figure 1. Intermediate pituitary-speciﬁ c ﬂ uorescence and transgene expression in Xenopus transgenic 
for GFP-PrPC, GFP-PrPCK81A, GFP-PrPCΔGPI, GFP-PrPCocta or GFP-GPI. (A) Schematic 
representation of the linear injection fragments pPOMC-GFP-PrP, pPOMC-GFP-PrPK81A, pPOMC-
GFP-PrPΔGPI, pPOMC-GFP-PrPocta and pPOMC-GFP-GPI containing the Xenopus POMC gene 
A promoter fragment (pPOMC), and the GFP-PrP, GFP-PrPK81A, GFP-PrPΔGPI, GFP-PrPocta and 
GFP-GPI fusion protein-coding sequence, which were used to generate transgenic Xenopus lines 102, 
140, 160, 170 and 150, respectively; SS, signal peptide sequence; octa, human octarepeat; *, location 
of the mutation of the metabolic cleavage site; GPI, glycosylphosphatidylinositol signal sequence. (B) 
Intermediate pituitary-speciﬁ c ﬂ uorescence in a living Xenopus F1 embryo (stage ~40, staging according 
to Nieuwkoop and Faber [31]; left panel) and in a black-adapted 6 month-old frog transgenic for GFP-
PrPCΔGPI (ventrocaudal view; right panel) as a representive example of the various transgenic Xenopus 
F1 and F2 lines used in this study. In adult Xenopus, the brain was lifted to reveal intense ﬂ uorescence 
in the intermediate lobe (IL), but not in the anterior lobe (AL) of the pituitary. Arrows indicate the 
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localizations of the ﬂ uorescent intermediate pituitaries expressing the fusion product; the positions of 
the eye (E), nose (N) and gut (G) are also indicated in the tadpole. Bars equal 0.5 mm. (C) Tissue lysates 
of neurointermediate lobes (NILs) and ALs from wild-type (wt) animals and animals transgenic for the 
GFP-PrPC (102), GFP-PrPCK81A (140), GFP-PrPCΔGPI (160), GFP-PrPCocta (170) or GFP-GPI (150) 
fusion protein were subjected to SDS-PAGE. Western blot analysis was performed using an anti-GFP 
antibody (α-GFP).
Biosynthesis of the newly synthesized mutated forms of the GFP-PrPC fusion protein in the 
transgenic Xenopus intermediate pituitary cells
To investigate the biosynthesis of GFP-PrPCK81A (#140), GFP-PrPCΔGPI (#160), GFP-
PrPCocta (#170) and GFP-GPI (#150), we monitored the fate of the newly synthesized fusion 
proteins in the respective transgenic Xenopus NILs by pulse and pulse-chase metabolic cell 
labeling and subsequent immunoprecipitation analysis (Fig. 2A).  In these experiments, wild-
type NILs and NILs transgenic for GFP-PrPC (#102) were used as controls. 
Following a 30-min pulse, the newly synthesized GFP-PrPC fusion protein was produced as 
two minor products of ∼45 and ∼48 kDa and a major product of ∼51 kDa (Fig. 2A, lane 3). 
Following a subsequent chase incubation of 180 min, these products were converted into a 
protein migrating at ∼55 kDa (Fig. 2A, lane 9). To examine whether the transgene products 
were N-glycosylated and/or GPI-anchored, the newly synthesized (mutated) GFP-PrPC 
proteins were treated with either peptide N-glycosidase F (PNgase F) that removes N-linked 
oligosaccharides, or phosphatidylinositol-speciﬁ c phospholipase C (PIPLC) that speciﬁ cally 
cleaves phosphatidylinositol anchors from proteins [33] (Fig. 2B-F). After a 30-min pulse 
and 180-min chase, PNgase F-treatment of the GFP-PrPC-transgenic NIL lysate resulted in 
an ∼47-kDa fusion protein (Fig. 2B, lane 4), suggesting that the 48- and 51-kDa GFP-PrPC 
products were mono- and di-N-glycosylated, respectively, and the 55-kDa GFP-PrPC protein 
was complex glycosylated. Treatment of the NIL lysates with PIPLC caused the 51- and 55-
kDa GFP-PrPC fusion proteins to migrate as ∼53- and ∼57-kDa products, respectively, due 
to the loss of the diacylglycerol moiety, indicating that the mutant protein was GPI-anchored 
(Fig. 2B, lane 5) [25]. Removal of the diacylglycerol moiety results in a shift of ∼2 kDa [7]. 
The biosynthesis of GFP-PrPCK81A was similar to GFP-PrPC biosynthesis (Fig. 2B and 
C). A GFP-PrPCK81A cleavage product was not detected in the chase incubation medium, 
suggesting that the GFP-PrPCK81A fusion protein was not metabolically cleaved (Fig. 2A, 
lane 16). In contrast, GFP-PrPC was cleaved to an ∼33 kDa product that was secreted (Fig. 
2A, lane 15) [25].
Three newly synthesized GFP-PrPCΔGPI fusion proteins were produced, namely two major 
products of ∼46 and ∼49 kDa, and one minor product of ∼43 kDa (Fig. 2A, lane 6). The 
rate of N-glycosylation of GFP-PrPCΔGPI was slower than that of GFP-PrPC, since after the 
30-min pulse still a major mono-N-linked glycosylated GFP-PrPCΔGPI (46 kDa) form was 
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found, while most of the GFP-PrPC protein was di-N-linked glycosylated (Fig. 2D, lanes 1 
and 2). Following the chase incubation, the 49-kDa product was the major GFP-PrPCΔGPI 
protein and the 43-kDa product the minor, suggesting that the majority of the GFP-PrPCΔGPI 
fusion protein was eventually di-N-glycosylated (Fig. 2A, lane 12). No mature form was 
observed, indicating that complex glycosylation of the GFP-PrPCΔGPI mutant protein did 
not occur. Following a 180-min chase incubation and subsequent PNgase F-treatment, the 
GFP-PrPCΔGPI protein migrated as a major 43-kDa product and a minor product of 46 kDa 
was detected (Fig. 2D, lane 4). As expected, after the 180-min chase and subsequent PIPLC-
treatment the migration of the newly synthesized 43- and 49-kDa GFP-PrPCΔGPI products 
was not affected (Fig. 2D, lane 5). The chase incubation medium did not contain a released 
GFP-PrPCΔGPI product and this mutant protein was thus not secreted (Fig. 2A, lane 18). 
This is surprising because the GFP-PrPCΔGPI fusion protein lacked the GPI achoring signal 
peptide and one would expect this product to be soluble and therefore secreted. It is likely 
that the GFP-PrPCΔGPI product did not reach the mid-Golgi compartment and remained in 
the early secretory pathway of the melanotrope cell. 
During a 30-min pulse the newly synthesized GFP-PrPCocta fusion protein was produced as 
a major product of ∼55 kDa, and two minor ∼49- and ∼52-kDa products (Fig. 2A, lane 7). 
Following the subsequent chase incubation, the GFP-PrPCocta proteins still migrated as 49-, 
52-, and 55-kDa products, indicating that the fusion protein was not complex glycosylated 
(Fig. 2A, lane 13). The amounts of the newly synthesized fusion products were clearly 
reduced and no products were released, suggesting that during the chase incubation the GFP-
PrPCocta proteins were degraded. The 52- and 55-kDa fusion proteins were mono- and di-
N-linked glycosylated since, after the 30-min pulse and 180-min chase incubation, treatment 
of the GFP-PrPCocta NIL lysate with PNgase F resulted in the detection of only the 49-kDa 
fusion protein (Fig. 2E, lane 4). PIPLC-treatment caused the 49-, 52-, and 55-kDa proteins 
to migrate as an ∼57-kDa product, indicating that at least the 55-kDa GFP-PrPCocta product 
was GPI-anchored (Fig. 2E, lane 5). Remarkably, following the pulse-chase incubation of the 
GFP-PrPCocta-transgenic NILs no product was found in the incubation medium, suggesting 
that the GFP-PrPCocta products were not cleaved and secreted (Fig. 2A, lane 19). 
The newly synthesized GFP-GPI fusion protein was produced as a single ∼33 kDa product 
(Fig. 2A, lane 5). Following a 30-min pulse and subsequent 180-min chase, a portion of 
the 33-kDa GFP-GPI fusion protein migrated as an ∼35-kDa product (Fig. 2A, lane 11), 
presumably due to a presently unknown post-translational modiﬁ cation. PNgase F-treatment 
did not affect the migration of the 33- and 35-kDa products, indicating that the GFP-GPI 
product was not subjected to glycosylation (Fig. 2F, lane 4). Following PIPLC-treatment, the 
33- and 35-kDa proteins migrated as ∼34- and ∼36-kDa, suggesting that the GFP-GPI fusion 
protein was GPI anchored (Fig. 2F, lane 5). As expected, we did not observe a GFP-GPI 
product in the incubation medium (Fig. 2A, lane 17).
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Figure 2. Biosynthesis of the mutated forms of the GFP-PrPC protein in transgenic Xenopus intermediate 
pituitary cells. (A) In lane 1, 5% of a total neurointermediate lobe (NIL) lysate (total) from wild-
type (wt) Xenopus was directly loaded on the gel. (A-F) Wt NILs and NILs transgenic for GFP-PrPC 
(102), GFP-PrPCK81A (140), GFP-PrPCΔGPI (160), GFP-PrPCocta (170) or GFP-GPI (150) were pulse 
labeled with [35S]-Met/Cys for 30 min (P30), or 30-min pulse labeled and chase incubated for 180 min 
(P30C180), and subsequently the proteins were extracted. (B-F) The extracted proteins were incubated 
in the presence (+) or absence (-) of peptide N-glycosidase F (PNgase F) or phosphatidylinositol-
speciﬁ c phospholipase C (PIPLC). In all cases, newly synthesized proteins extracted from the lobes 
or secreted into the incubation medium were immunoprecipitated using an anti-GFP antibody, the 
immunoprecipitates were resolved by SDS-PAGE on a 15% gel and the radiolabeled proteins were 
visualized by autoradiography. Asterisks in A indicate major NIL proteins (proPC2 and POMC) non-
speciﬁ cally interacting with the anti-GFP antibody.
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Figure 3. Biosynthesis and processing of newly synthesized POMC in wild-type (wt) Xenopus 
intermediate pituitary cells and cells transgenic for the GFP-PrPC (102), GFP-GPI (150), GFP-
PrPCK81A (140), GFP-PrPCΔGPI (160) or GFP-PrPCocta (170) fusion protein. (A) Neurointermediate 
lobes (NILs) from wt and transgenic animals were pulse labeled with [35S]-Met/Cys for 30 min and 
subsequently chased for 180 min. Newly synthesized proteins extracted from the lobes (5%) or 
secreted into the incubation medium (20%) were resolved by SDS-PAGE on 15% gels and visualized 
by autoradiography. (B) The amounts of newly synthesized 37-kDa POMC and the 18-kDa POMC-
derived product were quantiﬁ ed by densitometric scanning and are presented in arbitrary units (AU), 
relative to the amounts of newly synthesized actin. Shown are the means ± SEM (n = 3). Signiﬁ cant 
differences are indicated by ** (P < 0.01) or *** (P < 0.001). In all cases, animals were adapted to a 
black background for >8 weeks (long-term adaptation).
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Biosynthesis and processing of newly synthesized POMC in wild-type and the transgenic 
Xenopus intermediate pituitary cells
In long-term (>8 weeks) black-background-adapted GFP-PrPC-transgenic animals, the 
level of newly synthesized POMC remaining in the cells was reduced [26]. We therefore 
examined the effect of the transgene expression of the mutated GFP-PrPC proteins in long-
term (>8 weeks) black-background-adapted animals on the dynamics of POMC biosynthesis 
in the transgenic Xenopus melanotrope cells. For this purpose, we performed pulse-chase 
analysis of newly synthesized proteins produced in wild-type NILs and NILs transgenic 
for the mutated GFP-PrPC proteins, and secreted into the incubation medium. Besides 
the melanotropes, the Xenopus NIL consists of nerve terminals of hypothalamic origin 
that are biosynthetically inactive (the pars nervosa) and thus the radiolabeled proteins are 
synthesized by the melanotrope cells. Following a 30-min pulse labeling and subsequent 
3-hr chase incubation of wild-type and transgenic NILs, most of the 37-kDa POMC was 
processed to an 18-kDa POMC cleavage product which was subsequently secreted into the 
incubation medium (Fig. 3A). During POMC processing, the ﬁ rst endoproteolytic cleavage 
step generates the 18-kDa product which represents the N-terminal portion of 37-kDa 
POMC [34]. In the GFP-PrPC-transgenic melanotrope cells from animals black adapted for 
>8 weeks, the levels of the newly synthesized 37- and 18-kDa POMC proteins remaining in 
the cells were signiﬁ cantly decreased, while in the wild-type cells and cells transgenic for 
GFP-GPI, no signiﬁ cant differences in the levels of the POMC pool were observed (Fig. 3A 
and B) [26]. NILs transgenic for GFP-PrPCK81A, GFP-PrPCΔGPI or GFP-PrPCocta showed 
normal levels of newly synthesized 37- and 18-kDa POMC remaining in the cells and of 
18-kDa POMC secreted into the incubation medium (Fig. 3A and B). Thus, the long-term 
transgene expression of the mutated GFP-PrPC proteins in NILs of Xenopus adapted to a black 
background for >8 weeks did not affect the biosynthesis and processing of newly synthesized 
POMC nor the secretion of the POMC-derived products.  
Ultrastructure of wild-type and the transgenic Xenopus intermediate pituitary cells
Since in the melanotrope cells of GFP-PrPC-transgenic Xenopus the process of crinophagy 
was induced [26], we next examined the consequences of the transgene expression of the 
mutated forms of GFP-PrPC on the ultrastructure of the transgenic melanotrope cells (Fig. 
4). Electron microscopy studies were performed on intermediate pituitaries from long-term 
black-adapted wild-type, and GFP-PrPC-, GFP-PrPCK81A-, GFP-PrPCΔGPI-, GFP-PrPCocta- 
and GFP-GPI-transgenic animals. We found that in all cases the melanotrope cells transgenic 
for the various mutated forms of GFP-PrPC showed a well-developed rough ER, extensive 
Golgi areas and electron-dense secretory granules containing POMC-derived peptides, here 
referred to as POMC secretory granules, as these cells are highly active in synthesizing 
POMC. This ultrastructure is similar to that observed previously for the wild-type and GFP-
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GPI-transgenic melanotrope cells [26]. Intriguingly, however, only the melanotrope cells 
transgenic for GFP-PrPC showed the formation of electron-dense pleiomorphic lysosomes 
(crinosomes), while the wild-type, GFP-PrPCK81A-, GFP-PrPCΔGPI-, GFP-PrPCocta- and 
GFP-GPI-transgenic melanotrope cells did not contain such aberrant structures (Fig. 4A-F).
Figure 4. Electron microscopy on wild-type Xenopus melanotrope cells and cells transgenic for the 
GFP-PrPC, GFP-PrPCK81A, GFP-PrPCΔGPI, GFP-PrPCocta or GFP-GPI protein. Electron micrographs 
of wild-type (wt; A), GFP-PrPC- (102; B), GFP-PrPCK81A- (140; C), GFP-PrPCΔGPI- (160; D), GFP-
PrPCocta- (170; E) and GFP-GPI-transgenic (150; F) melanotrope cells. Animals were adapted to 
a black background for >8 weeks. Melanotrope cells from transgenic line 102 contain pleiomorph 
electron-dense crinosomes with capricious extensions, indicative of the process of crinophagy (B). Cr, 
crinosome; ER, endoplasmic reticulum; N, nucleus; Sg, secretory granules. Bars equal 1 μm.
Discussion
The aim of this study was to explore the biosynthesis of mutated GFP-PrPC fusion proteins in 
the secretory pathway of transgenic Xenopus laevis intermediate pituitary melanotrope cells 
and the effect of the transgene expression of the mutated proteins on POMC biosynthesis and 
processing, and secretion of the prohormone-derived peptides by these cells. We generated 
and analyzed transgenic Xenopus laevis that expressed GFP-PrPCK81A, GFP-PrPCΔGPI, 
GFP-PrPCocta or GFP-GPI fusion proteins speciﬁ cally in the intermediate pituitary cells, 
since transgene expression was under the control of a Xenopus POMC gene promoter 
fragment. The temporal and spatial expression patterns observed for the mutated GFP-
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PrPC proteins during early embryonic development of the transgenic Xenopus (from stage 
25 onwards and gradually speciﬁ c to the intermediate pituitary) resemble those found in 
Xenopus transgenic for POMC promoter-driven expression of GFP itself [28]. Moreover, the 
patterns are in line with the expression pattern of the endogenous POMC-derived α-MSH-
peptide in developing Xenopus [35]. In the tadpoles transgenic for the GFP-PrPCK81A, GFP-
PrPCΔGPI, GFP-PrPCocta or GFP-GPI fusion proteins, we never observed non-speciﬁ c brain 
ﬂ uorescence other than the ﬂ uorescence found in the intermediate pituitary. Also, all juvenile 
mutant GFP-PrPC-transgenic frogs showed ﬂ uorescence speciﬁ c in the melanotrope cells of 
the intermediate pituitary and never in the anterior pituitary or brain.
Our pulse-chase metabolic cell labeling studies indicated that in the transgenic melanotrope 
cells the biosynthesis and post-translational modiﬁ cations of the GFP-PrPCK81A fusion 
protein were similar to those of GFP-PrPC. Thus, the GFP-PrPCK81A fusion protein was 
initially synthesized as a 45-kDa protein that was subsequently GPI-anchored and stepwise 
mono- and di-N-linked glycosylated resulting in 48-kDa and 51-kDa GFP-PrPCK81A proteins, 
respectively. This ﬁ nding is in line with the fact that Xenopus PrPC contains two conserved 
N-glycosylation sites at amino acid residues 150 and 165 [27]. Like for GFP-PrPC, the high-
mannose type oligosaccharides attached to the 51-kDa fusion protein were further modiﬁ ed 
to yield complex sugar types on the 55-kDa GFP-PrPCK81A protein. We have previously 
shown that in the melanotrope cells 55-kDa Xenopus GFP-PrPC is endoproteolytically 
cleaved in the N-terminal region of the protein [25]. Since the 55-kDa GFP-PrPCK81A 
protein was not cleaved, we now demonstrate that Xenopus PrPC is endoproteolytically 
cleaved at lysine residue 81. In brain and transfected cell lines, mammalian PrPC is located at 
the plasma membrane and undergoes post-translational proteolytic cleavage at lysine residue 
110 (corresponding to residue 81 in the Xenopus protein) as part of its normal metabolism 
[13,36,37], suggesting that the metabolic cleavage site of PrPC is conserved from humans 
to amphibians. Our metabolic labeling studies on the mutated proteins further revealed 
that the newly synthesized GFP-PrPCΔGPI fusion protein was stepwise mono- and di-N-
linked glycosylated, although less efﬁ cient than the GFP-PrPC and GFP-PrPCK81A proteins. 
In contrast, removal of the GPI-anchor signal sequence prevented the N-glycosylation of 
mouse PrPC [38-40], indicating that in the mouse GPI-anchoring of PrPC is important for 
its N-glycosylation. The N-glycosylation of non-anchored mouse PrPC does occur when 
the distance of the glycosylation site from the C-terminus is increased [41]. The amino 
acid sequences of the C-terminal regions of mouse and Xenopus PrP have a low degree of 
sequence identity and Xenopus PrPC apparently carries a proper amino acid sequence and 
distance between the glycosylation site and its C-terminus for the N-glycosylation process to 
occur. Intriguingly, the absence of the GPI-anchor in the newly synthesized Xenopus GFP-
PrPCΔGPI fusion protein caused this product not to be complex glycosylated, presumably 
because the GFP-PrPCΔGPI protein did not reach the mid-Golgi, the compartment in the 
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secretory pathway where proteins are normally modiﬁ ed with complex sugar types [42]. As 
expected, mouse PrPC lacking the GPI-anchor was not detectable on the plasma membrane 
of transduced mouse ﬁ broblast cells, but was released into the medium [43]. Conversely, 
our work demonstrated that Xenopus GFP-PrPCΔGPI was not secreted into the incubation 
medium, again indicating that this mutant protein was not transported through the later stages 
of the secretory pathway. Thus the fate of the Xenopus GFP-PrPCΔGPI fusion protein in the 
secretory pathway is different from that of mouse PrPCΔGPI. The GFP-PrPCocta fusion protein 
was efﬁ ciently mono- and di-N-linked glycosylated, and also not complex glycosylated. 
Furthermore, since the amounts of the newly synthesized GFP-PrPCocta fusion products 
were reduced during the chase incubation and the steady-state levels were relatively low, the 
GFP-PrPCocta products were likely unstable and subjected to degradation. Although, except 
for the Xenopus sequence, the octarepeat is present in all known vertebrate PrP sequences 
[27], is known to bind Cu2+ ions [19,44,45] and protects against oxidative stress [46-48], we 
were surprised to ﬁ nd that the insertion of the human octarepeat in Xenopus PrPC apparently 
caused an instability of the protein in the Xenopus melanotrope cells.
The pulse-chase metabolic cell labeling studies on the Xenopus intermediate pituitaries 
transgenic for the mutated forms of the GFP-PrPC fusion protein further showed that the 
amounts of newly synthesized 37-kDa POMC and the 18-kDa POMC-derived product in 
the cells and incubation media were similar to those in the wild-type melanotrope cells. 
Furthermore, our electron microscopy studies revealed that the mutated forms did not affect 
the ultrastructure of the Xenopus melanotrope cells. These observations are remarkable since 
GFP-PrPC transgene expression caused lower levels of POMC remaining in the melanotrope 
cells and induced the process of crinophagy (i.e. lysosomal uptake of POMC secretory 
granules; [26]). Apparently, the fact that the intracellular fate of GFP-PrPC is different from 
those of its mutated forms, namely transport to the plasma membrane and metabolic cleavage 
of only GFP-PrPC, eventually results in crinophagy. Presumably, the high levels of the C-
terminal GPI-anchored PrPC cleavage product affect the endosomal/lysosomal system in the 
GFP-PrPC-transgenic Xenopus melanotrope cells in such a way that the POMC granules are 
engulfed by the lysosomes.
In conclusion, we have successfully targeted mutated forms of the GFP-PrPC fusion protein 
speciﬁ cally to the Xenopus intermediate pituitary melanotrope cells. Our transgenic studies 
on PrPC revealed the evolutionary conservation of its site of metabolic cleavage as well as the 
signiﬁ cance of the GPI anchor and the absence of the octarepeat for its proper biosynthesis 
in the secretory pathway.
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Chapter 6
General discussion
In the early nineteen seventies, little was known about the cause of neurodegenerative 
diseases. Nowadays, however, it is clear that these diseases result from abnormalities in the 
post-translational modiﬁ cation of certain proteins, leading to their accumulation. The aberrant 
mechanism may involve protein misfolding, abnormal proteolytic protein cleavage, reduced 
clearance of a partially degraded protein or anomalous pre-mRNA splicing. A particular 
protein that is improperly processed causes the malfunctioning of a distinct set of neurons and 
thus determines the clinical manifestations of the disease [1]. Prion diseases or transmissible 
spongiform encephalopathies (TSEs) are a group of neurodegenerative diseases caused by 
the notorious prion. These diseases include scrapie and bovine spongiform encephalopathy 
(BSE) in animals, and Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS) and fatal familial insomnia (FFI) in humans [2,3]. Prion diseases may present 
as genetic, infectious or sporadic diseases, all of which involve modiﬁ cation of the prion 
protein (PrP) [4]. The normal, cellular isoform of PrP (PrPC) is converted into its pathologic 
isoform (PrPSc) through a post-translational process during which it acquires a high β-sheet 
content [5]. The causative agent is devoid of DNA and RNA, and acts as a template upon 
which PrPC is refolded into a nascent PrPSc molecule [3]. During the last decades, more 
insight has been gained concerning the formation of PrPSc that has resulted in two hypothetical 
models for the conformational conversion of PrPC into PrPSc (see below) [6-9]. Since PrPC 
has a fundamental role in prion diseases, understanding the actual physiological function 
of PrPC may help in deciphering prion pathology and may even lead to the development of 
therapeutic approaches. Extensive research has been performed to unravel the highly debated 
normal physiological role of PrPC in the cell. However, the results obtained so far have not 
provided convincing answers. The research described in this thesis was aimed at examining 
molecular and cell-biological aspects of PrPC in the intermediate pituitary melanotrope cells 
of the South-African claw-toed frog Xenopus laevis. We used stable Xenopus transgenesis to 
generate melanotrope cells with transgene expression of PrPC in order to gain more insight 
into the biosynthesis and normal physiological role of PrPC. In this ﬁ nal chapter, we discuss 
the results obtained and put them in a broader perspective. 
Expression of PrP mRNA in Xenopus laevis
Determination of PrP mRNA expression sites and levels in a number of species may help 
us to identify cells that synthesize PrPC and therefore might help in linking PrPC to a certain 
function in these cells. Although transcripts of the mammalian PRNP gene and the PrPC 
protein are present in a large variety of adult peripheral tissues [10-12], PrPC is preferentially 
expressed in neurons [3,13]. Spatio-temporal mRNA expression studies on PrP and PrP-related 
proteins have been performed in Fugu rubripes [14], zebraﬁ sh [15], chicken [16] and mouse 
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[17,18]. In chapter 2, we explored the developmental expression and egg microinjection 
of Xenopus PrP mRNA as well as its expression in tissues of the adult frog. Xenopus PrP 
transcripts were maternally expressed, indicating that PrPC plays a role in very early Xenopus 
embryonic development. In addition, zygotic expression was detected at a low level from 
stage 1 onwards and markedly increased up to stage 13 after which the level of expression 
remained similar during further development. The tissue distribution studies in adult Xenopus 
revealed that PrP mRNA was expressed in stomach, liver, spleen, kidney and intestine, but 
most abundantly in the brain, pituitary and testis. This expression pattern resembles those 
found in mammalian tissues, including human and mouse, in which PrP is also expressed 
mainly in the central nervous system (CNS) [12,19-23]. Together, the observed temporal and 
spatial distribution of Xenopus PrP mRNA supports the view that PrP is involved in neuronal 
functioning. Nevertheless, our microinjection studies with Xenopus PrP mRNA in undivided 
fertilized Xenopus eggs showed no phenotype in that the microinjected embryos developed 
normally.
The Xenopus intermediate pituitary cell model
For several decades, Xenopus laevis has been used as an animal model system for 
developmental, endocrinological and molecular studies. Furthermore, this amphibian has 
the ability to adapt its skin color to its background, a process regulated by the melanotrope 
cells of the intermediate pituitary gland. Depending on background color, these cells are 
differentially innervated by neuronal cells of hypothalamic origin (e.g. strong inhibitory 
synapses are formed in white animals) and become highly active or inactive when the 
animal is kept on a black or white background, respectively. The Xenopus melanotrope cells 
constitute a homogeneous population of strictly regulated neuroendocrine secretory cells. 
In black-background-adapted Xenopus, these cells produce enormous amounts of its major 
biosynthetic product, the prohormone proopiomelanocortin (POMC). Newly synthesized 
POMC is transported through the regulated secretory pathway of these cells and undergoes 
various post-translational modiﬁ cations during its transport, such as N-linked glycosylation, 
sulfation and proteolytic processing yielding a number of bioactive peptides, including α-
melanophore-stimulating hormone (α-MSH). Once released into the blood stream, α-MSH 
mediates the process of background adaptation by causing dispersion of the pigment melanin 
in skin melanophores resulting in blackening of the skin [24]. In the active melanotrope 
cells, the steady-state levels as well as the newly synthesized levels of POMC are up to 30 
times higher than in cells derived from black-adapted in comparison with white-adapted 
animals. Upon black-background adaptation, the melanotrope cell is thus highly activated, 
which is reﬂ ected by an increased cell size and a highly developed biosynthetic machinery 
(reviewed by Roubos [25]). In order to synthesize and process high amounts of POMC in a 
black-adapted animal, a number of other proteins need to be upregulated in a similar fashion 
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as POMC. A differential screening approach on melanotrope cells of black-adapted versus 
white-adapted animals has led to the identiﬁ cation of several types of proteins that were 
coordinately expressed with POMC. Among these were the POMC-processing enzymes 
prohormone convertase 2 (PC2) and carboxypeptidase H, some members of the p24 family 
of putative endoplasmic reticulum (ER)-to-Golgi cargo receptors, the acidic neuroendocrine-
speciﬁ c secretory proteins secretogranin II and III, the V-ATPase accessory subunit Ac45 and 
the PC2-chaperone 7B2 [26-29]. All of these proteins somehow participate in the transport or 
processing of POMC in the regulated secretory pathway of the melanotrope cells. Using semi-
quantitative and real-time quantitative RT-PCR, we found that PrP mRNA was expressed in 
the Xenopus intermediate pituitary melanotrope cells. However, PrP mRNA expression was 
not upregulated in the melanotrope cells of black- versus white-adapted animals, and thus 
not coordinately expressed with POMC, suggesting that under physiological conditions PrPC 
is not involved in the transport or processing of the prohormone in the regulatory secretory 
pathway of these cells (chapter 2).
Functional studies on PrPC
The normal function of PrPC has received relatively little attention, presumably because 
much excitement has been created by the fascinating role of PrPC in TSEs. However, 
PrPC may play an important role in the CNS, since PrPC is highly expressed in neurons. 
Furthermore, a number of structural elements within the PrP sequence are conserved in 
evolution among many species, including mammals, birds, reptiles, amphibians and ﬁ sh, 
indicating a common physiological role [14,30-34]. At present, the normal physiological 
role of PrPC is still heavily under debate. Elaborate studies with a variety of cell-biological 
approaches in a number of species (knock-out mice, biosynthetic studies on hamster brain 
and transfections in mammalian cell lines) have resulted in a number of proposed functions. 
Initial skepticism about suggestions for a particular role was mainly due to the absence of a 
gross phenotype alteration in PRNP knock-out mice [35]. The identiﬁ cation of PrPC-binding 
proteins could provide insights into the function of PrPC and the molecular mechanisms 
involved in prion diseases. In recent years, many studies have been conducted to probe the 
interaction of PrPC with other molecules. The reported interaction partners of PrPC include 
laminin (important in neuronal cell adhesion and maintenance; [36]), the cell surface laminin 
receptor precursor (LRP) (essential for PrPSc propagation and for maintenance of PrPC levels; 
[37]), the stress-inducible protein 1 (STI1) (modulation of the interaction between PrPC and 
this ligand affects programmed cell death; [38]), glycosylaminoglycans (modulation of the 
conversion process; [39]) and caveolin (its association with PrPC has been related to the 
activation of Fyn tyrosine kinase; [40]). Binding of PrPC to signaling molecules suggests a 
role as a transmitter of information from the extracellular milieu to the inside of the cell and a 
trigger for a molecular cascade. This agrees with data on PrPC receptors and the role of PrPC 
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in cell survival. Furthermore, there is increasing evidence supporting a functional role for 
PrPC in copper metabolism. Several studies have indicated that the N-terminal octarepeat-
containing region of PrPC can bind copper [41]. A number of groups have investigated the 
physiological meaning of the copper binding (reviewed by Brown [42]). PrPC-deﬁ cient cells 
have a diminished copper content and lower superoxide dismutase activity [41,43]. These 
results suggested that PrPC may be a principal copper-binding protein in brain membrane 
fractions and controls the activity of other membrane-associated copper-binding proteins. 
In fact, cerebellar cell cultures from PrPC null mice are more susceptible to oxidative stress 
than those from wild-type mice [43,44]. The putative Cu2+-binding domain consists of two 
up to ten tandem repeats in mammals, birds, reptiles and ﬁ sh. Remarkably, the Xenopus PrP 
sequence does not contain a tandem repeat [30,45]. Consequently, the normal physiological 
role of Xenopus PrPC does probably not involve Cu2+ binding.
Fate of PrPC in transgenic Xenopus melanotrope cells
Since most of the above-mentioned studies on PrPC have been performed in in vitro systems, 
we decided to apply a more in vivo approach by combining the unique properties of the 
intermediate pituitary melanotrope cells with the technique of stable Xenopus transgenesis 
to drive transgene expression of either wild-type Xenopus PrPC or mutants thereof in a cell-
speciﬁ c manner and to gain more insight into the physiological role of PrPC in these cells 
(chapters 3 to 5). For this purpose, we generated DNA constructs containing the cDNA 
sequence encoding the protein of interest downstream of a POMC gene promoter fragment, 
which directs transgene expression speciﬁ cally to the melanotrope cells of the Xenopus 
intermediate pituitary [46]. The use of this cell-speciﬁ c promoter has a number of advantages. 
First, the cell-speciﬁ c transgenic system makes it possible to study a potentially toxic protein, 
since non-functional melanotrope cells are probably not lethal for the animal. Second, an 
effect observed in the transgenic cells must be a primary effect of the overexpression of the 
transgene product, and is not inﬂ uenced by the overexpression of the exogenous protein in 
neighboring cells that for instance control the target cells (in our case, e.g. the hypothalamic 
neurons innervating the melanotrope cells). Third, any phenotype at the organismal level can 
be attributed to the transgene expression in the melanotrope cells. 
To generate the transgenic animals, a linearized DNA construct containing PrPC fused to 
the C-terminus of the green ﬂ uorescent protein (GFP) was mixed with Xenopus sperm 
nuclei and the mixture was microinjected into unfertilized Xenopus eggs in several rounds 
of transgenesis to generate Xenopus transgenic for GFP-PrPC (chapter 3). The transgenic 
frogs could be easily and directly identiﬁ ed by visualization of GFP-PrPC expression in the 
intermediate pituitary of the embryo through a ﬂ uorescence microscope. We generated a 
number of F1 lines of transgenic animals producing the GFP-PrP
C fusion protein speciﬁ cally 
in the melanotrope cells with relatively low, moderate and high levels of transgene expression 
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(F1 lines #104, #105 and #102, respectively). Apart from the number of integrated transgenes, 
the F1 animals were genetically identical. 
For the biosynthetic and functional studies on PrPC described in this thesis (chapters 3 to 
5), we mainly used transgenic F1 line #102, since it was easier to study the biosynthesis of 
GFP-PrPC with high levels of transgene expression and a possible effect of the transgene on 
the melanotrope cells would be more severe. The temporal and spatial expression pattern 
observed for GFP-PrPC during early embryonic development of the transgenic Xenopus 
resembled that found in Xenopus transgenic for POMC promoter-driven expression of 
GFP itself [46]. In addition, all juvenile and adult frogs transgenic for GFP-PrPC showed 
ﬂ uorescence speciﬁ c in the melanotrope cells of the intermediate pituitary and we never 
observed anterior pituitary or brain ﬂ uorescence. Confocal microscopy studies conﬁ rmed 
that GFP-PrPC was targeted speciﬁ cally to the melanotrope cells in the pituitary and partly 
colocalized intracellularly with POMC. The GFP-PrPC fusion protein was localized in all 
compartments of the secretory pathway of the Xenopus melanotrope cells, but besides the 
plasma membrane most notably in the Golgi apparatus, indicating that the N-terminal fusion 
with GFP did not hamper trafﬁ cking of PrPC through the secretory pathway (chapter 3). In 
vitro studies on cultured baby hamster kidney, chinese hamster ovary, murine neuroblastoma 
(N2a) and murine septal cells transfected with GFP-tagged PrPC have shown that the fusion 
protein was localized to the Golgi apparatus and plasma membrane, and are thus in agreement 
with our in vivo observations [47-51]. 
We then studied the intracellular fate of PrPC. The majority of the fusion protein produced in 
the Xenopus melanotrope cells migrated as an ~55-kDa protein and a small amount as an ~51-
kDa product. The expected size of the GFP-PrPC fusion protein (excluding signal sequences) 
is ~46 kDa, indicating that the fusion protein was subjected to post-translational modiﬁ cations 
and thereby increasing its molecular mass. After removal of the N-linked oligosaccharides, 
the steady-state GFP-PrPC products migrated as an ~47-kDa protein and, like endogenous 
hamster PrPC [52], both the 51- and 55-kDa transgene products were thus N-glycosylated. In 
the transgenic melanotrope cells, the GFP-PrPC transgene product was mainly present as a 
monomer and only a small portion existed as a dimer, in line with previous studies on puriﬁ ed 
hamster PrPC, recombinant PrP and native PrPC from bovine brain [53-55]. The steady-state 
levels of GFP-PrPC in the transgenic Xenopus melanotrope cells were found to be dependent 
on the biosynthetic activity of these cells. In the active melanotrope cells from black-adapted 
animals, GFP-PrPC was upregulated and thus coregulated with POMC. GFP-PrPC was not 
detected in the anterior pituitary cells, as already indicated by the melanotrope cell-speciﬁ c 
GFP ﬂ uorescence in the transgenic tadpoles and frogs. This cell-speciﬁ c induction of GFP-
PrPC expression occurs because when the animal is adapting to a black background the POMC 
promoter becomes highly active only in the melanotrope cells; the melanotrope cells are 
controlled by neurons of hypothalamic origin that innervate the melanotropes differentially 
Chapter 6
114
depending on the background color of the animal, while the anterior pituitary cells are not 
involved in background adaptation [56]. We observed less difference in the activity of the 
POMC transgene promoter in black- and white-adapted animals than in the activity of the 
endogenous POMC gene promoter, probably because we used only a 529-bp fragment of the 
POMC gene promoter in the transgene construct [57]. The relatively small size of the POMC 
gene promoter fragment could also explain why no transgene expression was found in the 
anterior pituitary or brain (endogenous POMC is expressed not only in the intermediate but 
also in the anterior pituitary and in certain brain regions [58]). 
Next, we studied the biosynthesis of GFP-PrPC using metabolic pulse-chase cell labeling 
and immunoprecipitation analyses, and showed that in the transgenic melanotrope cells the 
GFP-PrPC fusion protein was initially synthesized as an ~45-kDa product. Subsequently, the 
initial product was rapidly GPI-anchored and stepwise mono- and di-N-linked glycosylated 
in the ER to give rise to an ~48-kDa GFP-PrPC form and the 51-kDa form, respectively, 
which is in line with the fact that Xenopus PrPC contains two conserved N-glycosylation 
sites at amino acid residues 150 and 165 [30]. Also, the N-glycosylation of PrPC was already 
observed at the steady-state level in the transgenic cells. The rapid GPI-anchoring and N-
glycosylation of the 48- and 51-kDa GFP-PrPC forms is consistent with the addition of a 
GPI-anchor and N-glycans during or soon after translation and translocation of polypeptides 
into the lumen of the ER [59,60]. Stanley Prusiner and co-workers had already shown that 
mammalian PrPC was GPI-anchored [61]. Since we could liberate the GFP-PrPC protein 
into the incubation medium when intact neurointermediate lobes (NILs) were treated with 
a GPI-anchor-cleavage enzyme, the fusion protein was located on the plasma membrane of 
the transgenic Xenopus melanotrope cells. This observation was conﬁ rmed in our confocal 
microscopy studies. The high-mannose type oligosaccharides attached to the 51-kDa fusion 
protein were further processed to yield complex sugar types on the 55-kDa GFP-PrPC protein, 
which is in line with results obtained for PrPC transfected into mouse N2a cells [62]. The 
glycomaturation most likely occurred during passage through the mid-Golgi [63,64]. We 
found for the ﬁ rst time that the mature 55-kDa GFP-PrPC protein was sulfated, presumably in 
the trans-Golgi network (TGN) [65]. The function of this post-translational modiﬁ cation of 
PrPC remains to be determined, although sulfation of other proteins accelerates their transport 
from the TGN to the cell-surface and/or promotes speciﬁ c protein-protein interactions 
[66]. Furthermore, a portion of the newly synthesized 55-kDa GFP-PrPC fusion protein, 
anchored by a GPI moiety to the outside of the plasma membrane of the melanotrope cell, 
was cleaved to an ~33-kDa product. The fate of the remaining C-terminal GPI-anchored 
Xenopus ΔPrPC fragment is at present unclear (chapter 3). The proteolytic cleavage of human 
PrPC at the plasma membrane is part of its normal metabolism in the brain and in cultured 
cells, and occurs inside the 106-126 neurotoxic region of the protein (between amino acid 
residues 110-111), leading to the formation of a soluble N-terminal fragment (N1) and a 
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GPI-anchored C-terminal fragment (C1) [67,68]. The group of Frédéric Checler found that 
human PrPC is subjected to α-cleavage activity by members of the ADAM (a disintegrin and 
metalloproteinase) family of zinc metalloproteases, notably ADAM10 and TACE (ADAM17) 
[69,70]. Which proteolytic enzymes are involved in the cleavage of Xenopus PrPC is presently 
unknown. The N-terminal cleavage of PrPC could be similar to the ectodomain shedding of 
several cell-surface proteins that are involved in processes, such as cell survival, signaling 
or morphogenesis [71]. Interestingly, some members of the ADAM family, like ADAM10, 
have been implicated in this ectodomain shedding [72]. Recent studies have shown that the 
tethering of the N-terminal region of PrPC to the membrane increases the level of intracellular 
free radicals and renders the cells more susceptible to oxidative stress [73]. Besides this role, 
the N-terminal region of PrPC may be involved in the interaction with cell surface receptors, 
such as the 37-kDa LRP [37].
Functional studies on PrPC in transgenic Xenopus melanotrope cells
With the availability of the Xenopus melanotrope cell-speciﬁ c PrPC transgene expression 
system we were in the position to try to obtain more understanding of the normal physiological 
role of PrPC by examining the effect of the transgene expression on the functioning of the 
transgenic cells (chapters 3 and 4). In the Xenopus melanotrope cell, the early secretory 
pathway and the processing compartments are highly specialized and committed to the 
biosynthesis of POMC. Transgenic intervention in this specialized neuroendocrine cell 
may result in the distortion of cell physiological processes and thus the POMC biosynthetic 
machinery. 
We studied the effect of four experimental manipulations on the functioning of the GFP-
PrPC-transgenic Xenopus intermediate pituitary cells. Using pulse and pulse-chase 
analyses, we ﬁ rst observed that the transgene expression of the GFP-PrPC fusion protein 
in the intermediate pituitary from 3-weeks-black-adapted Xenopus did not affect POMC 
biosynthesis and processing, and the secretion of the POMC-derived products. In addition, 
the steady-state levels of POMC as well as of other secretory pathway components, such as 
the POMC cleavage enzyme PC2, the p24δ1/2 proteins, and the protein-folding chaperones 
BiP and calnexin, were not changed in the transgenic melanotrope cells. These studies thus 
indicated that the transgene product did not affect the functioning of the melanotrope cell. 
Second, we exposed the melanotrope cells to the transgene product for a relatively long time 
period by adapting the GFP-PrPC-transgenic animals for >8 weeks to a black background. 
We found that now the secretory pathway of the active intermediate pituitary melanotrope 
cells was affected, namely a reduction of the levels of POMC remaining in the cells. This 
effect was not due to the transgenesis procedure per se, since Xenopus transgenic for POMC 
promoter-driven GFP-GPI did not affect the functioning of the melanotropes from 8-weeks-
black-adapted animals, indicating that the phenotype of the GFP-PrPC-transgenic cells was 
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due to the transgene expression of PrPC. Apparently, only a relatively long exposure of the 
transgenic melanotrope cells to the GFP-PrPC fusion protein caused a phenotypic effect, since 
in the transgenic cells of animals black adapted for 3 weeks the secretory pathway was not 
affected. 
As a third manipulation, the GFP-PrPC-transgenic melanotrope cells from 3-weeks-black-
adapted frogs were incubated in glucose-depleted medium resulting in a phenotype similar 
to that seen following the >8 weeks black-background adaptation. Since glucose depletion 
of cells is known to cause metabolic stress [74,75] and the GFP-GPI-transgenic melanotrope 
cells were not affected by energy deprivation, the melanotropes transgenic for GFP-PrPC were 
apparently sensitive to metabolic stress. Similarly, treatment of the transgenic melanotrope 
cells with an inactive form of glucose (L-glucose) and a non-degradable form of glucose (2-
deoxy-D-glucose) revealed this cellular phenotype. 
Fourth, we forced the transgenic melanotrope cells from Xenopus adapted for 3 weeks to a 
black background to produce unfolded POMC in the early secretory pathway by treatment of 
the cells with the reducing agent DTT. In GFP-PrPC-transgenic DTT-treated melanotrope cells, 
the disruption of the disulﬁ de bonds in newly synthesized POMC prevented the prohormone 
from arriving at the TGN and the cell was not able to properly handle the unfolded POMC 
pool accumulated in the early secretory pathway. 
Since our detailed pulse-chase metabolic cell labeling studies showed no faster transport 
and processing of POMC, and secretion of the POMC-derived peptides by the GFP-PrPC-
transgenic cells, the observed reduced levels of POMC can be explained by degradation of 
the prohormone. Such a degradation probably occurred through the lysosomal rather than 
the proteasomal pathway, since if the proteasomal pathway would be involved one would 
expect the amounts of the BiP protein to be increased [76-79], whereas the steady-state levels 
of BiP were actually reduced in the GFP-PrPC-transgenic melanotrope cells. The ﬁ nding 
of the reduced POMC levels was corroborated by our electron microscopy studies because 
transgene expression of GFP-PrPC in the Xenopus melanotrope cells caused an induction of 
crinophagy (lysosomal uptake of POMC secretory granules). The process of crinophagy has 
been observed in pancreatic exocrine cells of the rat during long-starvation circumstances [80] 
and in estrogen-stimulated rat pituitary cells [81]. Unfortunately, previous studies concerning 
the effect of PrPC overexpression on transfected cells or in transgenic animal models did 
not include an ultrastructural analysis [47-51,82]. Thus, we showed for the ﬁ rst time with 
our transgenic studies in a physiological context that transgene expression of Xenopus PrPC 
caused a malfunctioning of the secretory pathway and induced crinophagy in neuroendocrine 
cells (chapter 4). The importance of crinophagy for the regulation of hormone levels is not 
yet clear. 
As mentioned above, PrP mRNA was not coordinately expressed with POMC, suggesting 
that under physiological conditions PrPC is not directly involved in the transport or processing
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Figure 1. POMC biosynthesis and the process of crinophagy in GFP-PrPC-transgenic Xenopus 
intermediate pituitary cells. Upon black-background adaptation, the wild-type (left part of the ﬁ gure) 
and GFP-PrPC-transgenic (right part) melanotrope cell is highly activated in producing and processing 
of POMC. These large amounts of POMC can be divided into a slow and fast pool, which are differently 
transported through the secretory pathway of the cell. In the GFP-PrPC-transgenic melanotrope cells, 
the slow POMC pool was subjected to degradation by crinophagy. ER, endoplasmic reticulum; CNG, 
cis-Golgi network; TGN, trans-Golgi network; PM, plasma membrane; , POMC/POMC-derived 
peptides.
of the prohormone in the regulatory secretory pathway of the melanotrope cells (chapter 
2). Based on our results, we present a model regarding the process of crinophagy and its 
effect on POMC biosynthesis in the GFP-PrPC-transgenic Xenopus intermediate pituitary 
cells (Fig. 1). Upon black-background adaptation, most Xenopus melanotropes acquire the 
morphofunctional characteristics of high biosynthetic and secretory activities [83]. In the 
active melanotrope cell, about 80% of the newly synthesized proteins consist of POMC 
[26]. These large amounts of POMC can be divided into a so-called slow and fast pool, 
which are transported with different rates through the secretory pathway of the wild-type 
melanotrope cell. The fast pool contains newly synthesized POMC that is processed into 
POMC-derived products including 18-kDa POMC, which is secreted into the blood stream. 
However, the slow POMC pool remains relatively long in the early secretory pathway before 
being processed into the later stages of the secretory pathway (Fig. 1, left panel). When the 
GFP-PrPC-transgenic melanotrope cells were long-term exposed to the transgene product, 
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the fast POMC pool remained intact and thus most POMC was properly synthesized and 
processed into POMC-derived peptides. However, the slow POMC pool was now subjected 
to degradation by crinophagy. At present, it is not clear whether the slow POMC pool is 
degraded after it leaves the ER or when it has passed the Golgi apparatus (Fig. 1, right 
panel).
Mutational analysis of PrPC in transgenic Xenopus melanotrope cells
To explore the signiﬁ cance of a number of structural elements within the Xenopus PrP sequence 
for its proper biosynthesis, we generated and analyzed Xenopus with transgene expression of 
the GFP-PrPCK81A, GFP-PrPCΔGPI, GFP-PrPCocta or GFP-GPI fusion proteins under the 
control of the POMC gene promoter fragment (chapter 5). As we have already discussed, the 
GFP-PrPC-protein was correctly synthesized, N-linked and complex glycosylated, sulfated, 
attached to the plasma membrane and metabolically cleaved in the transgenic Xenopus 
melanotrope cells (chapter 3; [84]). The biosynthesis and post-translational modiﬁ cations 
of the non-cleavable form of GFP-PrPC were identical to those of GFP-PrPC, except that 
the GFP-PrPCK81A fusion protein was not subjected to metabolic cleavage. Therefore, 
the metabolic cleavage site in Xenopus PrPC corresponds to lysine residue 81, which is 
comparable to the human PrPC cleavage site (at lysine residue 110 in the human sequence). 
Removal of the GPI-anchor of Xenopus PrPC resulted in an N-glycosylated GFP-PrPCΔGPI 
fusion protein that was neither complex glycosylated nor transported towards the cell surface 
or endoproteolytically cleaved. This is surprising since non-anchored mouse PrPC was 
transported through the secretory pathway of transduced mouse ﬁ broblast cells and secreted 
into the medium, although N-glycosylation did not occur [85]. Thus, Xenopus PrPC has to be 
GPI-anchored for correct transport through the secretory pathway, proper post-translational 
modiﬁ cations, attachment to the plasma membrane and metabolic cleavage. Although a 
repeat region within the PrP sequence is present in all species except Xenopus [30,45], the 
insertion of the human octarepeat in Xenopus PrPC prevented complex glycosylation and 
correct transportation through the later stages of the secretory pathway, such that the mutant 
protein did not reach the plasma membrane and was not endoproteolytically cleaved. Instead, 
inclusion of the octarepeat domain in Xenopus PrPC caused an instability of the protein in the 
Xenopus intermediate pituitary cells. The Xenopus GFP-PrPCocta protein is likely not properly 
folded in the ER and therefore eventually degraded. Since the human octarepeat is known 
to bind up to four Cu2+ ions [41,86,87], the binding of Cu2+ may enhance the instability of 
the Xenopus GFP-PrPCocta protein in the early secretory pathway of the transgenic Xenopus 
melanotrope cells. The intracellular fate of GFP-PrPCocta was therefore different from that 
of GFP-PrPC, suggesting that following removal of the octarepeat from the ancestral PrP 
sequence the Xenopus PrP sequence diverged in such a way that insertion of the repeat did 
not allow its correct biosynthesis anymore. 
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Figure 2. Model of the induction of crinophagy in the GFP-PrPC-transgenic Xenopus intermediate 
pituitary cells. The intact GFP-PrPC fusion protein cycles between the plasma membrane and an 
early endosomal compartment. In the early endosome or at the plasma membrane, GFP-PrPC may be 
subjected to endoproteolytical cleavage. The resulting N-terminal GFP-ΔPrPC product is secreted and 
the C-terminal GPI-anchored ΔPrPC product may be externalized or directed towards the endosomal-
lysosomal system. The high amounts of the C-terminal ΔPrPC fragment may saturate the endosomal-
lysosomal compartments and induce uptake of POMC granules by the lysosomes (crinophagy). It is 
presently unclear whether the POMC granules are derived from the ER or the Golgi apparatus, or 
from both compartments. ER, endoplasmic reticulum; PM, plasma membrane; , GFP-PrPC; , 
N-terminal GFP-PrPC fragment; , C-terminal ΔPrPC fragment; , POMC/POMC-derived peptides; 
, endoproteolytic cleavage.
We already mentioned that, as part of its normal metabolism, mammalian PrPC undergoes 
cleavage within its N-terminal region [67,68], that the Xenopus GFP-PrPC protein is also 
subjected to endoproteolytical cleavage and that the metabolic cleavage site is conserved. 
The metabolical cleavage resulted in a 33-kDa N-terminal GFP-ΔPrPC fragment and a C-
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terminal GPI-anchored ΔPrPC product. Remarkably, none of the mutant GFP-PrPC proteins 
was cleaved. In order to examine whether, like the GFP-PrPC fusion protein (chapter 4; [88]), 
the mutant proteins caused the process of crinophagy (lysosomal uptake of POMC secretory 
granules), we analyzed the ultrastructure of the melanotrope cells transgenic for the mutants. 
Intriguingly, the electron microscopy studies revealed an overall normal ultrastructure and no 
crinophagy was observed (chapter 5). Apparently, since a general characteristic of the mutant 
proteins examined in our transgenesis study is the fact that they are not cleaved, GFP-PrPC-
cleavage and the presence of the resulting C-terminal GPI-anchored ΔPrPC fragment appear 
to be crucial for crinophagy. Based on these observations, we present a model concerning 
the induction of the process of crinophagy in the GFP-PrPC-transgenic Xenopus intermediate 
pituitary cells (Fig. 2). Mammalian PrPC clusters in sphingolipid- and cholesterol-rich, 
detergent-resistant microdomains (lipid rafts) of the plasma membrane [89-91]. On the basis 
of results obtained with detergent-resistent membrane isolates from the transgenic Xenopus 
melanotrope cells (van Rosmalen, J.W.G., unpublished observations), we assume that the 
Xenopus GFP-PrPC protein also accumulates in such lipid rafts. Not all PrPC molecules 
remain on the cell surface, but some constitutively cycle between the plasma membrane and 
endocytic compartments [92]. PrPC is known to be endocytosed either by clathrin-coated 
pits [93] or by caveolae-like membranous domains [94],  although the biological role of this 
internalization is presently unknown. Most of the internalized PrPC protein is returned to the 
cell surface intact. A portion of the endocytosed PrPC molecules is proteolytically cleaved, 
although it is not clear whether the endoproteolytical processing occurs in the endocytic 
compartments or at the plasma membrane (reviewed in [95-97]). The N-terminal cleavage 
product is then secreted and the GPI-anchored C-terminal fragment might be transported to 
the cell surface or internalized [92]. Studies with human PrPC have shown that ADAM10 
and ADAM17 proteases are involved in its cleavage [69,70]. Thus, members of the Xenopus 
ADAM family may play a role in the metabolic cleavage of the Xenopus GFP-PrPC fusion 
protein. In our model, high amounts of the intact GFP-PrPC protein cycle between the cell 
surface and an early endosomal compartment. The GFP-PrPC protein is partly subjected to 
endoproteolytic cleavage within the early endosome or at the plasma membrane, resulting in 
the N-terminal GFP-ΔPrPC secreted product and the C-terminal GPI-anchored ΔPrPC product. 
The C-terminal fragment might be externalized or further internalized by the endosomal-
lysosomal system. The high amounts of the C-terminal ΔPrPC fragment may saturate the 
endosomal-lysosomal compartments and induce uptake of POMC granules by the lysosomes. 
The lysosomes may engulf the POMC granules that are derived from either the ER or the 
Golgi apparatus. In this model, the presence of the C-terminal GPI-anchored ΔPrPC fragment 
causes the melanotrope cells to be sensitive to crinophagy. 
Finally, in analogy with the Alzheimer-linked amyloid-β precursor protein APP, namely 
that the secreted N-terminal APP cleavage product APPsα has been reported to function as 
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a growth factor (reviewed by Mattson [98]), the secreted N-terminal Xenopus GFP-ΔPrPC 
product may also function as a factor stimulating processes in cells surrounding the transgenic 
intermediate pituitary. We have however not found evidence for an extracellular effect of the 
cleaved and secreted N-terminal transgene product.
Future prospects
Research on PrPs has taken several unexpected directions over the past decades, and has 
resulted in a fascinating story on prion biology and a previously unknown mechanism 
of disease in humans and animals. Although the structure of PrP, the mechanism of PrPC 
transformation into PrPSc and the fundamental principles of prion biology have become 
reasonably clear, the normal physiological role of PrPC still remains elusive. Nevertheless, 
more knowledge is needed on the role of PrPC in the CNS as well as on the processes that 
determine its intracellular transport and its proteolytic processing by e.g. the ADAM family 
in a physiological context. Therefore, a well-deﬁ ned model system such as the Xenopus 
melanotrope cell may enhance the current understanding of the physiological role of PrPC. 
To explore this role of PrPC in more detail in vivo, a further extension of our studies on the 
transgenic Xenopus expressing GFP-PrPC or mutated forms of GFP-PrPC would be a logical 
step in the nearby future. For instance, microscopy studies could be used to enhance our 
understanding of PrPC. Total internal reﬂ ection ﬂ uorescence microscopy (TIRFM) on single 
GFP-PrPC-transgenic melanotrope cells has shown the appearance and disappearance of fast-
moving GFP-PrPC-containing vesicles of ~50-300 nm underneath the plasma membrane, 
indicating that GFP-PrPC is transported fast through the melanotrope cell and in different 
directions, including towards the plasma membrane (van Rosmalen, J.W.G., unpublished 
observations). Immuno-electron microscopy in combination with an anti-GFP antibody 
will provide detailed information on the exact localization of GFP-PrPC in the Xenopus 
intermediate pituitary cell. Co-labeling studies with anti-GFP and anti-POMC antibodies will 
determine if GFP-PrPC is transported through the secretory pathway in the same secretory 
vesicles as POMC and if GFP-PrPC is co-localized with the prohormone in the vesicles 
heading for lysosomal degradation. The C-terminal GPI-anchored ΔPrPC cleavage product 
might be directly involved in the degradation of POMC and may therefore be also localized 
in the crinosomes. Unfortunately, at present the C-terminal GPI-anchored ΔPrPC cleavage 
product cannot be detected because of the lack of an appropriate antibody. 
When analyzing the (mutated) GFP-PrPC-transgenic NILs by a number of biochemical 
techniques, the effect of transgene expression on the endogenous PrPC levels might be of 
interest. Previously, we extensively attempted to study the endogenous protein with a series 
of antibodies directed against Xenopus or mammalian PrPC peptides or recombinant proteins, 
but we have not been able to detect endogenous Xenopus PrPC. The group of Gabriella 
Tedeschi has recently claimed that they have generated a speciﬁ c polyclonal antibody raised 
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against Xenopus PrPC [99], but thus far we have not been successful in obtaining this antibody. 
Instead of the generation of antibodies, the use of RNA aptamers and the SELEX (systemic 
evolution of ligands by exponential enrichment) technique [100] could be exploited to design 
a molecular sensor for Xenopus PrPC. This approach has proven to be very effective for 
a number of proteins, including T4 DNA polymerase [101], riboﬂ avin [102], HIV type I 
Rev [103], human IgE [104] and oncostatin M [105]. The localization of the mutated GFP-
PrPC proteins in the transgenic melanotrope cells could be determined with immuno-electron 
microscopy studies in a similar way. For instance, the GFP-PrPCΔGPI and GFP-PrPCocta 
fusion proteins are not transported through the secretory pathway and are thus not located at 
the plasma membrane, but are probably stuck in the ER. 
Furthermore, we have already generated Xenopus transgenic for PrPC with GFP inserted N-
terminally of the GPI-anchor (PrPC-GFP-GPI) to study for example proteins binding to the 
N-terminus of PrPC. In order to perform functional analyses of these transgenic melanotrope 
cells, F1 lines should be generated by in vitro fertilization. 
Several groups have studied the interaction of proteins to the PrPC molecule and found several 
binding partners, such as laminin [36], LRP [37], STI1 [38], glycosylaminoglycans [39] and 
caveolin [40]. Under native conditions, the PrPC-GFP-GPI-, GFP-PrPC- and GFP-PrPC mutant-
transgenic melanotrope cells could be exploited to study binding proteins of Xenopus PrPC by 
using co-immunoprecipitation analysis with the anti-GFP antibody. Differences between the 
interacting partners of GFP-PrPC, PrPC-GFP-GPI and the mutated forms of GFP-PrPC could 
indicate speciﬁ city of the binding protein for structural elements like the N-terminal region, 
the octarepeat or the GPI-anchor. 
In addition, 2D-gel electrophoresis and mass-spectrometry analysis of the intermediate 
pituitary cells from Xenopus transgenic for the (mutated) GFP-PrPC fusion proteins might 
reveal detailed information on the protein content of the various transgenic cells. Preliminary 
2D-gel electrophoresis studies on wild-type, GFP-PrPC- and GFP-GPI-transgenic NILs 
showed affected protein patterns (e.g. reduced levels of BiP in NILs transgenic for GFP-PrPC; 
van Rosmalen, J.W.G., unpublished observations). 
Since the octarepeat is known to bind Cu2+ in vivo [41], it will be of interest to study the Cu2+-
binding characteristics of the GFP-PrPCocta and GFP-PrPC fusion proteins in the Xenopus 
melanotropes. 
Besides overexpressing (mutants of) PrPC, knocking down the expression of PrPC in Xenopus 
melanotrope cells may be an attractive approach. The technique of RNA interference (RNAi) 
is more and more commonly used to knock down the expression of any desired target protein 
[106]. Until now, efforts to induce stable RNAi in Xenopus via transgene-driven expression of 
inverted repeats has resulted in the knock-down of only exogenous (GFP) but not endogenous 
target proteins (e.g. the amyloid-β precursor protein APP, the transcription factor Rx, the 
putative cargo receptor p24δ2 and POMC) [107]. However, in the future new approaches 
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may be developed to successfully knock down the expression of PrPC in Xenopus, e.g. by 
transfection of primary Xenopus melanotrope cell cultures with small interfering (si)RNAs. 
In addition, following fertilization of Xenopus eggs, antisense morpholino oligonucleotides 
directed against the PrP sequence could be injected into embryos to downregulate PrPC 
expression and study the effect of this manipulation on Xenopus embryonic development.
In conclusion, the research described in this thesis has not resulted in the elucidation of 
the physiological role of PrPC, but provided more insight into the expression pattern of PrP 
mRNA, the biosynthesis and fate of (mutated forms of) GFP-PrPC, and the effect of (mutant) 
GFP-PrPC on the functioning of the Xenopus melanotrope cells. Using cell-speciﬁ c transgene 
expression, we were able to establish that overexpressed PrPC causes malfunctioning of the 
secretory pathway and induces crinophagy in Xenopus intermediate pituitary cells. Yet, more 
research will be necessary to clarify the physiological role of PrPC in order to contribute to 
deciphering prion pathology, which may eventually lead to the development of therapeutic 
approaches for Creutzfeldt-Jakob disease treatment.
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In mammals, prions are the causative agents of various neurodegenerative diseases (e.g. 
scrapie, mad cow and Creutzfeldt-Jakob disease) in which the three-dimensional structure of 
the normal cellular form of the prion protein (PrPC) is misfolded into the infectious scrapie form 
(PrPSc or prion). In the brain, PrPSc molecules tend to aggregate and spread rapidly from cell 
to cell. Despite its clear role in neurodegenerative diseases, the normal physiological function 
of PrPC remains elusive. The goal of the research described in this thesis was to exploit the 
melanotrope cells of the intermediate pituitary of the South-African claw-toed frog Xenopus 
laevis as a model system to study cell-biological aspects of Xenopus PrPC functioning in vivo. 
The Xenopus melanotrope cells constitute a homogeneous population of strictly regulated 
neuroendocrine secretory cells that are involved in the process of background adaptation 
of the animal. In the melanotropes of black-background-adapted Xenopus, the prohormone 
proopiomelanocortin (POMC) is proteolytically cleaved to a number of bioactive peptides, 
including α-melanophore-stimulating hormone (α-MSH). Once released into the blood, α-
MSH regulates blackening of the skin by causing dispersion of the black pigment melanin 
in skin melanophores. While adapting to a black background, the Xenopus melanotrope cells 
become highly active, whereas placing the animal on a white background causes these cells 
to be virtually inactive. Placing the amphibian on a white or black background thus allows 
physiological manipulation of the biosynthetic and secretory activity of the melanotrope 
cells.
Chapter 1 provides a general introduction to the various topics dealt with in this thesis, 
including a description of prion diseases, and the replication, structure, biogenesis and 
proposed roles of PrPC, as well as the use of the well-deﬁ ned neuroendocrine Xenopus 
intermediate pituitary melanotrope cells in combination with stable Xenopus transgenesis as 
a model system to examine Xenopus PrPC functioning.
The research described in the ﬁ rst experimental chapter of this thesis focuses on the 
temporal and spatial mRNA expression patterns of PrP in Xenopus (chapter 2). Xenopus PrP 
transcripts were expressed maternally and throughout embryonic development, most strongly 
from neurulation onwards and including the tadpole stage. Microinjection of Xenopus PrP 
mRNA into fertilized Xenopus eggs did not affect early embryonic development. In frogs, 
PrP mRNA was expressed predominantly in neuronal tissues, including the pituitary, which 
is also observed in mammals. Of special interest was the ﬁ nding that PrP mRNA levels were 
similar in the intermediate pituitary melanotrope cells of black- and white-adapted frogs and 
were thus not coregulated with POMC, indicating that in these cells the function of PrPC is 
not directly coupled to the POMC biosynthetic machinery.
In chapter 3, the technique of stable Xenopus transgenesis in combination with a POMC 
gene promoter fragment was used as a tool to express Xenopus PrPC fused to the green 
ﬂ uorescent protein GFP speciﬁ cally in the Xenopus melanotrope cells, and to study the 
biosynthesis and intracellular fate of GFP-PrPC in this highly specialized neuroendocrine 
cell. We found that in the intermediate pituitary the GFP-PrPC fusion protein was expressed 
from stage-25 tadpoles onwards. The levels of the GFP-PrPC protein were upregulated in the 
active melanotrope cells of black-adapted Xenopus and the fusion protein was subcellularly 
localized in all compartments of the secretory pathway, but most notably in the Golgi 
apparatus and at the plasma membrane.  Pulse-chase metabolic cell labeling studies revealed 
that the GFP-PrPC protein was initially synthesized as a 45-kDa product. Subsequently, the 
initial product was rapidly GPI-anchored and stepwise mono- and di-N-linked glycosylated 
to give rise to 48- and 51-kDa GFP-PrPC forms, respectively. Eventually the high-mannose 
type oligosaccharides attached to the 51-kDa fusion protein were further processed to 
yield complex sugar types on a 55-kDa GFP-PrPC protein. Furthermore, we revealed that 
the mature 55-kDa GFP-PrPC protein was sulfated and anchored to the plasma membrane, 
and a portion of it was cleaved. The 33-kDa N-terminal cleavage product was secreted 
into the extracellular medium. Mammalian PrPC has been shown to be also N-linked and 
complex glycosylated, and undergo post-translational proteolytical cleavage at the plasma 
membrane as part of its normal metabolism. Despite the high levels of transgene expression, 
the subcellular structures as well as POMC synthesis and processing, and the secretion of 
POMC-derived products remained unaffected in the transgenic melanotrope cells from 3-
weeks black-adapted frogs. In addition, the steady-state levels of POMC as well as of a 
number of other secretory pathway components were not changed in the transgenic compared 
with wild-type melanotrope cells.
Chapter 4 reports the functional analysis of Xenopus melanotrope cells transgenic for the 
GFP-PrPC protein. We examined the effects of three experimental manipulations on the 
functioning of the transgenic cells. First, when the transgenic Xenopus were adapted to 
a black background for a relatively long time period (>8 weeks), thus causing prolonged 
exposure of the melanotrope cells to the transgene product, the steady-state level of POMC 
was signiﬁ cantly decreased in the transgenic melanotrope cells. Although most of the 
prohormone was still properly synthesized and processed, the transgenic cells lacked the 
minor pool of newly synthesized POMC that normally remains relatively long in the early 
secretory pathway. As controls, we used melanotropes from wild-type Xenopus and Xenopus 
transgenic for the GPI-anchor of PrPC fused to GFP (GFP-GPI) to establish that any effect of 
the GFP-PrPC product on melanotrope cell functioning was not due to the transgenic procedure 
per se. Following the second manipulation, when the transgenic cells were metabolically 
stressed, the levels of newly synthesized POMC remaining in the cell were also signiﬁ cantly 
decreased. The third manipulation, forcing the transgenic cells to produce unfolded POMC, 
caused the decrease in the minor POMC pool as well. Finally, electron microscopy studies on 
the GFP-PrPC-transgenic melanotrope cells revealed an overall normal ultrastructure, except 
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that in the cells the formation of lysosomes taking up POMC secretory granules (crinophagy) 
was induced, likely causing the reduced POMC levels.
Chapter 5 describes a biosynthetic and functional analysis of transgenic Xenopus melanotrope 
cells expressing mutated forms of the GFP-PrPC fusion protein (the non-cleavable GFP-
PrPCK81A, the GPI-deleted GFP-PrPCΔGPI, the octarepeat-containing GFP-PrPCocta and 
the GFP-GPI mutant proteins). Similar to GFP-PrPC, the GFP-PrPCK81A mutant protein was 
stepwise mono- and di-N-glycosylated and complex glycosylated, but the mature mutant 
protein was not cleaved, demonstrating that Xenopus PrPC is endoproteolytically processed at 
lysine residue 81. The GFP-PrPCΔGPI and GFP-PrPCocta mutant proteins were also N-linked 
glycosylated, but these mutants were not complex glycosylated, indicating that the GPI/octa 
mutants did not reach the mid-Golgi compartment of the secretory pathway. Remarkably, 
removal of the GPI-anchor caused retention in the cell and thus did not allow secretion of 
GFP-PrPCΔGPI, and insertion of the octarepeat prevented cleavage. The transgene expression 
of the mutated forms of GFP-PrPC did not affect melanotrope cell functioning in that the 
ultrastructure as well as POMC synthesis and processing, and the secretion of POMC-
derived products were normal. These ﬁ ndings indicate that the metabolic cleavage site of 
PrPC is evolutionarily conserved and that the presence of the GPI-anchor and the absence of 
the octarepeat in Xenopus PrPC are important structural elements for its correct biosynthesis 
in Xenopus melanotrope cells.
Finally, in chapter 6 we discuss the results described in this thesis and put them in a broader 
perspective. We propose a model regarding the effect of overexpressed PrPC on the transgenic 
Xenopus intermediate pituitary cells. Based on our biosynthetic and functional studies on 
PrPC, we hypothesize that an excess of cleaved, GPI-anchored PrPC causes crinophagy.
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Prionen zijn de veroorzakers van verschillende neurodegeneratieve ziekten in zoogdieren 
(b.v. “scrapie” in schapen, de gekkekoeienziekte (BSE) en de ziekte van Creutzfeldt-Jakob). 
Hierbij is het normale cellulaire prion-eiwit (PrPC) verkeerd gevouwen zodat het infectieuze 
“scrapie” prion-eiwit (PrPSc of prion) wordt gevormd. De PrPSc-moleculen hebben de 
neiging om aggregaten te vormen en kunnen zich gemakkelijk van cel tot cel in de hersenen 
verspreiden. 
Alhoewel PrPC dus een duidelijke rol heeft bij de ontwikkeling van prionziekten, is de 
normale fysiologische functie van dit eiwit nog steeds niet opgehelderd. Het doel van het 
onderzoek, beschreven in dit proefschrift, was om de normale fysiologische functie van PrPC 
te bestuderen. Hierbij werden de melanotrope cellen van de hypofyse-middenkwab van de 
Zuid-Afrikaanse klauwkikker (Xenopus laevis) als modelsysteem gebruikt. De Xenopus 
melanotrope cellen bestaan uit een homogene populatie van nauwkeurig gereguleerde 
neuro-endocriene secretiecellen die betrokken zijn bij de achtergrondadaptatie van de huid 
van het dier. In de melanotrope cellen van een zwart-geadapteerde Xenopus worden grote 
hoeveelheden van het prohormoon pro-opiomelanocortine (POMC) gekliefd tot een aantal 
kleinere bioactieve peptiden, waaronder het α-melanofoor-stimulerende hormoon (α-MSH). 
Nadat α-MSH in het bloed is uitgescheiden, zal het ervoor zorgen dat de huid zwart wordt 
door middel van verspreiding van pigmentkorrels (melanine) in de melanoforen van de huid. 
Tijdens de adaptatie aan een zwarte achtergrond zullen de melanotrope cellen zeer actief 
worden, terwijl adaptatie aan een witte achtergrond de cellen vrijwel inactief maakt. De 
biosynthetische en secreterende activiteit van deze gespecialiseerde cellen kan dus op een 
fysiologische manier worden gereguleerd, namelijk door de dieren op een zwarte of op een 
witte achtergrond te plaatsen.
Hoofdstuk 1 geeft een algemene inleiding met achtergrondinformatie die nodig is om 
de verschillende onderwerpen die worden behandeld in dit proefschrift beter te kunnen 
begrijpen. Namelijk informatie over prionziekten, prionvermenigvuldiging en de structuur, 
biosynthese en voorgestelde functies van PrPC. Het gebruik van de goed-gedeﬁ niëerde neuro-
endocriene Xenopus hypofyse-middenkwabcellen als een modelsysteem in combinatie met 
stabiele Xenopus transgenese om de normale fysiologische functie van PrPC te onderzoeken 
komt ook aan bod.
Het onderzoek beschreven in het eerste experimentele hoofdstuk van dit proefschrift 
(hoofdstuk 2) heeft zich op de temporele en spatiële mRNA expressiepatronen in de 
amﬁ bie Xenopus laevis gericht. PrP-transcripten werden maternaal en gedurende de gehele 
embryonale ontwikkeling tot expressie gebracht, vooral vanaf de neurulatie tot en met het 
kikkervisstadium. Microinjectie van PrP-mRNA in bevruchte Xenopus eieren tastte de vroege 
embryonale ontwikkeling niet aan. Zoals ook waargenomen in zoogdieren, kwam PrP-
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mRNA in kikkers hoofdzakelijk tot expressie in neuronale weefsels waaronder de hypofyse. 
Interessant was de bevinding dat de PrP-mRNA niveaus hetzelfde waren in de melanotrope 
cellen van zwart- en wit-geadapteerde kikkers en dus niet gereguleerd waren samen met het 
prohormoon POMC, hetgeen suggereert dat de functie van PrPC niet direct gekoppeld is aan 
de POMC-biosynthesemachine in deze celllen.
In hoofdstuk 3 wordt de stabiele Xenopus transgenesetechniek gebruikt in combinatie 
met een POMC-genpromoterfragment als middel om het PrPC transgenproduct speciﬁ ek 
in de Xenopus hypofyse-middenkwabcellen tot expressie te laten komen. Vervolgens werd 
de biosynthese van PrPC en zijn intracellulair lot in deze zeer gespecialiseerde neuro-
endocriene cellen bestudeerd. We vonden dat het transgene PrPC-eiwit tot expressie kwam 
in de hypofyse-middenkwab vanaf stadium 25 van de kikkervis en verhoogd voorkwam in 
de actieve melanotrope cellen van zwart-geadapteerde Xenopus. Het transgenproduct kwam 
subcellulair voor in alle compartimenten van de secretieroute, maar was het meest duidelijk 
aanwezig in het Golgi-apparaat en op het plasmamembraan. Door de cellen radioactief 
gemerkte eiwitten te laten aanmaken, vonden we dat het transgene PrPC-eiwit in eerste 
instantie gesynthetiseerd werd als een product met een molecuulgewicht van 45 kDa. Hierna 
volgde een snelle koppeling van het eiwit aan een GPI-anker en een stapsgewijze mono- 
en di-N-gekoppelde glycosylering zodat respectievelijk de 48- en 51-kDa PrPC-eiwitten 
werden gevormd. Uiteindelijk werden de hoge mannose oligosacchariden aan het 51-kDa 
eiwit veranderd in complexe suikertypen wat leidde tot een 55-kDa PrPC-eiwit. Bovendien 
werd het 55-kDa PrPC-eiwit gesulfateerd, verankerd aan het plasmamembraan en gedeeltelijk 
gekliefd, waarna het 33-kDa klievingsproduct in het extracellulaire medium terecht kwam. 
Zoogdier-PrPC wordt ook N-gekoppeld, complex geglycosyleerd en ondergaat post-
translationele klieving op het plasmamembraan als onderdeel van zijn normale metabolisme. 
Ondanks de hoge transgene expressieniveaus waren zowel de subcellulaire structuren als 
de POMC biosynthese en verwerking, en de secretieproducten van POMC onaangetast in 
de transgene melanotrope cellen afkomstig van kikkers die 3 weken waren geadapteerd aan 
een zwarte achtergrond. Bovendien waren de “steady-state” niveaus van POMC en andere 
secretieroutecomponenten zoals het POMC klievingsenzym PC2, de p24δ1/2 eiwitten en de 
eiwitvouwingschaperonen BiP en calnexin niet veranderd in de transgene melanotrope cellen 
in vergelijking met de wild-type cellen.
Hoofdstuk 4 beschrijft een gedetailleerde functionele analyse van Xenopus melanotrope 
cellen welke transgeen zijn voor het PrPC-eiwit. We onderzochten het effect van drie 
verschillende experimentele manipulaties op het functioneren van de transgene cellen. Eerst 
werden de transgene Xenopi gedurende een relatief lange periode (>8 weken) geadapteerd 
aan een zwarte achtergrond. De aanhoudende blootstelling van de melanotrope cellen aan het 
transgenproduct resulteerde in een signiﬁ cant verlaagd “steady-state” niveau van POMC in de 
transgene melanotrope cellen. Hoewel het grootste deel van het prohormoon nog steeds goed 
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gesynthetiseerd en verwerkt werd, hadden de transgene melanotrope cellen een vermindering 
van de kleine hoeveelheid van nieuw-aangemaakt POMC dat normaal relatief lang in de 
vroege secretieroute blijft. Als controle gebruikten we melanotropen van wild-type Xenopus 
en Xenopus transgeen voor de GPI-anker van PrPC om vast te stellen of enig effect van het 
PrPC transgenproduct op het functioneren van de melanotrope cel niet zonder meer te wijten 
was aan de toepassing van de transgenesetechniek. Ten tweede werden de transgene cellen 
metabolisch gestresst en toen waren de niveaus van nieuw-aangemaakt POMC wat achterblijft 
in de cel ook signiﬁ cant verlaagd. Als derde experimentele manipulatie werden de transgene 
cellen gedwongen om ongevouwen POMC te produceren waardoor ook een verlaging van de 
kleine hoeveelheid POMC ontstond. Electronenmicroscopische studies toonden een normale 
ultrastructuur aan in de transgene neuro-endocriene cellen. In deze cellen vond echter wel de 
vorming plaats van lysosomen die POMC-secretieblaasjes opnemen (crinofagie), waardoor 
waarschijnlijk de gereduceerde POMC-niveaus werden veroorzaakt.
Hoofdstuk 5 beschrijft een biosynthetische en functionele analyse van transgene Xenopus 
melanotrope cellen welke gemuteerde vormen van het transgene PrPC-eiwit tot expressie 
brachten, namelijk de niet-kliefbare PrPCK81A, de GPI-gedeleteerde PrPCΔGPI en de 
“octarepeat”-bevattende PrPCocta mutanteiwitten. Net als PrPC zelf, werd ook het PrPCK81A 
mutanteiwit stapsgewijs mono- en di-N-geglycosyleerd en complex geglycosyleerd, maar het 
uiteindelijke mutanteiwit werd niet gekliefd. Dit toonde aan dat Xenopus PrPC endoproteolytisch 
gekliefd wordt achter het aminozuur lysine 81. De PrPCΔGPI en PrPCocta mutanteiwitten 
werden eveneens N-gekoppeld geglycosyleerd, maar deze mutanten werden niet complex 
geglycosyleerd wat aangeeft dat ze niet het midden-Golgi compartiment van de secretieroute 
bereikten. Opvallend was dat verwijdering van het GPI-anker dus niet leidde tot uitscheiding 
van het PrPCΔGPI-eiwit en toevoeging van de “octarepeat” de klieving voorkwam. Omdat 
zowel de ultrastructuur als de POMC-biosynthese en -verwerking en de secretie van POMC-
afgeleide producten normaal waren, werd het functioneren van de melanotrope cel dus niet 
aangetast door de transgenexpressie van de mutante vormen van PrPC. Deze bevindingen 
impliceren dat de metabolische klievingsplaats van PrPC evolutionair geconserveerd is en 
dat de aanwezigheid van de GPI-anker en de afwezigheid van de “octarepeat” belangrijke 
structurele voorwaarden vormen voor een juiste biosynthese van het Xenopus PrPC-eiwit in 
de melanotrope cellen.
Tot slot worden in hoofdstuk 6 de resultaten, welke beschreven staan in dit proefschrift, 
bediscussieerd en in een breder perspectief geplaatst. We stellen een hypothese op betreffende 
het effect van een overmaat aan PrPC op de Xenopus melanotrope cellen. Gebaseerd op 
onze biosynthetische en functionele studies aan PrPC veronderstellen we dat in een neuro-
endocriene cel een overmaat aan gekliefd, GPI-verankerd PrPC het proces van crinofagie 
veroorzaakt.
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Bloed, zweet en tranen. Dat zou zo’n beetje de omschrijving zijn van het AiO-schap. Ik moet 
zeggen dat ik gedurende mijn promotietijd alledrie deze facetten heb mogen meemaken, 
echter (deels gelukkig) op een andere manier dan hierboven bedoeld moet zijn. 
Doordat we gebruik maakten van de klauwkikker (het is echt géén pad hoor!) als modeldier 
heb ik veel amﬁ bieleven mogen scheppen. Echter, de keerzijde is dat ik jammerlijk meer 
bloed heb vergoten dan dat ik ooit van te voren gedacht zou hebben. Mocht het prion eiwit 
toch overdraagbaar zijn van kikker naar mens, dan ben ik wellicht de eerste die daar achter 
gaat komen... 
Het zal een hele opgave worden om alle mensen te bedanken die betrokken zijn geweest bij 
het tot stand komen van mijn boekje, maar ik zal het in vogelvlucht gaan proberen.
Zonder hierover een kansberekening gemaakt te hebben wil ik allereerst mijn promotor, 
Gerard Martens, hartelijk bedanken voor de leerzame periode op zijn afdeling Moleculaire 
Dierfysiologie. Ondanks onze verschillende gedachtengangen (dáár waren we het meerdere 
malen over eens) heb ik onze samenwerking als bijzonder plezierig ervaren. Je hebt een 
duidelijke eigen vaarroute voor ogen, welke veelal gedurfd is, maar uiteindelijk pluk je er 
toch vaak de vruchten van (en dat wordt keer op keer bewezen). Dat niet alleen de wetenschap 
telt in het leven, bewijs je door sociale interesse te tonen en discussies te voeren omtrent de 
koetjes en kalfjes in de samenleving; dit is niet voor elke hoogleraar weggelegd en heb ik als 
zeer postief beleefd.
François, jouw deur stond altijd open voor vragen omtrent de melanotrope cel, embryologie, 
fysiologie en andere zaken zoals ‘het potje van François’. Bedankt voor je kennis en 
interesse!
De afgelopen jaren zouden zeker niet zo geslaagd zijn geweest zonder de input van alle 
Moldiertjes. Om met mijn U-genoot te beginnen: Rob. Vanaf de eerste dag klikte het tussen 
ons. We hebben veel interesses gemeen (muziek, voetbal, biertjes), maar toch een duidelijk 
eigen sociaal leven: jij in Venlo en ik in Oss/Nijmegen. Vanaf deze plek wil ik je ontzettend 
bedanken voor de enorm leuke tijd, zowel op het lab als gedurende menig gezellige stapavond 
in Nijmegen! Ik mis de gelijkopgaande potjes tafeltennis in de kelder van het CDL: vrijdags, 
nadat we ons al in het zweet hadden gewerkt bij het voeren en verschonen van de kikkers 
(28°C), gingen we regelmatig hard-tegen-hard de strijd aan (deodorant en een koelcel konden 
daarna goed gebruikt worden). Succes met je carrière en je drukke leven in Venlo samen met 
Francien. 
Nick, je kwam binnen als stagiair, werd collega en bent voor mijn gevoel nooit meer weggegaan. 
Als über-relaxte collega en huisgenoot heb ik met jou de meeste tijd doorgebracht. Ontzettend 
bedankt voor je inzet bij experimenten (2D, gradiënten en transgenese), het oplossen van 
computerproblemen, je kookkunsten, de gezelligheid en niet te vergeten je luisterend oor. 
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Veel succes in Nijmegen en da de beste darter elke week môge winne.
Graag wil ik in alfabetische volgorde de andere huidige Moldieren (Astrid, Bart, Eric (wat 
moet het lab zonder jou?!), Jeroen, Jessica, Karen en Martine) heel hartelijk bedanken 
voor de goede sfeer en gezelligheid tijdens de lab- en Restofanturen, borrels, spel-, ﬁ lm- 
en stapavonden, BBQs, kerstdiners en als-de-baas-van-huis-is-zwemmiddagen. Jullie zijn 
fantastisch! Tevens wil ik Ron E. bedanken voor de goede kikkerzorgen, Tony voor het 
genereren van coupes, Geert voor de hulp bij het maken van losse melanotrope cellen en 
Theo en Paul voor hun inzet bij de elektronenmicroscopie.
Tranen heb ik gedurende mijn promotietijd veel gelaten, gelukkig alleen maar van het lachen. 
Het hoogtepunt was wel de BBQ 2004 bij Gerard thuis, onder meer Rick van H. was goed 
op dreef en ik was aan het eind van de avond anderhalve liter traanvocht armer (super!). 
Rick, bedankt voor je vrolijke inbreng (weet je nog: de ontmanteling van het blauwe Duitse 
systeem?) en ±1000 foto’s aan kikkervliezen die we gemaakt hebben. Ook de mensen die 
recentelijk vertrokken zijn of al wat langer weg zijn van het lab wil ik bedanken: Dorien, 
Gerrit (goeiedagschotel!), Heidi, Helma, Jacopo, Karel (ik denk nog regelmatig aan je), Kim, 
Marcel C. (het kost wat tijd, maar dan heb je ook wat!), Roland, Ron D. (RNA nie?), Susan, 
en Vincent (het was heel ﬁ jn wonen aan de Balladestraat).
Ik ben zeer trots op mijn paranimfen Leon van Berkom en René van Herpen die beide het 
traject van promotie al goed hebben volbracht. Leon, ik heb je leren kennen in de tijd dat 
je nog een angstaanjagende haarmat droeg en heb je gedurende de jaren op verschillende 
gebieden zien ontwikkelen: voetbal, kaarten, mountainbiken, ﬁ tness, karate en het drinken van 
biertjes(!). Maak je borst maar vast nat, als ik dadelijk in wat rustiger vaarwater terecht kom 
zal ik je snel gaan uitdagen voor een potje ouderwets Mario karten. Succes in je nieuwe functie 
bij Mercachem en veel geluk samen met Claudia. René, met jou heb ik al zoveel meegemaakt 
sinds dat we elkaar hebben leren kennen op het HLO, dat is niet samen te vatten in een paar 
zinnen. Ondanks dat we onze eigen weg hebben bewandeld en nog steeds bewandelen, komen 
we toch steeds in dezelfde omgeving terecht (we vonden het soms een beetje eng worden). Ik 
heb in ieder geval super veel van je geleerd en daar ben ik je heel dankbaar voor. Geniet van 
de mooie tijd samen met Mieke en succes bij Organon. Die schaakpartij gaan we overigens 
100% zeker afmaken! Leon en René, ontzettend bedankt voor jullie kameraadschap door dik 
en dun en ik vind het grandioos dat jullie me bij willen staan gedurende de ceremonie.
Zonder mijn studenten Eric (E. coli), Jurriaan (co-auteurschap, jars jars!) en Rik(kie on the 
piano) zou mijn boekje niet de inhoud gehad hebben die het nu heeft. Ik vond het geweldig 
om jullie te begeleiden. Bedankt voor jullie inzet, aanpassingsvermogen, gezelligheid en 
prettige samenwerking. Succes met de afronding van de studie en vergeet vooral niet te 
genieten gedurende de (eventuele) promotietijd.
In de researchtoren was de “zesde verdieping” toch wel een begrip, natuurlijk vanwege de 
wetenschappelijke kwaliteiten van de bewoners, maar ook van een feestje waren zij niet 
139
Dankwoord
vies. Mede door de inzet van de naaste collega’s (Ad, Alwin, Bas, Bé, Edwin, Femke, Frank 
de L., Frank O., Godfried, Gönül, Helma, Huib, Ineke, Jack, Jan K., Jan S., Lieke, Magda, 
Marcel N., Marco, Marianne, Marieke, Marion, Mariska, Marloes, Mietske, Peter, Ralph, 
Renato, Rick W., Rinske, Sharita, Susan, Walther, Wieke, Wiljan, Wilma, Yvet) heb ik een 
onvergetelijke tijd gehad (en waren deze feestjes altijd geslaagd!).
Naast collega’s wil ik tevens Arthur, Claudia, Donny, Heidi, Janneke, Martijn (Eindhoven de 
gekste!), Michiel P., Michiel van W., Nicole, Noor, Patrick, Rámon, Sanne, Thijs en Wendy 
bedanken voor jullie vriendschap en steun. Els, bedankt voor de gezellige etentjes en veel 
succes in Heidelberg.
Mijn familie en schoonfamilie wil ik graag bedanken voor jullie interesse in het werk (voor 
sommige was het gewoon studie) wat ik de afgelopen jaren heb uitgevoerd. Ik weet dat het 
niet meevalt om te begrijpen waar ik allemaal mee bezig was, maar alleen al de belangstelling 
heeft me heel goed gedaan.
Margaret, ik ben heel trots dat ik je “broertje” ben. Bedankt voor het uitwisselen van je 
levenservaringen en ik wens je heel veel warmte toe samen met Niels.
Zonder de goede basis, welke ik van mijn Pa en Ma heb meegekregen, zou ik hier nooit 
gestaan hebben. De vrijheid om te studeren, elk uur van de dag voor me klaar staan en de 
deur die altijd openstaat, waardeer ik enorm. Hartelijk dank voor jullie warme belangstelling, 
liefdevolle steun en vertrouwen.
De laatste regels zijn voor mijn allerliefste, Judith. Wat is het toch genieten om een fantastisch 
persoon als jou naast mijn zijde te hebben staan. Jouw onvoorwaardelijke steun, liefde en 
begrip hebben mijn promotietraject een stuk aangenamer gemaakt. Ik hou ontzettend veel 
van je en we gaan een heerlijke toekomst tegemoet.
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